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Abstract 
Leptin is a polypeptide hormone with important roles in a number of 
physiological pathways. Most significantly leptin acts a major regulator 
of energy metabolism and defects in hormone signalling form the basis 
of a number of human conditions, including morbid obesity, 
cardiovascular disease, and diabetes. Leptin is also an important 
immunomodulatory hormone and may contribute to a range of 
inflammatory diseases. For these reasons there is significant interest in 
the development of novel forms of leptin as possible therapeutic agents. 
Research into therapeutic applications of leptin has focused on 
attempts to engineer the leptin molecule to introduce properties such as 
improved affinity for the corresponding receptor, increased protein 
stability, and the development of both agonists and antagonists. These 
efforts have been largely based on rational engineering of the hormone 
based on structural studies and site-directed mutagenesis. Phage 
display of proteins and guided enrichment by selective biopanning is a 
powerful technique that allows the sampling of very large populations of 
protein variants.  
In this study I expressed functional leptin on the surface of filamentous 
phage and used this technique to synthesise a library of random mutant 
leptins in the form of a phage library. A selective procedure was 
developed based on immobilised leptin receptor and a competitive 
binding strategy to select novel variants from the leptin mutant library 
with increased receptor affinity. The mutants were characterised and 
leptin proteins expressed and purified. The recombinant leptins were 
analysed for receptor stimulating activity and receptor affinity 
determined in real-time studies using biointerferometry. A novel leptin 
mutant was recovered with increased receptor affinity and agonist 
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activity. This study established an approach for further phage based 
studies of leptin and other polypeptide hormones.   
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Introduction  
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1.1 Leptin Structure and Properties 
1.1.1 Identification of Leptin and the Leptin Receptor 
The past 50 years has seen a general increase in the levels of obesity 
in the general population, with some 700 million obese people 
worldwide, as defined by the WHO body mass index criteria (reviewed 
in Speakman and O'Rahilly, 2012). Views on the causes of obesity have 
swung alternately from a focus on consumption, to levels of physical 
activity, and metabolic dysfunction. It is now clear that the causes of 
obesity are complex and feature a significant genetic component, which 
probably accounts for at least 65% of the weight variation between 
individuals (reviewed in Speakman and O'Rahilly, 2012). Studies of the 
genetics of obesity date back to the early 1950s, and were initially 
stimulated by the rising incidence of coronary heart disease and 
diabetes (reviewed in Charlton, 1984). In 1950 a spontaneous obese 
mouse mutant was identified which exhibited an obese phenotype 
associated with hyperphagia and the locus was designated ob (Ingalls 
et al., 1950). This discovery was of interest as, for the first time, it was 
demonstrated that obesity and overeating could be associated with a 
specific genetic defect. Subsequently, in 1966, a second mutation, 
named db, was described in mice with a phenotype that included 
morbid obesity and diabetes (Hummel et al., 1966), once more 
stimulating research into the genetic basis of obesity and the 
relationship between excessive body weight and other metabolic 
defects. The mutation was shown to be recessive and db/db 
homozygous mice featured morbid obesity (approximately 50% heavier 
than wild-type litter mates), hyperphagia, and severe diabetes. In an 
interesting series of so-called parabiosis experiments db/db mice were 
surgically conjoined with wild-type mice to investigate the biochemical 
basis of the disorder (Coleman and Hummel, 1969). The wild-type mice 
in each paring died effectively from starvation, with very low levels of 
 3 
 
blood sugar, very low food intake, and no detectable liver glycogen at 
necropsy.  In contrast the db/db phenotype remained unchanged. This 
suggested the presence of a circulating factor in db mice that could 
dramatically suppress appetite in wild-type mice but that elicited no 
response in db mice. Similar experiments carried out with ob mice 
showed that when paired with wild-type mice their blood glucose and 
food consumption was reduced, and indeed when conjoined with db/db 
mice the ob mice would decrease food input to the level of starvation 
(Coleman, 1973), suggesting that the ob phenotype was caused by a 
deficit in the production of the postulated regulatory factor. This theory 
was subsequently confirmed when positional cloning of the ob locus 
lead to the identification of a structural gene in 1994 and the protein 
product, subsequently named leptin, was shown to regulate satiety 
(Zhang et al., 1994). The circle was closed when the product of the db 
gene was subsequently expression-cloned from a cDNA library and 
identified as the leptin receptor (OB-R) (Tartaglia et al., 1995). The 
mouse ob gene is located on chromosome 6 and transcribes an mRNA 
of approximately 4.5 kb (Isse et al., 1995). 
1.1.2 Leptin properties 
Leptin is a 16 kDa (146 amino acid) hormone for which a number of 
biological roles have established. Leptin is predominantly involved in 
the regulation of energy balance and body weight homeostasis and is 
thus classically considered a hormone (reviewed in Friedman and 
Halaas, 1998, Campfield, 2000). Leptin is constitutively expressed in 
adipose cells, where its chief role is to regulate food intake and energy 
expenditure (Maffei et al., 1995). Leptin was first isolated by Halas et 
al., and was named from the Greek word "lepton" meaning thin (Halaas 
et al., 1995). Though considered a hormone, leptin shares number of 
characteristics of a cytokine, and is structurally related to the class I 
cytokine and receptor family (Loffreda et al., 1998). Leptin exhibits 
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control over glucose metabolism and has been observed to act in a 
range of tissues in the periphery, including lymphocytes, and the 
reproductive system (reviewed in Farooqi et al., 1998). Besides its roles 
in the regulation energy balance leptin plays a role in a number of 
additional physiological processes such as control of blood glucose 
levels, bone remodelling and tissue regenerating (reviewed in 
Fruhbeck, 2001). Leptin circulates in the bloodstream in two different 
forms, free and bound form. Biologically, the free form is effective, while 
the other is bound to carrier proteins (Mantzoros and Moschos, 1998). 
Leptin concentrations in the bloodstream normally correlate with body 
fat percentage, and high levels of circulating leptin, or hyperleptinemia, 
can be observed in obese individuals (reviewed in Munzberg and 
Myers, 2005). 
Leptin has been crystallised, and the 3-D structure determined (Zhang 
et al., 1997, Fruhbeck, 2001). Leptin possesses a 4 -helix bundle 
structure similar to that of growth hormone and other class I cytokines. 
The binding domain of the receptor has been crystallised also and the 
ligand binding mechanism is believed to be similar to that of other class 
I cytokines. However, some aspects of the structural elements affecting 
the leptin binding to its receptor still remain unclear. A number of 
models of leptin/leptin receptor binding have been described and 
published. To date, six receptor isoforms have been characterised, all 
resulting from alternative splicing, with a common amino-terminal 
domain and variable truncations of the carboxy-terminal portion of the 
molecule. Only the long isoform (OB-Rb) is capable of transferring 
signal transduction (White et al., 1997). 
Engagement of leptin with its related receptor in the plasma membrane 
leads to the activation of intracellular signalling pathways, the 
predominant mediators being members of the JAK/STAT family 
(Gorissen et al., 2011). In addition to central role in metabolic regulation 
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a number of studies have shown that leptin has pleiotropic biological 
effects and dysregulation of this system may be important in the 
number of diseases including cardiovascular conditions, cancer 
susceptibility, and chronic inflammatory disorders (Beltowski, 2012). 
Given these multiple roles of leptin development of leptin agonists and 
antagonists may offer a number of novel therapeutic applications and at 
the same time provide useful tools for studying the nature of leptin and 
receptor interactions at the molecular level (reviewed in Gertler and 
Solomon, 2013). 
1.2 Biological Effects of Leptin 
1.2.1 Leptin in relation to obesity and satiety 
Leptin plays a significant role in regulating energy homeostasis 
(Frederich et al., 1995, Halaas et al., 1995). In general, leptin serum 
concentrations in healthy individuals exhibit a linear relationship with 
body fat levels (Considine et al., 1996b). The decline in the level of 
circulating leptin elicits a signal to the hypothalamus to stimulate 
appetite, metabolism and reduced energy expenditure in the body 
(Saladin et al., 1995). The key role of leptin in energy homeostasis has 
been explored through the analysis of mutant mice, defective in leptin 
synthesis or leptin receptor expression (Campfield et al., 1995). 
Injection of recombinant leptin, either peripherally or into the CNS, led 
to decreased feeding and weight loss. This effect not observed in db/db 
mice (defective in the leptin receptor). These and other studies 
suggested a role for leptin signalling both in peripheral tissues, and the 
brain. 
Leptin is predominantly a product of adipocytes and secreted into the 
circulation where it travels to the site of action in the brain to regulate 
metabolism and food intake (Zhang et al., 1994). Leptin acts on the 
neurones of the hypothalamus to signal changes in the metabolic 
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energy store. Several intracellular pathways transduce this signal; 
Janus kinase (JAK), signal transducer and activators of transcription 
(STAT) and c-AMP (O'Sullivan et al., 2007). Six splice alternatives of 
OB-R (leptin receptors) have recognized; the long form (OB-Rb) is 
considered to be highly expressed in neurons as a functional receptor, 
and signal transducing isoform (Ahima et al., 1996). The main target for 
leptin in neurons is OB-Rb, and this is expressed in two particular cell 
populations located in the arcuate nucleus. The first population 
expresses POMC (pro-opiomelanocortin) from which α-melanocyte-
stimulating hormone (-MSH) derives, and the second group of cells 
expresses neuropeptide Y (NPY) and agouti-related protein (AgRP). It 
is these neuropeptides that are the main mediators of appetite and 
satiety. Downstream engagement of melanocortin receptors by -MSH 
triggers anorexia (decreased appetite) (Cowley et al., 2001). NPY is an 
orexigenic, or appetite stimulating, neuropeptide, and AgRP inhibits -
MSH signalling. Leptin acts via OBR-b to inhibit neuronal expression of 
both NPY and AgRP, thus potentiating anoxeric signalling by -MSH 
(Elias et al., 1999). Given this central role of leptin in regulating appetite 
and satiety it has long been thought likely that defects in the leptin 
signalling pathway contribute to the origins of human obesity. However, 
it has become clear that the single gene defects observed in ob and db 
mice have little relevance to common forms of obesity observed in the 
human population. At the same time evidence suggests that more 
subtle defects in leptin signalling play an important role in the 
pathogenesis of morbid obesity. 
Hyperleptinemia is an important feature of human obesity and is directly 
associated with the body fat content (Considine et al., 1996a). Despite 
relatively high levels of circulating leptin the majority of obese subjects 
do not exhibit the normal control of appetite and satiety, suggesting a 
lack of reponse to leptin, a phenomenon termed “leptin resistance”. 
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Studies of leptin insensitivity in animal models suggest two major 
mechanisms underlying the falloff of leptin responses in obesity 
(reviewed in Balland and Cowley, 2015). Firstly a decreased rate of 
leptin uptake into the brain, and secondly a reduction in central 
responses to leptin. The phenomenon of leptin resistance is more 
relevant to human obesity then the documented single gene defects 
observed in the db and ob mice as most patients exhibit very high levels 
of circulating leptin together with reduced sensitivity to leptin signalling. 
The most useful animal models for this phenomenon are based of diet-
induced obesity (DIO) (Van Heek et al., 1997) and it has been shown 
that leptin responses begin to fall off after several weeks of a high fat 
diet. Decreased leptin transport into the arcuate nucleus of the 
hypothalamus has been demonstrated in DIO mice (Balland and 
Cowley, 2015) and this one probable contributor to decreased central 
responses to leptin. Leptin receptor expression appears to be unaltered 
in lean and obese individuals and a more likely cause of reduced leptin 
sensitivity appears to be changes in the downstream signalling 
pathway. Suppressor of cytokine signalling molecule SOCS-3 activity is 
increased in DIO mice, increasing the inhibition of leptin signalling 
pathways (Munzberg et al., 2004). The PI3K pathway is also important 
in leptin signalling and this pathway is disturbed by high levels of free 
fatty acids associated with morbid obesity (Metlakunta et al., 2008). 
1.2.2 Leptin and carbohydrate metabolism 
Levels of blood glucose are closely controlled by the hormones insulin 
and glucagon. Leptin has been demonstrated to directly downregulate 
the release of insulin from pancreatic islet cells (Emilsson et al., 1997) 
and at the same time stimulating gluconeogenesis (Hegyi et al., 2004). 
It has been shown that insulin and leptin can stimulate the same 
neuronal cells involved with appetite control. Both insulin and leptin can 
trigger the release of pro-opiomelanocortin (POMC) from a subset of 
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neurons. POMC release leads to the production of -melanocyte-
stimulating-hormone (-MSH) which acts as an anorectic signal, 
suppressing appetite (Schwartz et al., 2000). Leptin also suppresses 
the expression of agouti-related peptide (AgRP), which is an inhibitor of 
POMC, while insulin has the opposite effect on AgRP expression (Xu et 
al., 2005). There is significant crosstalk between the insulin and leptin 
signalling and it is believed this is mediated by the PI3K pathway 
(Kieffer et al., 1997). It is clear that leptin is an important link between 
carbohydrate and lipid metabolism. 
1.2.3 Control of leptin expression 
The level of adiposity seems to directly relate to serum levels of leptin 
(Campfield et al., 1995), though transient changes in leptin 
concentrations caused by fasting and feeding cannot be due to overall 
amounts of adipose tissue (Considine et al., 1996b). It has been shown 
that leptin expression and secretion is regulated by insulin (Saladin et 
al., 1995). In addition a number of other molecules have been shown to 
regulate leptin expression; these include tumour necrosis factor, 
interleukins and glucocorticoids (Grunfeld et al., 1996, De Vos et al., 
1995, Slieker et al., 1996). It remains to be shown whether these 
various factors stimulate increased leptin expression or in some cases 
simply drive the release of pre-synthesised cellular stores. 
Factors known to directly regulate leptin expression include 1,25 
dihydroxyvitamin D. Upstream response elements in the leptin promoter 
interact with the vitamin D receptor (VDR)-retinoid X receptor (RXR) 
complex, and it has been shown that leptin expression in rat adipocytes 
can be reduced by more than 80% by vitamin D treatment (Kaneko et 
al., 2015). Nuclear Factor-Y (NF-Y) is a transcription factor essential for 
the differentiation of a number of cell types, including pre-adipocytes. 
NF-Y response elements have been identified upstream of the leptin 
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promoter and NF-Y has been shown to be essential for leptin 
expression (Lu et al., 2015). 
Epigenetic mechanisms may be involved in the expression of leptin and 
it has been established that methylation of the proximal region of the 
leptin promoter is a significant determinant of leptin expression in 
human adult tissue (Marchi et al., 2011). In peripheral blood samples 
from human obese adolescents methylation of the leptin promoter was 
negatively associated with BMI (Garcia-Cardona et al., 2014). 
1.2.5 Leptin and human health  
Leptin has both hormone and cytokine characteristics and plays 
important roles in regulating energy homeostasis, basal metabolic rate, 
and immune responses (Farooqi et al., 2002). Moreover, it has 
proinflammatory effects, stimulating adaptive immunity and macrophage 
proliferation. 
Leptin administration has shown to be an effective therapy in some in 
vitro experimental animal models (Gorissen et al., 2011); for example in 
the ob/ob mouse model the morbid obesity and endocrine disorders 
were successfully reversed by treatment with recombinant leptin. In 
contrast, the proinflammatory activities of leptin suggest that the 
treatment of autoimmune disease would require the use of leptin 
antagonists (Martin-Romero et al., 2000). 
An antibody with antagonist activity for the OB-R has developed (Fazeli 
et al., 2006), and this reagent has also been used as a tool to enable 
crystallisation of the leptin receptor (Fazeli et al., 2006). A number of 
problems still remain to be resolved in the area of leptin therapeutics, 
not least how to access target sites in the central nervous system and 
to traverse the blood/brain barrier (Gertler, 2006). At least one small 
molecular reagent has been developed that can target receptors in the 
CNS, and this based on synthetic peptide (Rozhavskaya et al. 2000). 
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1.2.6 Leptin and the immune response 
Leptin has similarities to members of the long chain 4 helical cytokine 
family, and OB-R belongs to the type 1 cytokine receptor family (Zhang 
et al., 1997). Interestingly, OB-R is expressed widely on all immune 
cells (Fruhbeck, 2006), suggesting a potential mechanism by which 
leptin could influence immune responses. Regarding the involvement of 
key pathways, the immune system regulation by leptin may contain 
similar elements to those involved in energy homeostasis; namely 
JAK2-STAT3, MAPK and PI3K, a family of gene regulatory proteins 
(Matarese et al., 2005).  
As mentioned above leptin displays properties of a proinflammatory 
cytokine, and its activity driven by other proinflammatory cytokines, 
including most interleukins, and tumour necrosis factor (TNF) (Faggioni 
et al., 2001). These factors have been confirmed to increase leptin 
concentrations in serum during an inflammatory response (Otero et al., 
2005). Nutritional status has shown to be a major influence on the 
immune response, and studies of leptin deficient mice reported 
impairment of both cell mediated immunity and antibody production 
(Lord et al., 1998), confirming that leptin plays at least some part in 
mediating the interaction between nutrition and the immune response. 
Leptin upregulates phagocytic function in the innate immune system by 
enhancing the activity of phospholipase (Mancuso et al., 2004). Also, 
stimulates monocyte differentiation, and the expression of a range of 
lymphocyte CD markers (Matarese et al., 2005).  
Leptin has been shown to promote proliferation of human monocytes in 
vitro (Santos-Alvarez et al., 1999). Leptin also enhances the 
proliferation, activation and cytotoxicity of natural killer cells via STAT3 
signalling (Zhao et al., 2003). In the adaptive immune response leptin 
stimulates responses to acute infection, including T helper activation, 
and has been shown to enhance production of inflammatory cytokines 
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from human monocytes (Zarkesh-Esfahani et al., 2004). The clearest 
evidence for the role of leptin in modulating the adaptive immune 
response comes from studies of leptin deficient mouse (ob/ob) where it 
has been shown that administration of exogenous leptin reverses the 
defects in T cell activation observed observed in these strains (Lord et 
al., 1998). Similar defects in the adaptive immune system have been 
documented in cases of human leptin deficiency, and lymphocyte 
proliferation and cytokine production was increased by leptin treatment 
(Farooqi et al., 2002).  
There is accumulating evidence that leptin has demonstrable effects on 
cells of the immune system. In hypoleptinemia, such as during acute 
starvation, low levels of circulating leptin are associated with decreases 
in proinflammatory responses and increased risk of infection due to a 
reduction in T helper cell activity (Matarese et al., 2001). It has been 
shown that low concentrations of serum leptin are associated with 
increased susceptibility to infection; due to a reduction in T-helper cells 
and defects in thymic function (Calapai et al., 1998). Chronic idiopathic 
thrombocytopenic purpura (ITP) is characterized by the production of 
autoantibodies against antigens located on platelet membranes and the 
level of anti-platelet IgG was shown to be increased in response to 
leptin (Ren et al., 2006). Increasing evidence for the role of leptin in 
immunoregulation suggests that leptin may be considered a potential 
target for the treatment of inflammatory and autoimmune diseases in 
humans. 
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Figure 1.1 Actions of leptin. Leptin uses multiple mechanisms to 
modulate energy homeostasis through autocrine, paracrine and neural 
interactions. While many of leptins effects are mediated by the CNS, some are 
as the result of direct action on insulin target cells and pancreatic islet cells. 
 
 
1.2.7 Leptin and general physiology 
Obesity increases the risk of important health problems including 
hypertension, type 2 diabetes, atherosclerosis, some cancers. 
Hyperleptinaemia is a key feature of morbid obesity and given the 
pleiotropic effects of leptin it is likely that this, and other adipokines, 
exert a number of effects on general physiology. Since its initial 
discovery it has become clear that, besides regulation of appetite and 
energy expenditure, leptin is also involved in neuroendocrine signalling, 
immune function, and the modulation of glucose and fat metabolism 
(reviewed in Bluher and Mantzoros, 2009). The pleiotropic effects of 
leptin are mediated by specific leptin receptors in the hypothalamus and 
other organs, and in addition to direct and indirect effects on 
metabolically active tissues, leptin regulates several neuroendocrine 
axes. 
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1.2.7.1 Leptin and gender 
Analysis of levels of circulating leptin in humans reveals a significant 
gender difference (Saad et al., 1997, Licinio et al., 1998) with females 
having much higher concentrations of leptin than men, an effect not 
related to BMI (body mass index). The mechanisms responsible for this 
gender difference are not fully understood though a role for sex 
hormones has been considered (Pineiro et al., 1999). The most likely 
basis for this difference is the increased proportion of adipose tissue in 
women relative to men, and interestingly it has been shown that female 
adipocytes also secrete higher levels of leptin (Hellstrom et al., 2000). 
1.2.7.2 Leptin and fertility 
Obese women are characterized by similar co-morbidities to men, 
particularly type 2 diabetes and cardiovascular disease. They also 
develop some specific problems, including fertility-related disorders and 
some hormone-dependent forms of cancer.  
Sterility is a phenotypic feature of leptin receptor deficient ob mice, both 
male and female, and is suggestive of a role for leptin in regulating 
reproductive functions. Reproductive capacity can be restored in these 
mice by exogenous leptin administration (Chehab et al., 1996). 
In humans obesity is also associated with male infertility. Leptin not only 
stimulates the satiety centre via hypothalamic-mediated effects, but also 
functions as a metabolic and neuroendocrine hormone in regulating 
sexual maturation and reproduction, indicating that white adipose can 
act as an endocrine organ. Due to the presence of leptin receptors in 
testicular tissue, and on the plasma membrane of sperm themselves, it 
is likely that elevated leptin levels in the serum affect spermatogenesis 
in obese males. Leptin inhibits stimulation of Leydig cells by the 
gonadotropins, resulting in a decline in testosterone production 
(Davidson et al., 2015). It has been reported that excess leptin from 
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adipose tissue has deleterious effects upon androgen release and 
sperm production and results in increased germ cell apoptosis in testes 
(Isidori et al., 1999). 
Leptin null and leptin receptor defective mice exhibit low gonadotrophin 
concentrations, relatively immature reproductive organs, and impaired 
sexual maturation which can be restored in leptin null mice with 
exogenous administration of leptin (Kawwass et al., 2015).  
1.2.7.3 Leptin and cardiovascular disease 
There is a clear association between morbid obesity and the risk of 
cardiovascular disease and stroke. There are a number of possible 
mechanisms of this association both direct and indirect. Functional 
leptin receptor OBR-b is expressed in the myocardium and studies 
suggest a direct link between leptin signalling and cardiac remodelling 
and hypertrophy in response to hypertension (Yang and Barouch, 
2007). Leptin also has direct effects on vascular smooth muscle cells 
and can influence vascular hypertrophy (Zeidan et al., 2005). The most 
important effect of leptin on cardiovascular risk is most likely due to the 
inflammatory effects of this adipokine and central obesity is closely 
associated with cardiovascular disease (reviewed in Freitas Lima et al., 
2015). Leptin levels also play an important role in the origins of insulin 
insensitivity and disruption of glucose regulation, a major contributor to 
cardiovascular disease risk (Zhang et al., 1994). 
1.3 Leptin and the leptin receptor 
1.3.1 Structure of leptin 
Shortly after the identification of the human leptin gene, the protein was 
crystallised, and its 3-D structure determined (Zhang et al., 1997). The 
wild-type form of leptin has a tendency to aggregate at high 
concentrations and crystallisation was assisted by the use of a variant 
with a point mutation (E100) that resulted in much more soluble leptin 
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form that retained the native structure and function (Zhang et al., 1997). 
Leptin has an extended conformation with approximate dimensions of 
45Å x 25Å x 20Å; as illustrated in Fig. 1.2. It contains four antiparallel α-
helices named A, B, C and D, joined together by two long linkers AB 
and CD and a short loop BC. A short helix designated E, acts as a 
hydrophobic cap, which runs vertically to the main bundle of four helices 
(Zhang et al., 1997).  
The α-helix bundles of leptin show similarity to the long-chain helical 
cytokine family, of which GCSF (granulocyte colony-stimulating factor) 
and hGH (human growth hormone) are members (Zhang et al., 1997, 
Hill et al., 1993). While structurally these proteins exhibit conservation, 
leptin features sequence differences to other followers of the cytokine 
family helical long chain. However, the sequence conservation of leptin 
molecules between different vertebrates is highly similar in their 
secondary and tertiary structures, based on the crystal structure of 
human leptin (Huising et al., 2006). All vertebrate leptin molecules 
contain two critical cysteine residues (one at the carboxy terminus) that 
have been shown to form a disulphide bridge that is essential for 
biological function (Crespi and Denver, 2006).  
1.3.2 The leptin receptor  
Structurally, human leptin receptor (OB-R) is related to the class I family 
of cytokine receptors (Tartaglia et al., 1995). It is a single span 
transmembrane receptor, similar to the IL-6 and other gp130-family 
receptors (Walduck and Becher, 2012). The extracellular domain is a 
common element shared by the different isoforms, and comprises more 
than 800 amino acids. Five known isoforms of the receptor have been 
characterised all resulting from alternative splicing. The receptor 
isoforms differ in the relative length of the carboxy-terminal domain, 
which influences the degree of signalling associated with each form 
(Fig. 1.3) (Haniu et al., 1998). OB-Rb is the long, fully functional 
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isoform, comprising two cytokine receptor homology domains (CRH), 
one immunoglobulin-like domain (IGD) and four fibronectin type III 
domains (Fig. 1.2) (Myers, 2004). The OB-Rb cytoplasmic domain is 
approximately 301 residues in length and includes the highly conserved 
Box 1 motif which is essential for signalling via JAK kinase activation 
(Bjorbaek et al., 1997). A second Box domain, Box 2, has also been 
described in OB-Rb, and it has been suggested that this may have 
some as yet unclear role in signalling (Banks et al., 2000). The 
intracellular domain of OB-Rb features three critical tyrosine residues 
that mediate signalling through the JAK/STAT and MAPK pathways 
(Gorissen et al., 2009). Other isoforms of OB-R represent truncated 
forms of OB-Rb, with reduced intracellular domains. Isoforms OB-Ra, 
OB-Rc, and OB-Rd are truncated at the carboxy terminus and include 
the Box 1 domain. 
Isoform OB-Re lacks both the intracellular domain and the membrane 
spanning region and, in the mouse, is expressed a soluble leptin-
binding protein (Tu et al., 2010). The OB-Re transcript in humans lacks 
a poly-A tail and generation of this truncated form of OB-R is the result 
of protein cleavage (Zabeau et al., 2003). High levels of expression of 
OB-Ra and OB-Rc have been documented in the choroid plexus and 
brain microvessels and it has been speculated these isoforms may play 
a role in transport of leptin across the blood-brain barrier (Tartaglia et 
al., 1995). 
1.3.3 Leptin receptor isoforms 
Alternative splicing of the leptin receptor gene generates six different 
receptor isoforms (OB-Ra-f) that possess common extracellular and 
transmembrane domains but differ in their intracellular domains. OB-Rb 
includes the longest intracellular domain at 302 amino acids and is the 
only form that includes functional JAK2 and STAT binding sites 
essential for leptin signalling. Interestingly the other isoforms are 
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expressed at a higher level than OB-Rb and have a wider tissue 
distribution. Recent interest has focussed on possible roles for these 
relatively highly expressed isoforms. Despite the major role for OB-Rb 
in leptin signalling a specific knockout of the OB-Ra variant produced a 
unique phenotype (Li et al., 2013). The knockout mice exhibited 
decreased fasting blood glucose and improved glucose tolerance 
without changes in body weight or food intake. Other studies have 
shown that the OB-Ra isoform is important in leptin transport into the 
brain (Schwartz et al., 1996). OB-Rc differs by only a few amino acid 
residues from OB-Ra and there is speculation that both isoforms may 
possess overlapping activities. OB-Ra and OB-Rc are both expressed 
at a high level in the choroid plexus, lung, spleen, testis, muscle, and 
other tissues suggesive of a potential role for these forms in leptin 
signalling in peripheral tissues (Dam and Jockers, 2013). 
Heterodimerisation has been demonstrated between the different 
isoforms though not yet confirmed in vivo (White and Tartaglia, 1999). 
The relative abundance of the alternative spliced forms suggests that 
this is likely to occur and the possible effects on leptin signalling remain 
to be elucidated. 
1.3.4 Leptin signalling 
In common with other members of the class I cytokine receptor family 
OB-R lacks inherent tyrosine kinase activity and mediates signalling via 
interaction with members of the Janus kinase family (JAKs) and signal-
transducer-and-activators-of-transcription (STAT) molecules (Alberts, 
2002, Zabeau et al., 2004, Ahima and Osei, 2004). Multimerisation of 
OB-Rb is essential for activation of JAK/STAT signalling; but, 
heterodimerisation between different receptor isoforms can occur 
(Bjorbaek et al., 1997). 
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Figure 1.2 Leptin structure. Leptin is a member of the 4-helical cytokine 
family. It features 4 antiparallel -helices (A-D). Loops connecting the helices 
are designated AB, BC, and CD. Leptin contains a single disulphide bond 
between the c-terminal Cys146 and Cys96 locate in the CD loop. There are 
two major receptor binding sites: Site II which is located on the solvent 
exposed faces of helices A and C, and Site III which involves residues at the 
amino terminal end of helix D. 
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Figure 1.3. The leptin receptor (OB-R) and isoforms. Alternative 
splicing gives rise to 5 different isoforms sharing a common ligand-binding 
extracellular domain. OB-Rb is the longest receptor variant and the only one 
that contains all domains necessary for signalling. OB-Ra, OB-Rc, and OB-Rd 
possess a transmembrane domain but lack signalling activity. OB-Re lacks a 
transmembrane domain and is secreted as a soluble leptin binding molecule. 
At the amino-terminus 2 fibronectin folds combine to produce a cytokine 
receptor homology (CRH-1) domain. This is followed by an immunoglobulin-
like (IGD) domain and a second CRH domain (CRH-2) which together with the 
IGD region represents the major high affinity leptin binding site. 
 
 
Figure 1.4. Intracellular signalling pathways of leptin. Schematic 
diagram of signal transduction pathways stimulated by leptin. Dimerisation of 
the receptor leads to phosphorylation of key tyrosine residues and activation 
of JAK2 kinase and phosphorylation of STAT transcription factors. Signalling 
is downregulated by the action of SOCS3 and PTP1B.  
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JAK2 is constitutively associated with Box 1 and binding of leptin leads 
to receptor multimerisation, and activation of JAK2, initialising the 
kinase signalling cascade. Three key tyrosine residues Tyr985, Tyr1107, 
and Tyr1138, have been shown to be involved in leptin signalling (Fig. 
1.4) and all three possess a binding site for the downstream signalling 
molecule Src homology 2 (SH2) domain (Liongue and Ward, 2007). 
Activation of OB-Rb activates multiple signalling pathways, either 
directly or indirectly.  
When phosphorylated Tyr985 binds src-homology-2 domain protein 
(SHP-2) and activates the mitogen-activated-protein-kinase (MAPK) 
pathway and mediates negative feedback control of the leptin signalling 
pathway (Bjorbaek et al., 1997). The role of Tyr1077 seems to be less 
clear, and this residue is located in a hydrophobic region that is thought 
to be less accessible to ligands, and one study showed that mutation of 
Tyr985 and Tyr1138 prevented phosphorylation of Tyr1077, indicating that it 
is not capable of independent activation (Banks et al., 2000). Mutation 
of Tyr1077 does not abrogate leptin signalling in the hypothalamus 
(Banks et al., 2000). There is a report that Tyr1077 activated STAT5 in 
cell culture preparations of pancreatic cells (Hekerman et al., 2005), 
suggesting a possible role for Tyr1077 in some aspects of leptin 
signalling. Tyr1138 binds STAT3 which is then phosphorylated and 
mediates the major effects of leptin energy homeostasis and 
neuroendocrine regulation. Regulation of leptin signalling is mediated 
by a classic negative feedback pathway. OB-Rb signalling is associated 
with two adaptor molecules that act to downregulate pathway activation. 
Suppressor-of-cytokine-signalling-3 (SOCS-3) is upregulated by the 
action of transcription factor STAT3 and binds to Tyr985, leading to 
reversal of JAK2 activation (Munzberg and Morrison, 2015). In addition, 
phosphotyrosine phosphatase-1B (PTP1B) is upregulated by STAT3, 
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and acts to downregulate kinase pathway activation. In vitro 
experiments have documented the activation of additional STAT 
molecules by OB-R but, at least in vivo, STAT3 is the major mediator of 
leptin action. 
1.3.5 Leptin receptor binding 
Crucial to the goal of engineering leptin antagonists is understanding 
the mechanism of hormone binding to its receptor. The crystal structure 
of leptin has been elucidated (Zhang et al., 1997) and cloning of the 
leptin receptor (Tartaglia et al., 1995) stimulated research into the 
mechanism of hormone binding. Sequence similarity of OB-R to 
members of the class I cytokine/gp130 receptor family suggested that a 
similar binding mechanism would be involved (Iserentant et al., 2005, 
Peelman et al., 2006, Peelman et al., 2004). A number of models have 
been proposed based on the structure of the granulocyte colony 
stimulating factor (G-CSF) receptor and class I cytokine receptors 
(Iserentant et al., 2005, Zabeau et al., 2003) . Initially, binding of leptin 
to its receptor was assumed to be as a 1:1 stoichiometric complex, and 
this was suported by molecular techniques such as gel filtration 
chromatography, SDS/PAGE, and structural analysis (Devos et al., 
1997). Additional evidence generated by Hiroike et al, when they 
established a crystal structure of the G-CSF receptor and used this as a 
predictive model for leptin/leptin receptor binding (Hiroike et al., 2000). 
However, G-CSF, a member of a long chain cytokine family, binds its 
receptor in 2:2 ratio (Aritomi et al., 1999). The implications of this 
observation for the nature of leptin binding remain unclear, but the leptin 
receptor shows structural similarity to the G-CSF receptor; and 
intracellular signalling from the leptin receptor requires oligomerisation 
(Hiroike et al., 2000). 
Zabeau et al originally suggested a 2:4 ratio leptin/leptin receptor 
complex, which posited the interaction of two leptin molecules with four 
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leptin receptors via the receptors CRH-2 and immunoglobulin-like 
domains (Zabeau et al., 2005, Zabeau et al., 2004). Crystallised gp130 
has facilitated similar studies to use IL-6/gp130 receptor complex as a 
template with a 2:4 ratio for production leptin receptor complex in the 
mouse model (Peelman et al., 2006). Further insights into leptin 
receptor binding were established by the use of site-directed 
mutagenesis. 
Leptin shows similarities with cytokines of the gp130 family (Zhang et 
al., 1997) and possesses a 4-helix bundle structure. The leptin receptor 
is also related to those of the long chain 4-helix bundle cytokines, 
especially those of the gp130 group and the G-CSF receptor (Zabeau et 
al., 2005, Peelman et al., 2006). Cytokines of the 4-helical family 
characteristically bind their receptors with two or three distinct binding 
sites (Bravo et al., 1998) The IL-6 receptor comprises two receptor 
chains, IL-6Ra and gp130. The gp130 co-receptor contains a CRH 
domain and Ig-like domain (IGD), while IL-6R binds via a single CRH 
domain (Boulanger et al., 2003). Structural studies and site-directed 
mutagenesis have been used to identify three separate receptor binding 
sites on IL-6, sites I, II, and III. Two molecules of IL-6 use site I to bind 
to the CRH domains of two IL-6R chains. Site II interacts with the CRH 
domain of gp130, and site III of each IL-6 molecule binds to the IGD 
domain of each gp130 chain, resulting in the formation of a hexameric 
complex (Fig 1.5). At the same time it has been shown that IL-6 and 
gp130 alone can form a high affinity complex based on interaction of 
the IL-6 binding sites II and III alone (Chow et al., 2001). G-CSF forms a 
tetrameric complex with its receptor in a similar way using sites II and III 
and in both cases the site II/CRH interaction is the high affinity binding 
site (Tamada et al., 2006). Based on structural homology to other 
members of the 4-helical cytokine family sequences with apparent 
similarity to Sites I, II, and III were identified in the leptin structure, and 
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the functional significance of these regions has been confirmed by site-
directed mutagenesis (Iserentant et al., 2005, Peelman et al., 2006, 
Peelman et al., 2004). Based on the analysis of the related IL-6 and G-
CSF receptors a number of models of leptin receptor binding have been 
proposed (Iserentant et al., 2005, Peelman et al., 2006). Unlike the IL-6 
receptor there is no co-receptor equivalent to gp130 and the proposed 
model of leptin binding suggests a 2:4 quaternary complex involving 2 
leptin molecules and 2 leptin receptors (Peelman et al., 2014). The high 
affinity binding is that formed by the interaction of the leptin receptor 
CRH-2 domain and leptin binding site II. Dimerisation of the receptor is 
essential for receptor signalling (Zabeau et al., 2003). 
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Figure 1.5. IL-6-gp130 hexameric complex. Schematic diagram showing 
the proposed hexameric complex formed by binding of IL-6 to gp130 and IL-6 
receptor -chain (IL-6R). Two molecules of leptin interact with gp130 via Site 
II binding to the cytokine receptor homology (CRH) domain and Site III binds 
to the immunoglobulin-like domain (IGD) of a second gp130 molecule. Two IL-
6R chains interact with the complex via the Site I site of the leptin molecules. 
 
 
 
Figure 1.6. Leptin binding Site II. Crystal structure of leptin (1AX8) 
showing key residues contributing to receptor binding Site II (shown as 
spheres). Residues on the solvent exposed faces of helices A and C were 
identified by site-directed mutagenesis and affinity studies. Helix A is shown in 
blue, Helix B (red), helix C (yellow), & helix D (orange). 
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Site-directed mutagenesis has been used to identify key residues 
involved in receptor interactions (Peelman et al., 2006, Peelman et al., 
2004). The major high affinity binding interaction is between leptin site II 
and the CRH-2 domain, with a secondary association between leptin 
site III and the IGD domain. Site II is formed by the A and C helix, and 
site-directed mutagenesis was used to identify key residues in this 
region; Asp9, Thr12, Lys15, Thr16, and Arg20 (Zabeau et al., 2003) (Fig. 
1.6). Non-conservative substitutions at these positions resulted in a 
significant reduction in leptin receptor affinity. 
Similar studies were used to identify binding site III and located this to 
two regions: an area around the N-terminus of helix D, including 
residues Ser117, Ser120, Thr121, and Glu122 (Fig.1.7) (Niv-Spector et al., 
2005). Mutations of residues in site III did not reduce leptin affinity for 
the receptor but abolished signalling and STAT3 activation, supporting 
the dimerization model of receptor function (Peelman et al., 2006). 
Additional mutations in the putative Site I region suggested that leptin 
differs in some ways from other 4-helical cytokines. Substitutions of 
amino acids in the loop joining helices A and B resulted in the 
generation of antagonistic leptin variants with identical receptor affinity 
but abolished receptor signalling (Peelman et al., 2004). These 
residues, Leu39, Asp40, and Phe41 were originally mapped to a 
presumed Site I binding region, but subsequent modelling suggested 
that these residues actually contributed to Site III (Moharana et al., 
2014). In contrast to IL-6 leptin appears to bind its receptor in a 
quaternary complex. Hormone binding is a two stage process, with the 
initial interaction occurring between the CRH-2 domain and Site II of 
leptin. This leads to binding of a second leptin-receptor complex via 
interaction with leptin Site III and the IGD domains, producing a 2:2 
leptin-receptor stoichiometry (Fig. 1.8). Understanding the structural 
basis of leptin receptor affinity and separation of the binding and 
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signalling properties of leptin was an important step in the development 
of engineered leptin antagonists. 
1.4 Engineering leptin as a therapeutic 
These structural and mutagenesis studies formed the basis of a number 
of efforts to engineer modified forms of leptin that could act as agonists 
or high affinity antagonists with therapeutic application. Studies of leptin 
antagonists can be classified into three distinct approaches: modified 
leptin variants; synthetic peptides based on structural analysis of 
receptor interactions; antibody antagonists designed to disrupt receptor 
binding. 
1.4.1 Leptin mutants 
The earliest leptin mutant studies were reported by Verploegen and 
colleagues (Verploegen et al., 1997). Mutation of Arg128 to glutamic acid 
produced a leptin variant that bound the receptor with equivalent affinity 
to that of wild-type leptin but did not activate signalling. Administration 
of this leptin variant to mice lead to weight gain and hyperinsulinaemia. 
This antagonistic activity seemed to be species specific as these effects 
were not observed when the identical mutation was introduced into 
chicken and sheep leptin. Insights from structural studies lead to the 
development of rationally designed mutants based on knowledge of the 
leptin receptor binding motifs (Zabeau et al., 2015). These studies 
mainly used an alanine scanning mutagenesis approach coupled with 
structural comparisons to other members of the 4-helical cytokine 
family. Libraries of leptin muteins were generated and screened for 
receptor binding properties and bioactivity. An S120A-T121A mutant 
showed significant antagonist activity (Peelman et al., 2006), as did an 
alanine substitution variant 39-AAAA-42 (Niv-Spector et al., 2005). 
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Figure 1.7 Leptin binding Site III. Crystal structure of leptin (1AX8) 
showing key residues contributing to receptor binding Site III (shown as 
spheres). Critical residues in the amino-terminal region of helix D and the AB 
loop were identified by site-directed mutagenesis and affinity studies. Helix A 
is shown in blue, Helix B (red), helix C (yellow), & helix D (orange). 
 
 
 
 
Figure 1.8 Schematic of leptin receptor binding. Two molecules of 
leptin bind 2 molecules of OB-R via Site II interactions with the CRH-2 domain. 
Leptin Site III binds the immunoglobulin-like domain (IGD) of each OB-R 
molecule to form a quaternary complex. 
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Both muteins blocked leptin receptor clustering in solution, consistent 
with the proposed role of Site III in leptin receptor dimerisation. The 
mutations with antagonistic effect were clustered in the putative Site III 
region. Interestingly these mutants retained wild-type levels of affinity 
for the leptin receptor, evidence that the binding and signalling 
properties of leptin could be separated, and support for the dimerisation 
model of leptin signalling. It was clear that Site III-based antagonists of 
this kind would be more effective if they possessed a higher affinity for 
the leptin receptor than wild-type leptin and accordingly a number of 
groups investigated the isolation of novel leptin variants with increased 
receptor affinity. Given the large number of possible variants isolating 
leptin mutants with increased affinity required a different approach from 
simple alanine scanning mutagenesis. Shpilman et al used a yeast 
display approach to isolate novel high affinity leptin muteins from a 
diverse library of random mutants (Niv-Spector et al., 2012). One of 
these muteins D23L displayed a 60-fold increase in receptor affinity 
compared to wild-type leptin, and when combined with site III mutants 
produced a very efffective antagonist. Residue Asp23 is conserved in all 
known mammalian leptins. Though not included in the canonical Site II 
binding domain this residue is orientated toward the CRH-2 domain of 
the leptin receptor and mutation to any neutral or positively charged 
amino acid results in an increase in affinity. It is believed that the wild-
type Asp residue exerts an, as yet, uncharacterised repulsive effect on 
the leptin receptor which is neutralised by substitution with non-charged 
amino acids (Shpilman et al., 2011). Interestingly, when these high 
affinity mutations were applied to produce agonist variants of leptin 
there was no observable increase in receptor signalling activity in 
bioassays when these mutants were assessed. The explanation for this 
apparent discrepancy was that the mutants exhibited no change in kon 
for the receptor but showed an increase in koff, meaning that the high 
affinity agonists showed prolonged receptor engagement, which would 
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only be evidenced when the molecules were antagonists but would not 
produce an increase in signalling under conditions of full occupancy. 
1.4.2 Leptin peptides 
Short peptides have also been investigated that can bind specific sites 
on the leptin receptor and disrupt ligand binding (Otvos et al., 2011). 
These can act as either agonists or antagonists. Peptide agonists have 
been reported based on conserved leptin residues 116-122 
(Rozhavskaya-Arena et al., 2000), and these have potential for treating 
obesity resulting from defects in leptin production. An antagonistic 
peptide based on residues 70-95, part of helix C (Novakovic et al., 
2009) was described and shown to inhibit leptin signalling in vitro. 
1.4.3 Antibody antagonists 
Specific antibodies directed against leptin or the leptin receptor 
represent another approach to therapeutic intervention. One of the 
earliest studies used commercial anti-leptin antibodies to neutralise 
circulating leptin. This approach was used to investigate the role of 
leptin in thrombosis in a mouse model (Konstantinides et al., 2004). 
Later studies centered on the isolation of specific antibodies directed 
against the leptin receptor. Zabeau and colleagues used a synthetic 
nanobody library to isolate a series of recombinant antibodies that 
targeted different domains of the leptin receptor (Zabeau et al., 2012). 
Only antibodies targeting the CRH-2 domain were able to compete for 
leptin binding. A second class of antibodies directed against the Ig-like 
domain were able to abrogate leptin signalling by a non-competitive 
mechanism, and were able to block leptin-induced neuropeptide-Y 
expression in mice following daily intraperitoneal injection. The treated 
mice showed an increase in body weight and food intake. Monoclonal 
antibody 9F8 was raised against the leptin receptor and acts as a high 
affinity antagonist (Fazeli et al., 2006). The antibody was used to 
investigate the role of leptin in T cell proliferation. Crystallographic 
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analysis of 9F8 binding identified the basis of high affinity interactions 
with the CRH-2 domain of the leptin receptor (Carpenter et al., 2012). 
Antibody-based leptin antagonists are still under development and offer 
the possibility of high specificity in comparison to small molecule 
inhibitors. 
1.5 Phage biology and phage display 
Since its original description in 1985 (Smith, 1985) phage display has 
become a widely used approach to the study of ligand/receptor 
interactions. The ability to express a range of peptides and polypeptides 
on the surface of viral particles provides a powerful technique for the 
selective enrichment of proteins and has been applied to the 
engineering of antibodies, hormones, and functional enzymes. 
 
1.5.1 Filamentous phage 
Filamentous bacteriophage, including M13, f1 and fd, constitute a large 
family of bacterial viruses that can infect a range of Gram-negative 
bacteria. Structurally, have similar genomic organisation (Fig. 1.9) with 
a single-stranded DNA genome of about 6.4 kb (Russel et al., 1997). 
The virion is cylindrical in shape, about 7 nm in diameter and 900 nm 
long (Simons et al., 1981). The shaft of the virion contains 
approximately 2700 copies of major coat protein cpVIII. Minor coat 
proteins cpVII and cpIX (3-5 copies) cap one end of the virion, and at 
the other end, are 5 copies of minor coat protein cpIII. All these coat 
protein participate in the structural stability of the phage partials 
(Armstrong et al., 1981). Coat protein III (cpIII) features three linked 
domains that plays a central role in host cell recognition and infection. 
Translocation of the viral DNA into E.coli during infection is initiated 
through N1 domain while N2 mediates binding to the F’ pilus on the 
host cells, a crucial step in bacterial infection (Armstrong et al., 1981). 
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Figure 1.9. Structure of filamentous phage. The phage virion consists 
of a long cylindrical structure made up of approximately 2,700 copies of major 
coat protein cpVIII. It is approximately 900 nm long and 7 nm in diameter. This 
contains the single stranded page genome (approximately 6.4 kb). The end of 
the virion is capped with other minor coat proteins including 5 copies of cpIII. 
Coat protein III comprises 3 domains separated by flexible glycine linker 
regions. Domains N1 and N2 are important for the infection process while the 
carboxy terminal domain (CT) integrates cpIII into the virion structure and is 
often utilised as a fusion partner in phage display to display peptide on the 
phage surface. 
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The carboxy domain (CT) of cpIII incorporates the protein into the 
phage structure and is frequently used as a fusion partner to express 
foreign proteins and peptides on the phage surface (Rakonjac et al., 
1999). 
1.5.2 Phage life cycle 
Infection of host bacteria by filamentous phage infection does not lead 
to lysis, instead phage particles are produced and secreted through the 
cell wall into the growth medium. Infection is initiated when phage 
particles attached to the F pilus of male E. coli via interactions with the 
amino-terminus of coat protein cpIII (Marvin et al., 1994). Upon binding 
phage the pilus contracts until the viral particle is brought into contact 
with the cell wall, and fuses to deliver the single stranded genome into 
the bacterial cytoplasm. The circular phage genome enters the cell 
where it is converted into double stranded DNA. Rolling circle 
replication of the dsDNA produces multiple ssDNA copies of the 
genome which are then packaged into phage coat proteins to produce 
functional virions. Nascent phage are secreted into the periplasm where 
the functional virion is assembled. This transfer into the periplasm can 
be important for the expression and folding of a number of recombinant 
proteins as, in contrast to the cytoplasm, the redox environment of the 
periplasm favours the formation of disulphide bonds (Scott and Smith, 
1990).  
1.5.3 Phage display technology 
The technique of phage display was first described by George P Smith 
in 1985 (Smith, 1985) and was the result of insights into the assembly 
and structure of the phage virion. Smith engineered short stretches of 
random DNA coding for small peptides into the 5’ end of the minor coat 
protein cpIII structural gene. Growth of this phage library in a bacterial 
host generated a very large and diverse culture of phage particles each 
displaying a random peptide on the virion surface. These peptides were 
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then selected from solution using a suitable ligand, such as an antibody 
or receptor. Gene fusions to coat proteins cpVIII and cpIII have been 
successfully expressed on the surface of phage particles at various 
densities. 
The fundamental principle of phage display is that the displayed peptide 
(or polypeptide) is physically connected to the corresponding DNA 
coding sequence. This means that if the ligand is captured the 
corresponding DNA coding sequence is physically attached to the 
displayed peptide or polypeptide. The selected variants can therefore 
be infected into a bacterial host and used to generate an enriched 
library of phage. This process can be repeated in a process known as 
biopanning and used to isolate specific coding sequences (Smith, 
1985). This technology has been used to investigate a range of different 
receptor/ligand systems, and most widely for the recovery and 
engineering of recombinant antibodies (Burton and Barbas, 1992, 
Lerner et al., 1992). 
Phage display technology has become a widely used tool in the fields of 
protein engineering, cell biology and immunology (Smith, 1985). 
Originally used for small peptides the method was subsequently 
extended to the expression of larger molecules including antibody 
fragments, peptide hormones, and functional enzymes (Brigati et al., 
2004). Phage display peptide libraries have been used to identify 
preferred enzyme substrates and to select high affinity proteinase 
inhibitors (Tanaka et al., 1999). 
1.5.4 Phage display vectors 
Phage display was originally carried out by modifications to the native 
filamentous phage genome. Later approaches have almost all been 
based on the use of phagemid DNA vectors. Phagemids are a class of 
plasmids that include the f1 origin (f1 ori) of replication of filamentous 
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phage. The f1 ori enables the plasmid to be converted into single 
stranded form and be packaged into a functional virion. This packaging 
requires the infection of the bacterial host with a helper phage which 
provides the various viral coat proteins and directs replication and 
packaging of the plasmid in single stranded form (Russel et al., 1986). 
In fact a large percentage of plasmid vectors now include the f1 ori 
region by default and the term phagemid has become somewhat 
redundant and little used.  
Most commonly surface expression is achieved by creating a fusion 
between nucleotide sequence of the foreign polypeptide and coat 
protein cpIII coding region (Willats, 2002). Using this direct approach 
leads to the incorporation of fusion proteins into the phage body. In 
some cases this may compromise infectivity of the recombinant phage 
but this is not usually a problem as following rescue of phagemid 
libraries by helper phage a combination of wild-type and recombinant 
capsid proteins are used to assemble virions (Sidhu, 2001). 
Phage display systems can be classified according to the utilisation of 
coat protein genes. The majority of approaches use fusion to the 
carboxy-terminal region of cpIII as the mechanism for surface display. 
Valency of expression is often difficult to assess and it has been 
estimated that for some recombinant proteins more than 99% of the 
phage library expresses only wild-type cpIII from helper phage (Forrer 
et al., 1999). Low valency expression can be useful in situations where 
high affinity binding variants are sought as it leads to a more stringent 
selection process. In some cases modifications to the helper phage 
have been used to express fusion proteins on all five copies of cpIII in 
the phage coat, producing multivalent display (Sidhu, 2001). However, 
care must be taken not to reduce the infectivity of the recombinant 
phage particles. 
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1.5.5 Screening of Phage Display Libraries 
After phage display libraries have constructed they must be screened to 
remove non-specific binders or to recover variants of interest. Phage 
display enables the selection of specific proteins or peptides by 
selective enrichment of binding phage within sequential rounds of 
panning (Willats, 2002, Vaughan et al., 1996). Phage libraries can be 
enriched using a range of different approaches. Solid phase support of 
ligands is the most frequently used approach used for selection of 
binding phage (Crameri and Suter, 1993), but alternatives include liquid 
phase capture of ligand and phage using approaches such as 
biotinylation, and the enrichment of phage particles from cell surfaces 
using fluorescent cell sorting (Gretch et al., 1987, Lekkerkerker and 
Logtenberg, 1999, van Der Vuurst De Vries and Logtenberg, 1999). 
Phage have been used in vivo to isolate antibodies or peptides that bind 
to specific tissues or tumours (Hyvonen and Laakkonen, 2015, Gillespie 
et al., 2015). In this approach phage libraries are injected into animals 
and recovered from specific tissues by dissection and elution in an 
iterative process leading to specific enrichment. 
1.5.6 Conventional Biopanning Technique 
Biopanning is a process used for selecting phage clones from very 
large diverse libraries on the basis of affinity for an immobilised target 
and is a powerful method for studying protein-ligand interactions (Pande 
et al., 2010). Numerous proteins and peptides were isolated with high 
affinity, captured phage are eluted from an immobilised target and 
amplified in an E coli host cells (An et al., 2005). This enrichment 
process is repeated using the selected library generated in each round 
(Fig. 1.10). This technique has been used to investigate a range of 
different ligand interactions, most commonly those involving antibodies 
and antigens. From the late 1980s, phage antibody techniques grew 
into a major research field, offering the possibility of abandoning 
 36 
 
conventional immunisation procedures for the isolation of specific 
monoclonal antibodies. Moving beyond recombinant antibodies phage 
display has been applied in a wide range of protein engineering 
applications. 
 
 
 
 
 
 
Figure 1.10. Principle of biopanning. A highly diverse phage library is 
applied to a binding surface (typically between 1010 and 1012 virions). Non-
specific phage are removed by washing and bound phage are eluted by 
chemical or enzymic disruption of binding. Eluted phage are used to infect 
bacterial host and a new enriched library is produced. The process can be 
repeated until a desired population of phage clones is obtained. 
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Coupled with a suitable screening strategy phage display has been 
used to isolate novel variants of enzymes with new properties. 
Used in conjunction with mutagenesis phage techniques have been 
used to study the molecular evolution of proteins (Giordano et al., 
2001). Phage display has also been used to express and select a range 
of different proteins, receptors, and enzymes, including growth 
hormone. In addition to enzymes and receptors phage display has been 
used to express and select variants of a peptide hormone. In this study 
growth hormone was expressed as a fusion with phage protein cpIII and 
displayed on the phage surface (Bass et al., 1990). This enabled the 
functional selection of hormone mutants and probing of ligand/receptor 
interactions (Wells et al., 1993).  
1.6 Hypothesis and Aims 
Leptin is polypeptide hormone with pleiotropic effects on human 
physiology. Leptin has central effects on energy homeostasis via the 
central nervous system and direct effects on different tissues. In 
addition to its role in metabolism there is evidence that leptin can 
modulate the immune response and may play a role in a number of 
inflammatory diseases. The availability of novel leptin variants with 
modified receptor binding properties would enable the production of 
agonists and antagonists that can be used experimentally to probe the 
role of leptin in a number of physiological processes and may have 
therapeutic utility.  
The goals of this project are to achieve the expression of functional 
leptin on the surface of filamentous phage. A highly variable random 
mutant library of leptins will be produced and a selective strategy 
developed that will enable the enrichment of novel leptin muteins with 
enhanced receptor binding affinity. Selected clones will be converted to 
antagonists by site–directed mutagenesis, expressed and purified and 
assessed for their ability to modulate leptin signalling. 
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Our hypothesis is that by examining the relationship of functional 
domains of leptin it will be possible to devise an expression system that 
will allow the appropriate folding and display of active leptin on the 
surface of filamentous phage. Once this is confirmed this display 
approach will be then used to generate a diverse library of leptin 
mutants which will potentially contain novel variants with modified 
binding properties. Our second hypothesis is that through the use of 
appropriate binding and elution kinetics we will be able to select novel 
leptin mutants from this library with increased affinity for the leptin 
receptor. These mutants may have utility as leptin agonists and 
antagonists with potential therapeutic applications. 
Hyperleptinaemia and leptin resistance are both central features of 
morbid obesity and the development of superagonists may find use in 
addressing this problem. Increased affinity for the leptin receptor may 
allow more penetration of leptin into the brain and increased signalling 
in the arcuate nucleus and contribute to re-establishing normal 
regulation of satiety and appetite. Increasing evidence for pro-
inflammatory effects of leptin produced by central adipose tissue 
indicates that leptin antagonists may prove useful in the treatment of a 
range of clearly inflammatory conditions such as rheumatoid arthritis 
and other comorbidities associated with obesity such as cardiovascular 
disease, which is believed to driven in part by leptin-induced low level 
inflammation and direct effects on the vasculature. Disturbance of 
insulin production and signalling is another major complication of 
morbid obesity and in this case novel leptin antagonists may be used to 
ameliorate the effects of leptin on insulin signalling and glucose 
homeostasis. 
  
 39 
 
 
 
Chart showing planned strategy of project 
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Chapter Two  
 
 
 
 
 
Materials and Methods 
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2.1 Materials 
2.1.1 Suppliers of reagents and equipment 
Amersham Pharmacia Biotech    Little Chalfont, UK 
Applied Biosystems     Foster City, Ca, USA 
Bio-Rad Laboratories    Hemel Hempstead, UK 
Cambridge Biosciences    Cambridge, UK 
Costar      Cambridge, UK 
ECACC        Porton Down, UK 
Eppendorf      Cambridge, UK 
Fisher       Loughborough, UK 
Geneflow        Staffordshire, UK 
Gibco       Paisley, UK 
Invitrogen        Paisley, UK 
Merck BDH        Lutterworth, UK 
Melford laboratories        Ipswich, UK 
Millipore         Bedford, USA 
MWG Biotech     Munich, Germany 
Nalgene Nunc International      Paisley, UK 
New England Biolabs       Massachusetts, USA 
Oxoid       Basingstoke, UK 
Pierce       Rockford, IL, USA 
Promega        Southampton, UK 
Qiagen Ltd        Crawley, UK 
Roche Diagnostics       Mannheim, Germany 
R&D Systems       Abingdon, UK 
Santa Cruz Biotechnology      Santa Cruz, SA 
Sigma-Aldrich       Poole, UK 
Sorvall      Stevenage, UK 
Stratagene        La Jolla, USA 
Syngene      Staffordshire, UK 
Unicam      Cambridge, UK 
VWR       Lutterworth, UK 
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2.1.2 Bacterial growth media 
All chemicals from SIgma-Aldrich unless indicated. 
SOC medium (1 L) 
Bacto Tryptone (VWR) 20 g 
Bacto Yeast Extract (VWR) 5 g 
5M NaCl.  2 ml 
1M KCl.  2.5 ml 
MgCl2 10 ml 
MgSO4 10 ml 
1M glucose 20 ml 
 
Luria-Bertani (LB) medium  (1 L) 
Bacto-tryptone (VWR) 10 g 
Bacto Yeast Extract (VWR) 5 g 
NaCl 10 g 
Adjust to pH 7.5 with NaOH. Make up to 1 L with distilled water 
For solid media add 15 g Bacto-Agar (VWR) 
 
2 x YT medium (1 L) 
Bacto-tryptone (VWR) 16 g 
Bacto Yeast Extract (VWR) 10 g 
NaCl 5 g 
Adjust to pH 7.0 with NaOH. Make up to 1 L with distilled water 
For solid media add 15 g Bacto-Agar (VWR) 
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2.1.3. Plasmids, Bacterial Strains and Cell Cultures. 
The plasmids, bacteria and the cell lines which are used throughout this 
study are listed in the following table. 
 
 
Material Source 
pcDNA3-OB-Rb Dr. B Carpenter 
pJuFo 
Prof Reto Crameri, SIAF, Davos, 
Switzerland. 
pET21a(+) Merck, Nottingham, UK 
pComb3 
Dr. C Barbas, Scripps Research Institute, 
San Diego, USA 
XL1 -Blue E. coli strain Agilent Technologies, Stockport, UK 
BL-21(DE3)pLys Agilent Technologies, Stockport, UK 
VCSM13 helper phage Agilent Technologies, Stockport, UK 
CHO-K1. Chinese hamster 
ovary 
European Collection of Animal Cell 
Cultures 
HEK298. Human embryonic 
kidney cells 
ECACC  
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2.1.4 Antibiotics  
Medium and cell culture involved in the final concentration of antibiotics 
that prepared by sterilised and filtration and then stored as 1000 fold 
stock. 
Antibiotic Diluent Final 
Concentration 
Supplier 
Ampicillin distilled water 100 µg/ml Sigma-Aldrich 
Chloramphenicol 50% ethanol / H2O 30 µg/ml Sigma-Aldrich 
Kanamycin distilled water 15 µg/ml Sigma-Aldrich 
Tetracycline 50% ethanol / H2O 15 µg/ml Sigma-Aldrich 
 
2.1.5 Buffers 
All chemicals from Sigma-Aldrich unless indicated. 
Phage Elution Buffer 
Glycine  200 mM pH 2.2 
Phage Neutralising Buffer 
Tris Base 2M (pH unadjusted) 
Phage Precipitation Buffer 
PEG 6000 20% 
NaCl 2.5 M 
 
ELISA Coating Buffer 
Na2CO3 
Na2HCO3 
NaN3 
 
Phosphate Buffered Saline (10x) 
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NaCl  80 g 
KCl  2 g 
Na2HPO4  14.4 g 
KH2PO4 2.4 g  
Adjust pH to 7.4 
 
Tris Buffered Saline (TBS) (10x) 
Tris  60.6 g 
NaCl  87.6 g 
Adjust pH to 7.4 with 1 M HCl 
 
Blocking Buffer 
BSA 3 g 
10xTBS 10 ml 
Add distilled water to 100 ml  
 
TAE (50x) (1 L) 
EDTA  (500 mM) 
TRIS Base 120 g 
Add distilled water to 1 L 
 
SDS-PAGE Running Buffer 
Tris (Sigma) 25 mM (pH 8.8) 
Glycine 192 mM 
SDS (Sigma) 0.1% (w:v) 
 
SDS-PAGE Sample Buffer (2x) 
Tris-HCl 50 mM 
SDS  4% (w:v) 
Glycerol  20% (v:v) 
Bromophenol blue  0.004% (w:v) 
2-mercaptoethanol 10% (v:v) 
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SDS-PAGE Transfer Buffer 
Tris-HCl (pH 8.8) 10 mM 
Glycine 192 mM 
SDS 0.05% (w:v) 
 
Acrylamide/Bisacrylamide 
40% acrylamide/bisacrylamide (37.5:1) (BioRad). 
 
Ammonium persulphate 
2% (v:w) ammonium persulphate was made in sterile deionised H2O. 
12% Polyacrylamide Gel 
Running buffer   30 ml 
Acrylamide/bisacrylamide   12.5 ml 
Ammonium persulphate (2%)   1 ml 
Deionised H2O  11.5 ml 
TEMED  20 µl 
 
4% Polyacrylamide Stacking Gel 
Stacking buffer   10 ml 
Acrylamide/Bisacrylamide   2 ml 
Ammonium persulphate (2%)  500 µl 
Deionised H2O  7.5 ml 
TEMED                   15 µl 
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2.2 General Methods 
2.2.1 Isolation of plasmid DNA 
Small scale miniprep DNA was prepared using the Wizard miniprep kit 
(Promega). A single colony was picked from freshly streaked agar plate 
and used to inoculate a 10 ml culture of LB medium (60 µg/ml 
ampicillin; 1% glucose (w:v)). The culture was grown overnight in a 
37°C shaking incubator at 200 rpm. The next day the bacterial cells 
were pelleted by centrifugation at 2000 xg for 10 min, and the pellet was 
resuspended in 250 µl of cell resuspension solution (50 mM Tris-HCl pH 
7.5, 10 mM EDTA, and 100 µg RNAse) and transferred to an eppendorf 
tube. Bacteria were lysed by the addition of 250 µl cell lysis buffer (0.2 
M NaOH, 1% SDS) and gently mixed before incubation at room 
temperature for 5 min. The lysate was neutralised by addition of 300 µl 
neutralisation buffer (1.32 M potassium acetate), mixed gently by 
inversion and centrifuged at 13,000 xg for 5 min. The cleared 
supernatant was mixed with 500 µl of column binding buffer and bound 
to a Qiagen purification column. The column was washed using 750 µl 
of column wash solution (80 mM potassium acetate 8.3, mM Tris-HCl 
pH 7.5, 40 mM EDTA, 55% ethanol) and residual ethanol removed by 
centrifugation at 13,000 xg for 5 min. DNA was eluted by the addition of 
50 µl of deionised H2O and centrifugation at 13,000 xg for 10 min. 
2.2.2 PCR Amplification 
Routine PCR amplification was carried out using Promega GoTaq hot 
start DNA polymerase. Primers were made up to a 100 pmol/µl stock 
dilution in TE buffer and used to make a working dilution of 1 pmol/µl of 
each primer. A typical reaction was a volume of 50 µl containing the 
following components: 
 
Promega reaction buffer (10x)   5 µl 
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dNTPs (10 µM)  1 µl  
Mg2+ buffer (25 mM)   5 µl 
primers (1 pmol/µl each)   2 µl  
H2O  40 µl 
Hot Start GoTaq (5U/µl)   0.2 µl  
 
A typical amplification was carried out using the following parameters: 
The reactions were cycled using the following parameters: 
Enzyme activation 95°C  2 min 
30 cycles of: 
Denaturation 94°C  1 min 
Annealing 55°C  1 min 
Extension 72°C  1 min 
 
The amplification was completed with a polishing step at 72°C for 5 min 
2.2.3 Restriction Digest of DNA 
Restriction enzymes and restriction reaction buffers were obtained from 
Promega. 
A typical digestion reaction comprised the following: 
DNA  5 µg 
Reaction buffer (10X) 10 µl 
Enzyme (10 U/µl)    5 µl 
H2O up to 100 µl  
 
Reactions were incubated at the appropriate temperature for 2 hours. 
Samples were analysed by agarose gel to ensure complete digestion of 
each reaction.  
2.2.4 Agarose gel electrophoresis 
All agarose gels were prepared in TAE buffer and heated for 1-2 min in 
a microwave oven. The molten agarose (30 ml) was cooled, ethidium 
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bromide added, and poured into the casting deck of a minigel tank. The 
gel was covered with TAE buffer and the sample, mixed 1:10 with 
loading dye (0.25% bromophenol blue, 0.25 % xylene cyanol, 30 % 
glycerol). A voltage of 100V was applied for 15-30 min and visualized 
on a UV transilluminator and captured using a video camera unit. 
 
2.2.5 Purification of DNA fragments from agarose gels 
Linearised vector DNA and PCR products were purified by agarose gel 
electrophoresis. Agarose gels were cast with a single slot well and 
samples loaded (typically 100 µl). PCR products were resolved by 
running at 70 V for 40 min. Large DNA fragments were resolved by 
running overnight at 30 V. DNA bands were identified under long 
wavelength UV light and excised with a scalpel. DNA was extracted 
using the PCR-Prep kit (Qiagen) using manufacturer’s instructions. Gel 
fragments were dissolved in 800 µl of membrane binding buffer, 
captured on binding columns and washed with wash solution. DNA was 
eluted with 60 µl of TE and quantified by Nanodrop. 
2.2.6 Ligation of DNA fragments 
Ligations were carried out in a volume of 20 µl with an insert/vector ratio 
of 3:1. DNA concentrations were estimated from imaging of agarose 
gels. T4 DNA ligase and buffer were obtained from Promega. 
Ligation reactions were set up as follows: 
Vector  100 ng 
Insert  60 ng 
Ligase buffer  2 µl 
DNA ligase  1-5 µl 
H2O to a final volume 20 µl. 
Reaction was incubated overnight at 15ºC.  
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2.2.7 Heat shock transformation of E coli 
A 50 µl aliquot of commercial competent E.coli was thawed on ice, 3 µl 
of plasmid DNA or ligation reaction was added to the vial and mixed 
gently, and incubated on ice for 5 min. The tube was transferred to a 
preheated water bath at 42˚C for 30 seconds and rapidly placed on ice 
and allowed to chill for 2 min. Cells were recovered in 250 µl of SOC 
medium at 37°C for 1 hour and an aliquot of transformed cells plated 
onto an LB agar plate containing appropriate selective antibiotics and 
incubated overnight at 37˚C. Random colonies were picked from the 
plate and sub cultured into 10ml medium containing appropriate 
antibiotics and incubated at 37˚C in shaking incubator. DNA was 
extracted by miniprep and tested by sequencing analysis. 
2.2.8 Electroporation of E coli (XL1-Blue 
For library synthesis electrocompetent TG1 cells were used (Lucigen, 
Cambridge, UK). A 50 µl aliquot of was thawed on ice and placed in 0.1 
cm cuvette (Invitrogen). 5 µl of ligated DNA was mixed with the cells 
and the cuvette placed into the electroporator (E.coli Pulser, BioRad) 
and a pulse of 1700 V applied. The cuvette was removed from the 
electroporator and the cells flushed out with 2 ml SOC medium 
(GIBCO), and incubated at 37°C with shaking for 1 hour. A 2 µl aliquot 
of electroporated cells was plated out onto selective agar media and 
incubated overnight at 37°C to assess the efficiency of transformation. 
The remaining culture was added to 1 L of LB medium for phage 
rescue. Sixty random colonies were picked from the agar plate and 
transferred into 10 ml medium containing appropriate antibiotics and 
grown overnight in a 37°C shaking incubator. Plasmid DNA was 
extracted from each culture by miniprep and sequence analysis. 
2.2.9 Phage rescue 
Library phage rescue is a process used to convert phage library into 
phage particles prior to enrichment. 10 ml of 2xYT media containing 
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appropriate antibiotics, inoculated with 10 µl of cells contain phagemid 
DNA, and grown at 37°C. After turbidity of the culture reached 
approximately 0.6 OD600nm units 50 µl of helper phage (VCMS13) was 
added to the culture and incubated at 37°C for 20 min. The infected 
culture was then grown overnight at 200 rpm and 37°C to produce 
phage particles. The following day the culture was centrifuged for 20 
min at 2,000 g. The cleared supernatant was transferred to a glass 
cylinder tube containing 10 ml each of 5M NaCl and 40% PEG 4000, 
mixed and incubated in ice pocket for 2 hours to precipitate phage. The 
mixture was centrifuged for 30 min at 2,000 g; the pellet was collected 
and resuspended in 1 ml of PBS/Tween. Stocks were titered to 
determine the phage concentration and stored at -80°C. 
2.2.10 Phage titration  
XL1-Blue host was grown to an OD600nm of approximately 0.8 in LB 
containing tetracycline (20 µg/ml). Samples of phage were diluted 
serially in the range of 10-4 and 10-5 and 10 µl aliquots used to infect 1 
ml of mid-log XL1-Blue host. Infection was carried out for 30 min at 
37°C and then aliquots of the infected culture were plated onto selective 
agar media. The plates were incubated overnight at 37°C and the 
number of resistant colonies determined by counting. Each titering 
procedure included an uninfected host sample to verify contamination 
had not taken place. The phage titre was calculated from the number of 
colonies obtained and dilution of the sample. 
2.2.11 Protein estimation by Bradford assay 
Bradford assay was used for the rapid estimation of protein 
concentration. The assay was calibrated using a standard curve 
produced from a range of BSA concentrations in distilled H2O. Samples 
were measured using serial dilutions ranging from 50 µg/ml to 1.25 
µg/ml. Protein was detected by the mixing of 800 µl from each sample 
dilution with 200 µl of the Bradford reagent. The reaction was incubated 
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for 5 min at room temperature and absorbance measured by 
spectrophotometer at 595 nm. Results were plotted graphically and 
related to the BSA standard curve to determine protein concentration 
(Sambrook and Gething, 1989).  
2.2.12 SDS-PAGE 
SDS-PAGE analysis was performed as described by Laemmli 
(Laemmli, 1970) using a Miniprotean II apparatus (Bio-Rad). Plates 
were cleaned thoroughly and assembled with 1 mm spacers. Buffer 
recipes and gel preparation were as described by Sambrook and 
Russell (Sambrook and Russell, 2001). Acrylamide gels were 15% 
unless stated in the text. When necessary samples were reduced by 
treatment with DTT (50 mM) prior to gel analysis. Gels were typically 
run at 150 volts for 30 min then 40 volts until the dye front reached the 
bottom of the gel. Gels were visualized by staining with Coomassie 
brilliant blue for 1 hour at room temperature, followed by destaining for 
90 minutes at room temperature. 
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CHAPTER 3  
 
 
 
 
Phage Surface Display of Human 
Leptin 
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 3.1 Introduction 
The initial goal of this project was to investigate whether functional 
leptin could be expressed on the surface of phage virions. It was 
already established that leptin from a range of species could be 
expressed in a bacterial host (Campfield et al., 1995, Altmann et al., 
1995, Gertler et al., 1998). However, in all cases the protein was 
expressed as inclusion bodies and required refolding for biological 
activity. Clearly this would be unsuitable for phage display applications. 
Leptin is a non-glycosylated peptide hormone that contains a number of 
disulphide bonds. Expression and folding of recombinant proteins in an 
E coli host can be problematic given the redox potential of the bacterial 
cytoplasm and lack of mammalian chaperone proteins (Francis and 
Page, 2010). Structural analysis of leptin showed that a critical 
disulphide bond is formed between Cys96 and Cys146 at the carboxy 
terminus (Zhang et al., 1997). This interchain bond is essential for 
correct folding and biological activity and in addition has been shown to 
be critical for secretion (Boute et al., 2004). Thus it was not clear that it 
would be possible to produce and export functional leptin from a 
bacterial host without the need for refolding. 
Previous studies, in particular of immunoglobulin fragments in E coli 
provided evidence that it was possible to form disulphide bond 
formation during if the proteins were exported into the periplasm during 
heterologous expression (Skerra and Pluckthun, 1988, Better et al., 
1988). This suggested at least the potential for leptin to be secreted in 
active form. A second concern was the importance of the carboxy 
terminus of leptin with regard to receptor binding. The most common 
approach to phage display of peptides and polypeptides is to fuse their 
coding sequences to the amino terminal coding region of coat protein 
cpIII. This is described in the schematic diagram of commonly used 
phage display vector pCOMB3 (Fig. 3.1). As discussed in chapter 1 one 
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of the major receptor binding sites of leptin, Site III, includes residues 
located at the tip of the D Helix which is located at the carboxy terminus 
of leptin. As the most common approach to phage display involves the 
creation of fusion proteins to the amino terminus of coat protein cpIII, 
there was the potential for steric hindrance or otherwise disruption of 
this binding site. Interestingly, human growth hormone was successfully 
expressed on the phage surface using this cpIII fusion approach 
(Lowman and Wells, 1993). Similarly to leptin growth hormone is a 
member of the class I cytokine family and thus suggests the possibility 
that this technique could be applied to leptin. 
Attempts to express cDNA libraries on the surface of phage also 
encountered difficulties with the cpIII amino-terminal fusion approach. 
Most cDNA libraries produce inserts with stop codons and poly-A 
stretches at the 3’ end. This means that reading through into the cpIII 
fusion partner would be prevented for most inserts. To circumvent this 
Crameri and Suter developed an alternate indirect phage display 
approach (Crameri and Suter, 1993). In the pJUFO vector the cpIII 
gene is fused to the leucine zipper domain of the jun transcription 
factor. A second promoter drives expression of the leucine zipper 
domain of the fos transcription factor which is expressed as an amino 
terminal fusion to cDNA inserts. Co-expression of these two moieties 
and translocation to the bacterial periplasm leads to dimerisation of the 
jun and fos domains and indirect physical tethering of the cDNA 
encoded polypeptide to the phage surface (Fig. 3.2). The advantage of 
this approach is that the placing the cDNA sequence at the 5’ end of the 
fusion protein prevents interruption of expression by potential stop 
codons. With respect to leptin expression this vector would leave the 
carboxy-terminal domain of the hormone free for potential interactions 
with the receptor. We aimed to explore both of these approaches to the 
expression of functional leptin on the phage surface. 
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Figure 3.1. Schematic diagram of phage display vector pCOMB3.  
The vector comprises a lacZ promoter which drives expression of phage coat 
protein III (cpIII) amino terminal fusions.  Secretion of fusion proteins into the 
periplasm is directed by the pelB secretion leader. The f1 origin allows the 
rescue and packaging of pCOMB3 as phage. 
 
 
 
Figure 3.2 Schematic diagram of phage display vector pJUFO. 
Expression of leucine zipper jun fused to coat protein cpIII is driven by a lacZ 
promoter and directed to the periplasm by secretion leader pelB. Displayed 
genes are cloned downstream of the fos leucine zipper gene as a carboxy 
terminal fusion and secreted into the periplasm. Fos and jun dimerise in the 
periplasm to indirectly link expressed polypeptides to phage coat protein. 
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If phage expression can be achieved the next goal would be to develop 
a selection strategy that could be used to enrich leptin mutants. This 
strategy will focus on the use of commercial recombinant leptin 
receptor. The receptor will be immobilised on a plastic surface and use 
to specifically bind leptin phage. Successful phage selection strategies 
have been developed for phage antibodies. Studies have demonstrated 
the importance of the kinetic conditions during selection (Duenas et al., 
1996). Phage display presents a number of difficulties in controlling the 
kinetics of binding and recovery. The most commonly used phage 
display vectors involve the expression of both recombinant and wild-
type virion coat proteins. Proteolytic breakdown of heterologous fusion 
proteins in the cytoplasm and the contribution of wild-type coat proteins 
from helper phage mean that many of the expressed phage are “bald”, 
that is they comprise only wild-type coat proteins (Baek et al., 2002).  
Given that we are attempting the selection of high affinity leptin mutants 
then the ratio of phage-leptin to leptin receptor may be a key factor in 
the success or failure of the strategy. To establish a competitive binding 
scenario would require that the receptor binding sites were the limiting 
factor during selection. In the case of phage antibodies, selection of 
high affinity variants has been achieved by limiting the availability of 
antigen to provide suitable kinetic conditions to establish competition 
between large libraries of variable antibodies (Hawkins et al., 1992). In 
this study the leptin receptor will be coated directly onto ELISA wells 
and the efficiency of capture will be difficult to determine. Further, as it 
is technically very challenging to determine the valency of leptin 
expression on the phage particles and the number of “bald” phage then 
this may require an empirical approach. The inclusion of denaturants 
could be used as an approach to destabilise leptin-phage binding and 
so select for higher affinity mutants. Urea has been employed as a 
denaturant to enable the selection of proteins with increased folding 
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stability from phage libraries (Shin et al., 2006). Other chemicals such 
as diethylamine have been used to destabilise antibody-antigen 
interactions as a strategy for phage selection of high affinity variants 
(Schier and Marks, 1996). We will investigate this approach and study 
the effects of leptin-phage binding in the presence of denaturants. 
The goals of this part of the study are to investigate the possibility of 
expression functional leptin on the surface of filamentous phage and 
then use this technique to establish a selection strategy for high affinity 
variants. 
3.2 Methods 
3.2.1 Cloning of leptin cDNA into phage display vectors pCOMB3 
and pJUFO 
The starting template was leptin E100 in obtained in the form of an 
expression plasmid construct pet21a-E100 (a gift from Dr. B Carpenter). 
It has been previously shown that substitution of a tryptophan by 
glutamine at position 100 increases solubility of recombinant leptin 
(Zhang et al., 1997) without effects on binding or function. We decided 
to use leptin-E100 as starting material for our study in order that we 
would be able to obtain good yields of recombinant proteins when they 
were ultimately expressed and purified. For the purposes of this study, 
and as its properties are unchanged with regard to binding and 
signalling, we refer to this as wild-type leptin (wt-leptin). 
The pET21a-E100 plasmid was diluted 1:1000 in distilled water to 
provide PCR template DNA. Primers were designed to amplify the 
coding region of leptin (excluding the secretion leader). Two sets of 
primers were designed to enable the cloning of the cDNA fragment into 
the two phage display vectors pCOMB3 and pJUFO (Table 3.1).  
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Table 3.1. primers used for amplification and cloning of leptin 
cDNA into phage display vectors.  Primers pc-ob-1 and pc-ob-2 were 
used to cloned human leptin cDNA into phage display vector pCOMB3. 
The forward primer pc-ob-1 contained a Xho I restriction site 
(underlined) and the reverse primer contained a Spe I restriction site. 
Primers jufo-ob-1 and jufo-ob-2 (forward and reverse respectively) were 
used to amplify leptin cDNA for cloning into the pJUFO and contained 
restriction sites for Xba I and Kpn I (underlined). Primers pcomb-1 and 
jufo-seq were used as sequencing primers to confirm the constructs. 
 
The PCR reactions were set up as follows:  
(GoTaq Hot Start Reagents , Promega) 
Template DNA (2 ng/µl)    2 µl 
GoTaq polymerase (5 U/µl)  0.25 µl 
Taq reaction buffer (5x)     10 µl 
MgCl2 (25 mM)       5 µl 
dNTPs (10 µM)       1 µl 
Primer mix (forward + reverse; 1 pmol/ul)       2 µl 
H2O     29 µl 
The reactions were cycled using the following parameters: 
Enzyme activation 95°C 2 min 
30 cycles of: 
Denaturation 94°C 1 min 
Annealing 55°C 1 min 
Extension 72°C 1 min 
 
Primer  
pc-ob-1 GCGCGCCTCGAGGTGCCCATCCAAAAAGTCCAAGATGAC 
pc-ob-2 GCGCGCACTAGTGCACCCAGGGCTGAGGTCCAGCTGCCA 
jufo-ob-1 GCGCGCTCTAGAGTGCCCATCCAAAAAGTCCAAGATGAC 
jufo-ob-2 GCGCGCGGTACCTTATCAGCACCCAGGGCTGAGGTCCAGCTGCCA 
pcomb-1 GGTGGCGGCCGCAAATTC 
jufo-seq TACGGCAGCCGCTGGAT 
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The amplification was completed with a polishing step at 72°C for 5 min.  
The reactions were analysed by agarose gel electrophoresis (2.2.4) and 
PCR products purified using a QIAquick kit (Qiagen) (2.2.5). 
10 µg of phage vector pCOMB3 was digested in a 100 µl reaction with 
10 units each of Xho I and Spe I in reaction buffer B (Promega). The 
reaction was incubated for 5 hours at 37°C. 10 µg of phage vector 
pJUFO was digested in a 100 µl reaction with 10 units each of Xba I 
and Kpn I in reaction buffer D (Promega). The reaction was incubated 
for 5 hours at 37°C. Digested vectors were purified by slot gel agarose 
electrophoresis (2.2.4) and extracted with a DNA extraction kit (2.2.5). 
The concentration of purified DNA was estimated by Nanodrop.  
The leptin cDNA amplification products were purified and 5 µg of each 
was digested with the appropriate enzyme combinations (pCOMB3 - 
Xho I/Spe I; pJUFO – Xba I/Kpn I) for 5 hours at 37°C. Digests were 
resolved by agarose gel electrophoresis, excised, and purified using the 
QIAquick kit (2.2.5). 50 ng of each product was ligated into 100 ng of 
digested phage vector (2.2.6) overnight at 15°C and transformed into 
XL1-Blue competent cells (2.2.7). Transformed cells were plated out 
overnight on LB-agar (ampicillin 60 µg/ml; tetracycline 20 µg/ml). Single 
colonies were picked and used to produce plasmid miniprep DNA 
(2.2.1). Constructs were confirmed by sequencing. The constructs were 
named pc3-ob and jufo-ob. 
Phage particles were produced from each plasmid by phage rescue. 10 
ml cultures of pc3-ob and jufo-ob were grown in LB media (ampicillin 60 
µg/ml, tetracycline 20 µg/ml) until the OD600nm reached 0.8. 100 µl of 
VCMS13 helper phage was added and allowed to infect the cultures for 
30 min at 37°C without shaking. The cultures were inoculated into 100 
ml of 2xYT medium (ampicillin 60 µg/ml, tetracycline 20 µg/ml, 
kanamycin 30 µg/ml) and grown overnight in a shaking incubator at 
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37°C and 200 rpm. The following day the phage cultures were 
centrifuged at 4,000 rpm for 30 min to pellet bacterial cells. Phage 
particles were precipitated by the addition of 10 ml of 5 M NaCl and 10 
ml of 40% PEG-6000 and incubation on ice for 2 hours. Phage particles 
were recovered by centrifugation at 4,000 xg for 30 min and 
resuspended in PBS/Tween (0.1% v:v). The concentration of phage 
was determined by titration (2.2.9), adjusted to 1010 virions per ml and 
stored at -80°C. 
3.2.2 Generation of high affinity leptin control by site-directed 
mutagenesis 
In order to investigate the binding characteristics of mutant leptins it 
was necessary to produce a control leptin mutant with high affinity. 
Gertler et. al. described a leptin mutant in which an aspartic acid at 
position 23 was substituted with leucine (L23). This variant exhibited an 
an approximately 30-fold increase in affinity for the leptin receptor 
(Gertler and Elinav, 2014). To prepare this mutant we used a PCR site-
directed mutation technique. The starting template was phage vector 
pJUFO containing leptin cDNA (pjufo-ob). 
The codon mutation was introduced using the Q5 mutagenesis kit (New 
England Biolabs). The principle of this technique is to produce a linear 
PCR product in which the desired mutation is introduced at the 5’ end of 
either the forward or reverse primers. Following inverse PCR 
amplification using a high fidelity DNA polymerase the reaction mixture 
is treated with a combination of a kinase, ligase, and restriction enzyme 
Dpn I. The de novo DNA lacks methylation and so is resistant to Dpn I 
digestion. This results in the degradation of the original template DNA 
and blunt-ended ligation of the PCR product to create the mutated 
circular plasmid which is then transformed into host bacteria (Li et al., 
2008).  
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L23-1 CTCATTTCACACACGCAGTCAGTCTCCT 
L23-2 ATTGATCCTGGTGACAATTGTCTTGATG 
 
Table 3.2 Primers used to generate leptin L23.  The forward primer 
L23-1 introduced a leucine codon (shown underlined) at position 21 of human 
leptin coding sequence. The 5’ end of the reverse primer L23-2 corresponds to 
the preceding codon (22) in the antisense direction.  
 
 
A number of colonies were picked for confirmation by minprep (2.2.1) 
and sequencing, and phage produced by phage rescue (2.2.9). 
 
3.2.3 Leptin receptor binding assay 
As a source of pure leptin receptor we used a commercial preparation 
of leptin receptor extracellular domain fused to the Fc domain of human 
IgG (R & D Systems, Oxford). The receptor was diluted to a 
concentration of 100 µg/ml in PBS and coated onto ELISA wells in 50 µl 
of coating buffer. To establish the optimum coating density of receptor, 
both in terms of economy and efficiency a range of concentrations were 
investigated from 12.5 ng/µl to 500 ng/µl. Aliquots of leptin-Fc were 
coated overnight at 4°C. The next day wells were blocked with 400 µl of 
1% BSA/PBS for 1 hour at room temperature. Wells were washed 5 x 
with 400 µl of PBS/Tween (0.1% v:v). 50 µl of biotinylated leptin (20 nM) 
was added to the wells and incubated for 1 hour at room temperature. 
The wells were washed 8 x with 400 µl PBS/Tween. 50 µl of 
streptavidin-horseradish peroxidase conjugate (1:10,000; Sigma, UK) 
was added and incubated for 30 min at room temperature. Wells were 
washed 8 x with 400 µl of PBS/Tween and developed with 50 µl of 
3,3’,5,5’ tetramethylbenzidine substrate (Promega, UK). After 
developing for 15 min at room temperature the reaction was stopped by 
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the addition of 50 µl of 0.2 M H2SO4 and the OD450nm was determined in 
a plate reader. 
Recombinant human leptin (Sigma, UK) was biotinylated using the EZ-
Link sulfo-NHS-biotin reagent (Thermo-Scientific, UK). Following the 
manufacturer’s protocol 1 ml of human leptin (1 mg/ml; 62.4 µM; in 
PBS) was mixed with 125 µl of EZ-link-NHS biotin reagent (10 mM) to 
produce a 20-fold molar excess of biotin. The reaction was incubated 
for 20 min on ice and then quenched with 10 ul of 1 M Tris pH 7.0 to 
stop the reaction. Excess biotin and salts were removed by passing the 
mixture down a desalting column (Zeba Spin; Thermo-Scientific). The 
leptin protein concentration was determined using Nanodrop analysis 
and adjusted to a 50 µM stock solution and stored at -80°C. 
Phage binding to immobilised leptin receptor was measured initially by 
two methods; elution and immunodetection.  
Phage binding and elution 
ELISA wells were coated overnight at 4°C with 50 µl of leptin receptor-fc 
fusion protein at a concentration of 250 ng/µl in coating buffer. The next 
day wells were blocked with 400 µl of 1% BSA/PBS for 1 hour at room 
temperature. Wells were washed 5 x with 400 µl of PBS/Tween (0.1% 
v:v). 100 µl of phage suspension (1010 virions/ml) were added and 
allowed to bind for 1 hour at room temperature. The wells were washed 
8 x with PBS/Tween and bound phage eluted by 15 min of incubation 
with 100 µl of 0.2 M glycine pH 2.2. Eluted phage were used to infect 1 
ml of mid log XL1-Blue host culture for 30 min at 37°C. Aliquots of 
infected host were spread on LB-agar (ampicillin 60 µg/ml), incubated 
overnight at 37°C and the number of infective phage determined the 
next day by colony counting. 
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Immunodetection of phage binding 
ELISA wells were coated overnight at 4°C with 50 µl of leptin receptor-fc 
fusion protein at a concentration of 250 ng/µl in coating buffer. The next 
day wells were blocked with 400 µl of 1% BSA/PBS for 1 hour at room 
temperature. Wells were washed 5 times with 400 µl of PBS/Tween 
(0.1% v:v). 100 µl of phage suspension (1010 virions/ml) were added 
and allowed to bind for 1 hour at room temperature. The wells were 
washed 8 times with PBS/Tween and 60 µl of anti-M13 horseradish 
peroxidase antibody (1:10,000 in PBS/Tween) added (GE Healthcare, 
UK). The wells were incubated for 1 hour at room temperature and then 
washed 8 times with 400 µl of PBS/Tween. Wells were then developed 
by the addition of 50 µl of 3,3’,5,5’ tetramethylbenzidine substrate 
(Promega, UK). After developing for 15 min at room temperature the 
reaction was stopped by the addition of 50 µl of 0.2 M H2SO4 and the 
OD450nm determined in a plate reader. 
3.2.4 Binding of leptin-phage in the presence of denaturants 
ELISA wells were coated with leptin receptor-fc fusion protein (50 µl of 
250 ng/ml in coating buffer) overnight at 4°C. The following day the 
wells were blocked with 400 µl of 1% BSA in PBS for 1 hour at room 
temperature. Wells were washed 5 x with PBS/Tween. 100 µl aliquots 
of phage (1010 pfu/ml) were mixed with a range of concentrations of 
denaturant and added to the receptor-coated well. Two denaturants 
were investigated, urea and diethylamine, both used routinely in protein 
folding studies and antibody affinity analysis. Wells were incubated for 1 
hour at room temperature and then washed 8 x with PBS/Tween. 60 µl 
of anti-M13 horseradish peroxidase antibody (1:10,000 in PBS/Tween) 
added (GE Healthcare, UK) was added and the wells were incubated 
for 1 hour at room temperature and then washed 8 x with 400 µl of 
PBS/Tween. Wells were developed by the addition of 50 µl of 3,3’,5,5’ 
tetramethylbenzidine substrate (Promega, UK). After developing for 15 
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min at room temperature the reaction was stopped by the addition of 50 
µl of 0.2 M H2SO4 and the OD450nm determined in a plate reader. 
 
3.2.5 Phage binding competition by leptin 
ELISA wells were coated with leptin receptor-fc fusion protein (50 µl of 
250 ng/ml in coating buffer) overnight at 4°C. The following day the 
wells were blocked with 400 µl of 1% BSA in PBS for 1 hour at room 
temperature. Wells were washed 5 x with PBS/Tween. 100 µl aliquots 
of phage (1010 pfu/ml) were pre-mixed with recombinant human leptin 
(Sigma, UK) to produce range of competing concentrations (1 nM to 
800 nM) and added to the receptor-coated wells for 1 hour at room 
temperature. Wells were washed 8 x with PBS/Tween and 60 µl of anti-
M13 horseradish peroxidase antibody (1:10,000 in PBS/Tween) added 
(GE Healthcare, UK). Wells were incubated for 1 hour at room 
temperature and then washed 8 x with 400 µl of PBS/Tween. Wells 
were developed by the addition of 50 µl of 3,3’,5,5’ tetramethylbenzidine 
substrate (Promega, UK). After developing for 15 min at room 
temperature the reaction was stopped by the addition of 50 µl of 0.2 M 
H2SO4 and the OD450nm measured using a plate reader. 
 
3.3 Results 
3.3.1 Cloning of leptin cDNA into phage display vectors pCOMB3 
and pJUFO 
PCR amplification of the leptin E100 cDNA template produced a single 
product of approximately 400 bp for both the pCOMB3 and pJUFO 
primer pairs (Fig. 3.3). The product was purified, digested with Xho 
I/Spe I and Xba I/Kpn I respectively and ligated into the linearised 
phage vectors. The ligations were transformed into XL1-Blue competent 
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cells and plated onto LB-agar to produce colonies. Sequencing of 5 
minipreps from each transformation identified the correct constructs. 
The pCOMB3 construct contained leptin E100 cDNA cloned in-frame 
with the pelB secretion leader and coat protein cpIII (Fig. 3.4) and was 
designated pc3-ob. The pJUFO construct contained the leptin E100 
cDNA cloned in-frame with the fos leucine zipper reading frame (Fig. 
3.5). The construct was designated pc3-ob and used to produce phage 
particles by phage rescue (2.2.9). 
3.3.2 Generation of high affinity leptin control by site-directed 
mutagenesis 
The mutagenesis reaction produced a clear product of approximately 
400 bp and after enzyme treatment with kinase, ligase, and restriction 
enzyme Dpn I the self-ligated DNA was transformed into competent 
cells and grown overnight to produce colonies. 10 clones were selected 
and used to produce miniprep DNA (2.2.1) and confirmed by 
sequencing. Of the ten plasmid preps 8 showed the correct sequence 
(Fig. 3.6). This construct was termed L23 and was used to produce 
phage particles (2.2.9). 
3.3.3 Leptin receptor binding assay 
Optimisation of leptin receptor immobilisation showed that below a 
threshold concentration of 62.5 ng/ml the signal obtained from binding 
of biotinylated leptin was approaching that of background non-specific 
binding (Fig. 3.7). The concentration of biotinylated leptin was 
calculated to be in excess and so the data obtained was a qualitative 
estimate of the level of bound receptor. As the concentration of receptor 
was increased the detected signal increased and appeared to plateau 
above 250 ng/µl (Fig. 3.7). Accordingly 250 ng/µl was selected as the 
coating concentration for subsequent binding experiments.  
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Figure 3.3 PCR amplification of human leptin cDNA.  Agarose gel 
electrophoresis of PCR amplification of human leptin cDNA with primer pair 
pc-ob-1/pc-ob-2 (pCOMB3) and primer pair jufo-ob-1/jufo-ob-2 (pJUFO). Both 
reactions produced a clear product of approximately 400 bp. 
 
 
 
Figure 3.4. Sequence of pCOMB3 leptin construct. The figure shows 
the confirmed sequence of the pc3-ob plasmid construct. The leptin cDNA 
sequence is shown shaded and was insert in-frame between the pelB leader 
sequence and coat protein cpIII coding region. 
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Three different phage preparations were investigated for binding to the 
leptin receptor; pc3-ø – these were phage prepared from empty phage 
vector pCOMB3 and included as a non-specific background control; 
pc3-ob- ø – these were leptin fusion phage prepared from the pCOMB3 
leptin construct pc3-ob; and jufo-ob-ø, phage particles prepared from 
the pJUFO leptin construct jufo-ob. The experiment also contained 
uncoated wells as a background control. 
The number of colonies produced by elution of the control phage and 
leptin phage from pc3-ob from receptor-coated wells was similar to that 
obtained from uncoated control wells and represented a background 
non-specific adherence of phage particles (Fig. 3.8). As a proportion of 
phage added to the well these levels of eluting phage were 
approximately 1:106 which is typical of phage selection background 
binding levels (Smith and Scott, 1993). This indicated that there was no 
detectable functional leptin expressed on the surface of the pc3-ob 
phage. This contrasted strongly with the signal obtained from the jufo-
ob and L23 mutant phage, which showed a significant level of phage 
binding as determined by the differential in the number of infective 
phage particles eluting from the receptor coated wells. The number of 
jufo-ob phage eluting from uncoated wells was also equivalent to 
background, indicating the specific nature of the binding observed. 
From these data it was clear that fusing leptin directly to the amino 
terminus of phage coat protein cpIII rendered the molecular biologically 
inactive. Having established that functional leptin was only expressed 
on the surface of phage produced from the pJUFO vector, we focused 
on this construct for the remainder of the project. 
Using elution and plating onto solid medium as a means of determining 
phage binding proved rather unsuitable as an assay. There was a 
significant of error inherent in the process, risk of contamination given 
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the high phage titres being used, and acquiring data required 24 hours 
of incubation followed by colony counting. Accordingly we investigated 
the use of immunodetection using a commercial anti-M13 monoclonal 
antibody conjugated to horseradish peroxidase (GE Healthcare, UK). 
Repeating the leptin receptor phage binding experiment showed that 
this approach would be successful and more efficient than phage 
titering as a means of determining phage binding.  
Using wells coated with the same density of leptin receptor (250 ng/ml) 
in coating buffer we were able to demonstrate specific binding of phage 
produced from the jufo-leptin construct, and of the mutant L23 phage 
construct, also based on the pJUFO phage display vector (Fig. 3.9). 
Once again the pCOMB3 no insert control and pCOMB3-leptin phage 
showed only a background level of binding that was comparable to the 
signal obtained from uncoated ELISA wells. 
3.3.4 Binding of leptin-phage in the presence of denaturants 
Having established the functionality of the pJUFO leptin construct and 
the high affinity mutant control an attempt was made to develop 
conditions that would lead to the selection of leptin variants. The leptin-
phage preparation were bound to immobilised leptin receptor in the 
presence of different concentrations of denaturants to investigate 
whether it would be possible to discriminate the different phage 
preparations on the basis of receptor affinity. 
Binding the phage constructs in the presence of increasing levels of 
urea did not show a decrease in receptor binding as a function of urea 
concentration (Fig. 3.10). Phage binding was approximately constant 
throughout the range from 0 to 1M urea. At a concentration of 2M urea 
there an abrupt reduction in phage binding of both the jufo-ob and L23 
phage. There was no evident difference in receptor affinity under these 
conditions. 
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Figure 3.5. Sequence of pJUFO leptin construct jufo-ob. The figure 
shows the confirmed sequence of the jufo-ob plasmid construct. The leptin 
cDNA sequence is shown shaded and was insert in-frame at the 3’ end of the 
fos leucine zipper coding sequence and was terminated by a stop codon. 
 
 
Figure 3.6 Sequence of L23 mutant construct. The codon change 
introducing a leucine residue at position 23 (highlighted) and confirmed by 
sequencing.  The construct was based on the pJUFO-leptin construct jufo-ob. 
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Figure 3.7. Leptin binding assay optimisation. Recombinant leptin 
receptor (extracellular domain fused to immunoglobulin Fc domain) was 
coated onto ELISA wells at different concentrations. Efficiency of coating was 
determined by binding of biotinylated human leptin. Data shown are the mean 
of 3 experiments. 
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Figure 3.8. Phage binding to immobilised leptin receptor. Human 
leptin receptor Fc fusion protein was coated onto ELISA wells and used to 
investigate the binding properties of different phage preparations. The 
experiment included uncoated ELISA wells as a control (con). Empty control 
phage (pc-3-ø) showed only background levels of binding on both the leptin 
receptor coated wells and uncoated (con) wells, as did phage made from the 
pCOMB3 leptin construct (pc3-ob-ø). Phage from the pJUFO leptin construct, 
jufo-ob-ø showed background binding to the uncoated wells but eluted at a 
high frequency from leptin receptor coated wells. Phage from the high affinity 
L23 pJUFO construct, L23-ob-ø, also bound to the receptor coated wells. 
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When phage were bound in the presence of diethylamine (DEA) there 
was a gradual reduction in receptor binding (Fig. 3.11) with increase 
concentration of denaturant, with complete displacement at 
approximately 80 mM DEA. Both the jufo-ob and L23 phage showed 
similar responses with no apparent discrimination between the wild-type 
and high affinity mutant phage. 
3.3.5 Phage binding competition by leptin 
Figure 3.12 shows the results obtained from competitive binding of the 
phage preparations in presence of increasing concentrations of leptin. 
In the case of wild-type jufo-ob phage the binding was reduced to 50% 
of maximum at a concentration of approximately 20 mM. The high 
affinity mutant L23 phage were displaced by 50% at a concentration of 
approximately 40 nM leptin. This specific competitive approach 
appeared to be able to discriminate the wild-type and mutant leptin 
constructs. 
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Figure 3.9. ELISA determination of phage binding to immobilised 
leptin receptor.  
Human leptin receptor Fc fusion protein was coated onto ELISA wells and 
used to investigate the binding properties of different phage preparations. The 
experiment included uncoated ELISA wells as a control (con). Phage binding 
was detected using anti-M13 HRP conjugate. Data shown mean ± SD (n=3). 
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Figure 3.10. Effect of increasing urea concentration on the binding 
of leptin-phage to immobilised leptin receptor. The effect of increasing 
concentrations of urea on the binding of phage particles from control (pc3-ø ), 
pJUFO leptin construct (jufo-ob-ø) and the high affinity L23 pJUFO construct 
(L23-ob-ø) to immobilised leptin receptor. Phage binding was detected by 
ELISA using anti-M13-HRP conjugate. Data shown are mean ± SD (n=3). 
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Figure 3.11. Effect of increasing DEA concentration on the binding 
of leptin-phage to immobilised leptin receptor. Binding of control 
phage (pc-3-ø), phage from the pJUFO leptin construct (jufo-ob-ø), and high 
affinity L23 pJUFO construct (L23-ob-ø) in the presence of increasing 
concentrations of DEA was determined by ELISA using anti-M13-HRP 
conjugate. Data shown are mean ± SD (n=3). 
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Figure 3.12. Competitive binding of leptin-phage to immobilised 
leptin receptor in the presence of increasing concentrations of 
recombinant human leptin. Empty control phage (pc-3-ø) showed only 
background levels of binding. Binding of phage from the pJUFO leptin 
construct (jufo-ob-ø) was reduced increasing concentrations of leptin, and was 
50% of maximum at a leptin concentration of approximately 20 nM. A similar 
profile was obtained for binding of phage from the high affinity L23 pJUFO 
construct (L23-ob-ø) and binding was reduced to 50% of maximum at a leptin 
concetration of approximately 40 nM. Data shown are mean ± SD (n=3). 
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3.4 Discussion 
In this part of the study we successfully expressed functional leptin on 
the surface of bacteriophage. It was interesting that expression in 
phage vector pCOMB3 was unsuccessful. As this produced an amino 
terminal fusion to phage coat protein cpIII this result suggests that the 
carboxy terminus of leptin is required for biological activity. This is 
perhaps not surprising given the presence of an essential interchain 
disulphide bond involving a cysteine residue at the carboxy terminus. 
Using the pJUFO phage vector removed this obstacle and subsequent 
binding studies unequivocally demonstrated specific binding of leptin-
phage to the immobilised leptin receptor.  
Attempts to develop an elution strategy for the recovery of high affinity 
mutants initially focused on the use of denaturants to discriminate the 
wild-type from control L23 phage. These were unsuccessful. Urea did 
not produce a gradual loss of binding but instead resulted in a 
catastrophic loss of binding at a concentration of 2 M urea. This 
probably reflected unfolding of both the receptor and leptin and 
complete loss of function. It is known that phage particles are stable in 
concentrations of urea up to 6 M (Smith and Scott, 1993) so the 
likelihood is that the phage themselves were still intact and viable at the 
2M level. In protein folding studies it has previously been shown that a 
range of proteins will spontaneously unfold at concentrations of urea of 
2 M and above. It was hoped that leptin binding would be partially 
disrupted at urea levels below this, this did not prove to be the case. 
Diethylamine (DEA) and the related compound triethylamine have both 
been used previously to determine antibody affinities by disruption of 
ELISA and other binding assays and it was hoped that as a mild 
denaturant DEA would produce a gradation of disruption as the 
concentration increased. This indeed did prove the case but it did not 
lead to discrimination between the wild-type and high affinity control 
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phage. DEA is an alkaline compound and its effect on binding may not 
have resulted from mild denaturation but instead from a severe pH shift 
disturbing receptor interactions. 
The use of leptin was a means of moving away from denaturants and 
the risk of perturbing protein structures and instead competing 
specifically with the leptin-phage for occupancy of the receptor binding 
site. This approach proved particularly successful and we were able to 
establish a binding regime that discriminated the wild-type phage from 
the high affinity control mutant. This experiment was also interesting in 
that it provided indications that the leptin-phage were behaving in a 
non-classical way in the binding experiments. Theoretically if each 
phage virion was bearing 1 molecule of leptin then a 100 µl aliquot of 
phage would contain approximately 109 leptin molecules. This would 
suggest a theoretical concentration of approximately 20 picomolar. In a 
classical binding competition experiment a 50% reduction in binding 
would occur when the concentrations of the competing molecules were 
equal (assuming equal affinity), yet in the case of wild-type jufo-ob 
phage this concentration was 20 nanomolar. Clearly the leptin-phage 
moieties were behaving in a non-classical way and this could have 
been due to a “mass effect”, that is the phage were not undergoing free 
diffusion. The molecular weight of an M13 virion is approximately 35 
MDa, compared to leptin at 16 kDa and this disparity in size may be 
influencing the binding kinetics. Another possibility is that each phage 
particle carries more than one molecule of leptin and the binding 
kinetics are affected by the valency of leptin display. It would be 
technically very challenging to establish the number of leptin molecules 
on the surface of phage and it would be also be variable. For these 
reasons establishing the conditions of phage binding and enrichment 
were of necessity empirical. Leptin competition proved the successful 
approach and was able to discriminate the high affinity control mutant 
from wild-type leptin. 
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This stage of the project proved successful and I was able to express 
functional leptin on the surface of filamentous phage. This is the first 
time active leptin has been expressed in an active form from bacteria 
without the need for refolding, albeit at a low level. This was a 
demonstration that folding of a four helical peptide hormone could be 
achieved by export to the bacterial periplasm and could prove a 
significant advance in the area of protein engineering and phage display 
of this class of hormone and cytokine. I was able to establish a specific 
selection strategy based on competition with wild-type recombinant 
leptin, and this was able to discriminate normal leptin from a high affinity 
mutant control. The next stage of the project was to synthesise a 
diverse library of leptin mutants in phage form and use the selection 
strategy to identify novel mutants. 
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Chapter 4  
 
 
 
 
 
Synthesis and Enrichment of Leptin 
Mutant Library 
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4.1. Introduction 
As described in the preceding chapter we had now accomplished an 
important initial step of the project and established a method for 
expressing functional leptin on the surface of filamentous phage. This 
development would now allow the use of phage display techniques to 
express and select very large diverse libraries of leptin muteins for 
novel functional forms. This chapter will describe the synthesis of a 
leptin mutant library and enrichment of the library using a leptin receptor 
selection strategy. 
Mutagenesis is a frequently used strategy for probing relationships 
between protein structure and function. In the case of leptin some of the 
earliest studies following the cloning of the cDNA sequence involved 
deletion analysis to determine the functional domains of the hormone 
(Imagawa et al., 1998). Given the size of the leptin poypeptide and the 
huge number of potential variations arising from substituting one or 
more amino acid residues most studies have used a targeted, or 
“patch”, mutagenesis approach where a specific region is subject to a 
limited number of mutations and analysed for functional changes. In this 
particular study our aim was to target the leptin cDNA coding sequence 
in a completely random way to generate a large library of leptin muteins 
with potentially new properties. As we intended to enrich on the leptin 
receptor non-functional mutants would be discarded during the phage 
selection process. This is a powerful technique and would enable us to 
analyse very large libraries of diverse leptin mutants. The requirement 
was for a mutagenic approach that would produce the requisite number 
of random mutations with a non-biased distribution of mutations in 
terms of both type and position in the sequence.  
A range of mutagenesis techniques have been developed, each with 
different advantages and disadvantages. Site-directed mutagenesis of 
single stranded template DNA was first described by Zoller and Smith 
 82 
 
(Zoller and Smith, 1982), and the efficiency of the technique was 
subsequently improved upon by Eckstein (Nakamaye and Eckstein, 
1986). This method was limitied to small substitutions or deletions and 
large scale random mutagenesis initially depended on chemical 
modification of DNA templates or plasmid propagation in specialised 
bacterial strains with high intrinsic mutation rates (Fabret et al., 2000). 
The advent of PCR technology lead to rapid advances in mutagenesis 
techniques. Error prone PCR uses modified reaction conditions to 
introduce random mutations in the amplified DNA template (McCullum 
et al., 2010). This approach can lead to biases in the nature of the 
nucleotide substitutions and more recently this technique has been 
improved by the introduction of mutant DNA polymerase enzymes with 
modified proof-reading properties (Biles and Connolly, 2004). This 
technique has been used in a range of protein engineering studies 
including antibody optimisation (Turner et al., 2014) and modification of 
hormone receptors (Hatayama and Ide, 2015). For this study we used a 
commercial kit based on a modified Taq polymerase and which includes 
buffer components that optimised the introduction of random nucleotide 
changes wtih an unbiased frequency to ensure a high diversity of 
mutants. 
The library will be cloned into the pJUFO phage display vector and 
selected on the leptin receptor using leptin competition to enrich high 
affinity variants. Candidate mutants will be sequenced and then 
expressed and purified in order that they can be characterised.  
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4.2 Methods 
4.2.1. PCR Mutagenesis of Leptin cDNA and Cloning into pJUFO  
The starting template for random mutagenesis was the leptin E100 
cDNA cloned into phage vector pJUFO. A Genemorph II Random PCR 
mutagenesis kit was used (Agilent Technologies) to amplify the cDNA 
template and introduce random mutations at a controlled frequency. 
Using the manufacturer’s guidelines the amplification reaction was 
setup to produce an average of 1-2 mutations per molecule. Leptin 
cDNA was amplified using the lib-1 and lib-2 primers shown in Table 
4.1. These primers were designed to flank the leptin cDNA cloning site 
of the jufo-ob construct and amplify the entire leptin cDNA. The Xba I 
and Kpn I restriction sites were included in the primer sequences to 
allow cloning of amplification products into pJUFO to create the mutant 
library.  
 
lib-1 GCACACGGTGGTTGCAGATCTTCTAGA 
    Xba I 
lib-2 ACGACTCACTATAGGGCGAATTGGGTACC 
    Kpn I 
 
Table 4.1. PCR primers for leptin cDNA amplification and cloning into pJUFO. 
Primers lib-1 and lib-2 flanked the Kpn I and Xba I cloning sites (underlined) of pJUFO 
and amplified the complete leptin E100 cDNA sequence.  
 
The PCR reaction was setup as follows: 
Mutazyme reaction buffer (10 x) 5 µl 
dNTPs (40 mM) 1 µl 
primer mix (250 ng/µl each) 0.5 µl 
Mutazyme polymerase (2.5 U/µl) 1 µl 
Template DNA (100 ng/µl) 1 µl 
H2O 41.5 µl 
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The reaction was cycled using the following conditions: 
95°C 2 min 
25 cycles of: 
95°C 30 s 
55°C 1 min 
72°C 1 min 
 
The reaction was terminated with a 10 min incubation at 72°C. 
Five separate reactions were carried out and then pooled and purified 
using Qiagen purification kit (2.2.5). Purified PCR products were 
digested for 5 hours at 37°C with 10 units each of Xba I and Kpn I, 
resolved by agarose gel electrophoresis and recovered by gel 
extraction (2.2.5). Phage vector pJUFO (10 µg) was digested with 20 
units of Xba I and Kpn I and resolved by agarose gel electrophoresis 
(2.2.4). Linearised vector was recovered the agarose gel (2.2.5) and 
ligated to 1 µg of digested PCR products (2.2.9) overnight at 15°C. The 
50 µl ligation reaction was precipitated with 500 µl of 100% ethanol and 
pelleted by centrifugation at 13,000 xg for 20 min. The DNA pellet was 
washed with 70% ethanol and redissolved in 20 µl of distilled H2O. 
Aliquots of ligation (5 µl) were electroporated in bacterial host XL1-Blue 
and recovered in 1 ml of SOC medium for 1 hour at 37°C. Bacteria were 
plated onto a series of 20 cm x 20 cm agar plates contained 2xYT 
medium with 60 µg/ml of ampicillin, 30 µg/ml of tetracycline, and 1% 
glucose (w:v). Following overnight growth at 37°C the bacterial colonies 
were scraped off the plate and resuspended in 50% glycerol to produce 
a stock.  
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Phage Rescue 
To produce leptin phage particles and aliquot of the glycerol stock (5 x 
108 cfu) was inoculated into 100 ml of 2xYT medium (ampicillin 60 
µg/ml; tetracycline 30 µg/ml, glucose 1% (w:v) and incubated in a 
shaking incubator at 200 rpm and 37°C until the turbidity reached 
approximately 0.8 OD600nm. At this point 10
10 virions of VCSM13 helper 
phage were added and the culture incubated for 30 min at 37°C without 
shaking. The culture was then used to inoculate 200 ml of 2xYT 
medium (ampicillin 60 µg/ml; tetracycline 30 µl, kanamycin 30 µg/ml) 
and incubated overnight at 37°C and 200 rpm. 
Phage particles were precipitated by the addition of PEG 6000 and 
NaCl to a final concentration of 20% and 2.5 M respectively. The 
suspension was incubated on ice for 2 hours and the phage particles 
recovered by centrifugation at 4,000 rpm for 30 min. The phage pellet 
was resuspended in PBS/Tween and adjusted to give a titre of 1010 
pfu/ml. 
To assess the quality of the mutant library 60 random clones were 
picked for miniprep and sequencing. 
4.2.2 Enrichment of Leptin Mutant Library 
Based on the results obtained in the previous chapter a competitive 
selection strategy was used to enrich the leptin phage library.  
ELISA wells were coated with recombinant human leptin receptor in the 
form of the extracellular domain fused to the human immunoglobulin Fc 
domain (R and D Systems). The receptor was coated onto the ELISA 
wells at a concentration of 250 ng/ml in coating buffer overnight at 4°C. 
The wells were blocked with 400 µl of 3% BSA (w:v) in PBS at room 
temperature for 1 hour. The wells were washed 5 times with 400 µl of 
PBS/Tween (0.1% v:v). A 100 µl aliquot of phage library (1010 
phage/ml) was mixed with human leptin (Sigma) to a final concentration 
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of 40 nM and added to the well. The well was incubated for 2 hours at 
room temperature and then washed 8 times with PBS/Tween. Bound 
phage were eluted by the addition of 100 µl of 1 µM leptin and 
incubation at room temperature for 30 min. This approach was used to 
elute phage specifically rather than relying on the more conventional 
acid elution using glycine. The phage suspension was used to infect 1 
ml of XL1-Blue bacterial culture (OD600nm 0.8) for 30 min at 37°C. The 
infected bacterial host was spread onto a 20 cm x 20 cm 2xYT agar 
plate (ampicillin 60 µg/ml; tetracycline 30 µl, glucose 1% (w:v)) and 
incubated overnight at 37°C. The next day the bacterial colonies were 
scraped from the agar surface and resuspended in 30 ml of 50% 
glycerol. This stock was used to generate phage for the next round of 
selection as described in section 4.2.1. The enrichment process was 
repeated 4 times. At each round an aliquot of enriched library (100 µl; 
1010 pfu/ml) was analysed by ELISA against immobilised leptin 
receptor. Random clones were picked from the round 2 and final round 
4 enriched libraries. The clones were grown to prepare miniprep DNA 
(2.2.4) and sequenced.  
4.2.3 Characterisation of mutant clones 
Selected phage clones were grown to produce phage particles and 
used to investigate their affinity for the leptin receptor. ELISA wells were 
coated overnight at 4°C with 50 µl of leptin receptor-fc fusion protein at 
a concentration of 250 ng/µl in coating buffer. The next day wells were 
blocked with 400 µl of 1% BSA/PBS for 1 hour at room temperature. 
Wells were washed 5 times with 400 µl of PBS/Tween (0.1% v:v). 100 
µl of phage suspension (1010 virions/ml) were added and allowed to 
bind for 1 hour at room temperature. The wells were washed 8 times 
with PBS/Tween and 60 µl of anti-M13 horseradish peroxidase antibody 
(1:10,000 in PBS/Tween) added (GE Healthcare, UK). The wells were 
incubated for 1 hour at room temperature and then washed 8 times with 
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400 µl of PBS/Tween. Wells were then developed by the addition of 50 
µl of 3,3’,5,5’ tetramethylbenzidine substrate (Promega, UK). After 
developing for 15 min at room temperature the reaction was stopped by 
the addition of 50 µl of 0.2 M H2SO4 and the OD450nm determined in a 
plate reader. 
 
4.3 Results 
4.3.1 Library synthesis 
The mutagenesis PCR gave a clear single product of approximately 400 
bp which corresponded to the predicted leptin cDNA size. The products 
were pooled and purified and digested with Xba I and Kpn I. Following 
ligation into pJUFO the ligation was electroporated into XL1-Blue host 
cells. Electroporation resulted in a total of approximately 250 x 103 
colonies and this was the total library size. 
To assess the mutation rate in the library 60 random clones were 
picked and used to prepare miniprep DNA (2.2.4). Sequencing of these 
minipreps showed that in 60 random clones analysed there were a total 
of 36 with a mutant protein sequence and 24 wild-type sequences 
(including 3 clones with silent mutations).  
These mutations broke down as follows:  
Stop codons  3 
Non-conservative substitutions  29 
Semi-conservative substitutions  6 
Conservative substitutions  13 
Single mutants 27 
Double mutants 4 
Triple mutants 4 
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Quadruple mutants 1 
 
Analysis of the mutant sequences showed that of the 60 clones 26 were 
single mutants, 5 were double mutants, 4 had 3 mutations, and 1 had 4 
separate mutations. The wild-type leptin sequence was preserved in 20 
of the 60 clones sampled. Figure 4.1 shows the distribution of the amino 
acid mutations found in the leptin sequence. The library was considered 
to have the appropriate distribution and frequency of mutations to 
proceed to the enrichment process. 
4.3.2 Enrichment of leptin mutant library 
The leptin mutant library was enriched for 4 rounds on immobilised 
leptin receptor with a competitive concentration of recombinant human 
leptin of 40 nM. To assess the approximate frequency of phage binding 
at each round of enrichment aliquots of each enriched library were 
tested by ELISA against immobilised leptin receptor (Fig. 4.2). 
Following an initial increase in binding of approximately 30% between 
the initial mutant library and enriched library 2, the level of phage 
binding to leptin receptor appeared to plateau at rounds 3 and 4. This 
may have been a result of binding of a high frequency of wild-type leptin 
phage, given that sequencing indicated that approximately 40% of 
starting library inserts had the wild-type leptin sequence. The inclusion 
of a competitive concentration of leptin in the panning process may 
have displaced these wild-type clones to some extent and this may 
account for the increase in binding between the starting library and the 
round 1 library. To answer this question would require an analysis of the 
clones represented in the enriched libraries. Accordingly 50 random 
clones were sequenced from the round 2 and final round 4 libraries. 
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Library sequencing 
50 random clones were picked from round 2 and round 4 and used to 
prepare miniprep DNA (2.2.4) which were sequenced  
Sequencing of minipreps from round 2 showed that in 50 random 
clones analysed there were a total of 41 with a mutant protein 
sequence, 4 clones were truncated by stop mutations, 3 contained the 
wild-type leptin sequence, and 2 sequences were unreadable. The 
mutations in round 2 were distributed through the cDNA sequence, with 
88 residue positions from 146 (60%) showing one or more mutations. 
The presence of wild-type and truncated sequences suggests that the 
enrichment strategy still lead to a degree of background binding of 
phage despite the use of a competitive concentration of leptin. It was 
anticipated that the selection of specific phage with increased affinity 
would be evidenced by the presence of repeated sequence changes in 
the sequencing data or an accumulation of mutations in a narrow range 
of residues known to play a role in receptor binding. Arbitrarily assigning 
a cutoff for repetition and considering positions with 3 or more 
mutations the following residues were subject to repeated substitutions 
in the round 2 library; I14, I17, D23, I24, S29, V30, K33, Q56, P69, V73, 
S102, G103, L104, G112, and V123. Mutations at position D23 have 
been previously shown to play a major role in leptin affinity (Shpilman et 
al., 2011) and it is possible that this mutation appeared here as a result 
of the selection strategy. However, given that 88% of possible leptin 
positions showed an alteration it was likely that round 2 contained a 
significant background of random mutations, making it impossible to 
easily identify mutations leading to possible functional changes. 
Accordingly, two more rounds of enrichment were carried out to 
produce the round 4 library and sequence analysis carried out once 
more. 
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The enriched round 4 library showed a narrower distribution of 
substitutions compared to round 2 with 61 of 146 positions (42%) 
showing substitutions (Fig. 4.4). A number of the mutations observed in 
round 2 were seen again in round 4. The known functional position D23 
occurred twice more in the round 4 library. Combining the results from 
round 3 and round 4 showed that the most commonly observed 
mutation was at position T121A/T121S which together was observed 8 
times, suggestive of an important role (Fig. 4.5). A second mutation, 
T37A was observed 5 times in round 4. Interestingly the T37A mutation 
only appeared in combination with the T121S mutation, suggesting a 
possible cooperative effect on receptor affinity of the two modifications 
(Fig. 3.4).  
Considering both libraries together a number of mutations seen in the 
current study were previously described in the only other random 
mutagenesis leptin study, based on yeast expression and display 
(Shpilman et al., 2011). This comparison is shown in Table 4.1. 
Interestingly the T121S/A mutation was not observed in this previous 
study. 
Based on the relatively high frequency of the T37/T121 mutant, this 
clone was selected for further analysis to investigate its binding 
properties. 
 
Figure 4.1. Distribution of mutations in leptin mutant library. 
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Figure 4.2. Enrichment of mutant leptin library. Binding of phage from 
round 1 to 4 (R1-R4) of enrichment. Control phage pc3-ø were generated from 
empty pCOMB3 vector and showed only background binding to leptin receptor 
coated wells. Data shown is mean +/- SD (n=3).  
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Figure 4.3. Mutations in enriched Round 2 library. The clone number 
is shown in the left hand column and the observed mutations indicated 
alongside. 50 clones were sequenced, 4 clones contained the wild-type leptin 
sequence, 4 clones were truncated by stop codons and 1 sequence was 
unreadable. 
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Figure 4.4. Mutations in enriched Round 4 library. The clone number 
is shown in the left hand column and the observed mutations indicated 
alongside. The repeated mutations T37A and T121S are shown in bold. 50 
clones were sequenced, 3 had the wild-type leptin sequence, 3 contained stop 
codons, and 5 sequences were unreadable. 
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Figure 4.5. Comparison of round 2 and 4 libraries. Mutations observed 
in the Round 2 enriched library are indicated in yellow, and those in Round 4 
shown in light grey.  
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Clone Number Sequence Change 
1 S25F/L49M 
2 A125T/S132Y 
3 D23G/L68M/S97F/S132Y 
4 D23G/V30D/Y119H 
5 K11R/Q34R/T37A/F92C/S97Y/I136V 
6 S97Y 
7 D23G/G112S 
8 S109F 
9 D23G, T37A, G44D 
10 T12I 
11 D23H 
 
Table 4.1 Leptin sequence changes reported in yeast enrichment study. 
The table shows leptin amino acid changes associated with increased affinity 
previously reported in a leptin mutant yeast display study (Shpilman et al., 
2011). Identical mutations observed in round 2 or round 4 are highlighted in 
yellow, and identical positions showing a non-identical mutation are shown 
underlined. 
 
 
 
 
  
 96 
 
4.3.3 Characterisation of mutant clones 
Two clones were selected for further analysis. Clone E09, a 
T37A/T121S double mutant, and clone G03, a T121S single mutant, 
were grown to produce phage particles (2.2.9). Phage titres were 
adjusted to 1 x 1010 virions/ml and OB-R binding investigated. Wild-type 
leptin phage were included and phage binding to OB-R was determined 
by phage ELISA in the presence of increasing concentrations of 
competing leptin (Fig. 4.6). Both leptin mutant clones E09 and G03 
showed increased binding relative to wild-type leptin. This showed that 
the T121S mutant in isolation was able to increase the affinity of leptin 
for its receptor.  
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Figure 4.6. Competitive binding of phage clones to ObRb. Competitive 
binding of clone G03 (T121S), E09 (T37A/T121S double mutant), and wild-
type leptin phage WT to Obr. Data shown are the mean and SD (n=3). 
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4.4 Discussion 
In this part of the project we successfully synthesised a diverse library 
of leptin mutants and selectively enriched it on immobilised leptin 
receptor using a competitive strategy. The initial library contained 
250,000 clones and approximately 50% of these contained a single 
amino acid substitution. The size of the initial library guaranteed 
oversampling of all available single residue leptin variants. 
Enrichment of the leptin library did not show a large increase in the 
number of eluting phage, as is generally seen with phage antibody 
libraries where a thousand-fold increase in phage binding is typically 
observed (Burton and Barbas, 1992). In fact it is our experience that 
enrichment of phage polypeptide or cDNA libraries tends to produce a 
qualitative shift in the phage population rather than a large increase in 
binding frequency (Dr P Watson, personal communication). The reason 
for this phenomenon is not clear but a likely explanation is the effect of 
heterologous expression on bacterial growth rates. Thus when each 
enriched library is recovered from bacterial culture there is the potential 
for outgrowth of clones in which the cDNA is deleted or truncated by a 
mutant stop codon. The effect of differential growth rates leads to a 
constant level of irrelevant background phage clones at each round of 
enrichment.  
This effect may have been evident in the sequencing data obtained 
from the Round 2 library. There was a significant proportion of non-
productive clones in which the leptin cDNA was absent or truncated by 
stop codons. This phenomenon occurred even though the phage were 
bound to immobilised leptin receptor, washed stringently, and eluted 
specifically with displacing concentration of leptin. In the round 2 library 
88 or 146 positions (60%) were found to have mutations, suggesting 
that a number of the clones represented background noise. Under 
these conditions the strategy employed to establish whether the 
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enrichment has been successful is to study the distribution of clones 
based on sequence analysis looking for evidence of function or the 
frequency of repetition of given clones. In the case of the round 2 library 
3 positions were found to be mutated 4 times, these were glycine 103, 
glycine 112, and valine 123. One of these positions, G112 has been 
previously described in the only other published leptin random 
mutagenesis study (Shpilman et al., 2011). As this position was never 
mutated in isolation it is not possible to ascertain whether it plays an 
important role in leptin binding. G112 is located in a small -helix in the 
loop between helix C and the amino terminus of helix D and thus may 
contribute to the site III binding site. It is possible that only two rounds of 
enrichment was not sufficient to eliminate the random mutation 
background from the leptin library and so a further two rounds of 
enrichment were carried out.  
The round 4 library showed mutations in 61 or 146 possible positions 
(42%) which may have been evidence for the effects of selection on the 
population distribution in the library. Based on frequency of repetition 
we selected two clones expressing the most commonly observed 
mutations T37A and T121S. Measurements of competitive leptin 
receptor binding showed that the double mutant and the single T121S 
mutant exhibited an apparent increase in receptor affinity. Interestingly 
the T121S mutant was not observed in the only previous published 
study of leptin random mutagenesis (Shpilman et al., 2011). This study 
identified mutants with increased receptor affinity and identified D23 as 
a key position that influenced receptor binding. D23 mutants were 
observed in the current study but with a lower frequency than the T37A 
and T121S mutations. The most likely explanation for this is that the 
selective ligand employed by Shpilman et al was a recombinant form of 
the receptor that was restricted to residues 428-635, encompassing the 
CRH2 domain which only interacts with leptin binding site II. 
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Figure 4.7. Leptin structure and T37 and T121 residues. 3-D structure 
of human leptin (Zhang et al., 1997) with the positions of residues T37 and 
T121 indicated. Residue T37 lies in an undefined region of the molecule which 
comprises the long loop between helix A and helix B (indicated by dotted line). 
This portion of the molecule consists of only a few residues that were resolved 
in the crystal structure but are adjacent to residue T121 (indicated by orange 
spheres). Both are in the region contributing to binding site III. 
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The T121 position has been identified as a key residue involved in the 
site III binding site and so would not have been enriched in the 
Shpilman study which focused on site II as the major binding site of 
leptin. Interestingly, in our study the leptin receptor form was the 
complete extracellular domain, which would include all possible leptin 
binding sites. This raises the question of why we did not recover a 
predominance of D23 mutations in the enriched libraries, as described 
by Shpilman et. al. The recovery of T121 mutants in the current study 
suggests that site III may play a more significant role in leptin receptor 
binding than previously considered. One possible explanation is the 
form of receptor we used. The recombinant leptin receptor obtained 
from R & D systems was in fact a fusion protein in which the 
extracellular receptor domain was fused to human immunoglobulin Fc 
domain. This construct is used commercially as it offers a simple 
purification strategy for the recombinant protein, i.e. affinity 
chromatography on protein A. As a by-product however the receptor will 
spontaneously dimerise via the Fc domain. Thus, in contrast to the 
Shpilman study, based on monomeric receptor domain, our selection 
was carried out on receptor dimers. This may well have affected leptin 
binding kinetics and favoured the isolation of site III mutants.  
The apparent increase in receptor affinity described for the mutants 
isolated in round 4 may have been due to influences such as surface 
density on the phage structure or some other unknown effect of phage 
display. To formally address these possibilities required the expression 
and purification of the mutant proteins. At the same time synthesis of a 
T37A single mutant would enable investigation of the effect of this 
position on receptor binding in isolation. Finally, a T121 mutant has 
been previously described (Peelman et al., 2004) and characterised as 
an antagonist with binding activity but lacking in receptor activation. 
This mutant was in fact a site-directed double mutant S120A/T121A and 
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so expression of the T121S double mutant will be investigated for 
receptor binding and activation. The following chapter deals with the 
synthesis, expression, and purification of the selected mutants and their 
characterisation in receptor binding and activity assays. 
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CHAPTER 5  
 
 
 
 
Expression and Characterisation of 
Leptin Mutants 
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5.1 Introduction 
In the previous chapter we identified a number of leptin mutants isolated 
from enrichment of the leptin phage library. Based on evidence of 
sequence repetition two clones were screened for leptin receptor 
binding and found to show evidence of increased affinity. In this part of 
the study we aimed to introduce these mutants into a bacterial 
expression vector and produce purified protein for each to further 
investigate their properties. One mutant contained the T121S mutation 
and the second contained the T37A mutation in combination with 
T121S. Single mutants will be prepared to investigate the effects of 
each mutation in isolation. A leptin bioassay will be carried out to study 
the ability of the mutants to activate the receptor and binding studies will 
be carried out to estimate receptor affinity. A further study of receptor 
binding kinetics will be carried out using biolayer interferometry (Shah 
and Duncan, 2014).  
 
5.2 Methods  
5.2.1 Generation of mutant leptin constructs 
In order to investigate the binding characteristics of mutant leptin 
proteins it was necessary to produce the T37A/T121S double and 
single mutant expression constructs in pET21a. A commercial inverse 
PCR site-directed mutagenesis approach was used. The starting 
template was a pET21a construct containing leptin E100 (gift from Dr B. 
Carpenter). 
Following inverse PCR amplification using a high fidelity DNA 
polymerase the reaction mixture was treated with a combination of a 
kinase, ligase, and restriction enzyme Dpn I. De novo DNA was then 
transformed into host bacteria (Li et al., 2008). The primers used are 
shown in Table 5.1. 
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T37A-F gCCGGTTTGGACTTCATTCCTGGGCT 
T37A-R GACTTTCTGTTTGGAGGAGACTGACTGCGT 
T121S-F tCAGAGGTGGTGGCCCTGAGCAGGCTG 
T121S-R GGAGTAGCCTGAAGCTTCCAGGACAC 
 
Table 5.1. Primers used to generate T37A and T121S leptin 
mutants. The forward primer T37A-F introduced an alanine codon (mutation 
shown underlined) at position 37 of the human leptin coding sequence. The 5’ 
end of the reverse primer T37A-R corresponds to the preceding codon (36) in 
the antisense direction. The forward primer T121S-F introduced a serine 
codon (mutation shown underlined) at position 121 of the human leptin coding 
sequence. The 5’ end of the reverse primer T121S-R corresponds to the 
preceding codon (120) in the antisense direction 
 
 
 
A number of colonies were picked for confirmation by minprep (2.2.1) 
and sequencing. After confirmation the respective leptin inserts were 
recloned into pET21a. The constructs were designated pET-37A/121S, 
pET-37A and pET-121S. 
5.2.2 Expression of leptin in E. coli 
An E. coli expression system was used to express the recombinant 
leptin proteins. The pET21a constructs were transformed into Novagen 
competent cells (BL21- DE3 (pLysS). Protein culture induced by the 
addition of IPTG (isopropyl-β-D-thiogalactopyranoside) during the 
exponential growing phase. 
Briefly, 50 µl of competent cells were transformed with 2 µl of the 
expression constructs. Transformed cells were plated onto LB-agar 
plates (60 µg/ml ampicillin, 2% glucose (w:v)) and grown overnight at 
37°C. Fresh single colonies were used to carry out protein expression. 
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A 100 ml starter culture (2xYT, 60 µg/ml ampicillin, 1% glucose (w:v)) 
was inoculated with a single colony and incubated overnight at 30°C 
and 200 rpm. The starter culture was used to inoculate 1L of 2 x YT 
medium and incubated at 37°C, 200 rpm until the OD600nm reached 0.6-
0.8. Expression was then induced by the addition of IPTG to the culture 
to a final concentration of 1 mM. The induction process was allowed to 
proceed for 4 hours and cells harvested by centrifugation at 4000 xg for 
20 min. The cell pellet was stored at -80°C. Culture samples (1 ml) were 
taken immediately prior to induction (T0) and at 4 hours (T4). 
Preparation of Inclusion Bodies (IB) 
Enzymatic lysis by lysozyme is one of the methods that used in this 
thesis. The pellet from a 1 L culture was thawed and resuspended in 
ice-cold lysis buffer (10 mM Tris-HCl, 10 mM DTT, 1 mM EDTA and pH 
8.0). Lysozyme was added to final concentration 500 µg/ml, followed by 
30 min incubation on ice, mixing by inversion every 5 min. Inclusion 
bodies (IB) were harvested by centrifuging the lysed cells for 20 min at 
4000 g. The pellet was suspended in 25 ml of cold washing buffer (50 
mM Tris-HCl, 10 mM DTT, 1 mM EDTA, 1% (v:v) Triton X-100 and pH 
8.0); centrifuged at 4000 xg for 20 min and the supernatant discarded. 
This washing step was repeated a total of five times, the final wash 
using H2O, to remove residual detergent. 
Refolding of Leptin Proteins 
Leptin proteins were folded using a previously described protocol 
(Sandowski et al., 2002). IB were solubilised in 50 ml of deionized cold 
solubilisation buffer (40 mM Tris-HCl, 8 M urea, 10 mM cysteine, and 
pH 11.3), and mixed vigorously at intervals. Deionisation was performed 
by adding 1 g of TMB mixed bed ion-exchange resin to freshly prepared 
solubilizing buffer. The mixture was incubated at 4°C for 2 hour, and 
filtered before used. The solution was diluted in an equal volume of 
arginine buffer (40 mM Tris, 500 mM arginine), mixed gently, and 
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incubated at 4°C for 30 min. The solubilized proteins were refolded by 
overnight dialysis to remove urea. Stepwise dialysis was against 5 L of 
pre-cooled refolding buffer (10 mM Tris, pH 9 at 4°C), and continued for 
60 hours with six buffer changes. Refolded protein was analysed by 
SDS-PAGE analysis. 
5.2.3 Purification of recombinant leptin  
Gel filtration chromatography was used for final purification of refolded 
leptins. Size fractionation was carried out using a Sephacryl S-200HR 
120 ml column. Refolded leptin (4 mg/ml) was loaded onto the column 
(2% of total column volume) and eluted with gel filtration buffer (25 mM 
Tris-HCl, 150 mM NaCl, and pH 8.0) at a flow rate of 1 ml/min. Elution 
was monitored by UV detector and fractions collected automatically. 
Samples of flow through (100 µl) were assayed for protein content by 
Bradford assay and major leptin forms identified by native gel and SDS-
PAGE analysis. Purified monomeric leptin was dialysed overnight 
against PBS and concentrated to 1 mg/ml and stored at -80°C.  
5.2.4 Leptin Bioassay 
Bioactivity of recombinant leptin was measured using a STAT-3 
promoter driven dual assay luciferase reporter approach. The dual 
assay luciferase assay system was supplied by Promega. The assay 
measures the induction of firefly luciferase from a STAT-3-regulated 
promoter and includes constitutively expressed Renilla luciferase for 
normalisation of output. 
The assay required four separate plasmids: pcDNA3-OB-Rb (containing 
full-length leptin receptor); SIE-TK-firefly luciferase (containing the firefly 
luciferase gene with inducible promoter); STAT-3 plasmid (expressing 
STAT-3); and phRL-CMV (containing the Renilla luciferase gene driven 
by a constitutive promoter). Assay components were a kind gift from 
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Prof. Richard Ross (University of Sheffield). Plasmids were transiently 
transfected into HEK293 cells using Lipofectamine-2000 (Invitrogen).  
HEK293 (human embryonic kidney cells) were seeded into 12-well 
plates at a density of 1.5 x 105 cells per well in DMEM/Ham’s F12 (1:1) 
media, supplemented with 10% FCS, 100 µg/ml penicillin/streptomycin, 
2 mM L-glutamine, and 15 mM HEPES. Cells were incubated at 37°C in 
5% CO2. After 18 hours the media was exchanged for 800 µl of 
transfection (as above minus penicillin/streptomycin). A mix of the four 
plasmids was prepared (pcDNA-OB-Rb 7.5 µg, SIE-TK-firefly 7.5 µg, 
STAT-3 7.5 µg, and phRL-CMV 3.75 µg) and added to 6 ml of 
OPTIMEM media. The mix was incubate at room temperature for 5 min. 
Lipofectamine-2000 (67.5 µl) was added to 6 ml of OPTIMEM and 
incubated at room temperature for 5 min. The two solutions were mixed 
and incubated for a further 25 min at room temperature. The DNA 
transfection mix was then added to the wells (200 µl). 
After 16 hours of incubation at 37°C with 5% CO2 the medium was 
exchanged for starvation medium (DMEM/Ham’s F12 supplemented 
with 2 mM L-glutamine, 15 mM HEPES, and 1 mg/ml bovine serum 
albumin). Test samples were added to the wells and cells incubated for 
6 hours. 
The dual luciferase assay was performed as instructed by the 
manufacturer. Cells were lysed with passive lysis solution (250 µl/well) 
and 50 µl samples of lysate assayed for Renilla and firefly luciferase 
activity in a dual injection luminometer (Berthold). Fold induction of 
firefly luciferase activity was calculated based on normalised activity 
relative to Renilla control. 
5.2.5 BLItz kinetic binding assay 
BLItz (FortéBIO, Portsmouth, UK) is a proprietary system for studying 
protein ligand interactions. The operating principle is based on biolayer 
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interferometry. Special optical probes generate a standing wave of laser 
light which self-interferes to produce a signal. Proteins and other 
molecules can be attached to the probe tip and this produces a shift in 
the interference pattern which can be measured in real time. Immersion 
into buffers containing ligands that interact with the target protein can 
detect and measure protein/protein interactions in real time and 
produce data which are used to calculate the kinetics of the interaction. 
Parameters determined included the on rate, off rate, and the calculated 
kd of the interaction.  
BLItz probes coated with protein A (FortéBIO) were used in this study. 
A new protein A coated probe was first hydrated in PBS for 10 min at 
room temperature. The tip was then introduced into a 4 µl aliquot of 
human leptin receptor Fc-fusion at 100 µg/ml concentration (R and D 
Systems). Binding of the receptor-Fc chimera was measured in real 
time to ensure coating occurred. The tip was then washed in PBS for 1 
min with oscillation. The background interference signal was 
determined. Samples of wild-type and mutant leptins were prepared in 
PBS using a range of different concentrations to establish data with 
which to determine the binding kinetics and kd. A separate equilibrated 
probe was used to investigate each leptin concentration. The probe was 
immersed in a 4 µl aliquot of leptin sample and real time binding data 
captured. The probe was then immersed in PBS and dissociation 
kinetics measured as the leptin diffused from the probe.  
 
5.3 Results 
5.3.1 Synthesis of leptin mutants 
Synthesis of the leptin T37A/T121S double, and T37A and T121S 
single mutants was confirmed by sequencing. Reading frames were 
correct and each showed only the desired mutation.  
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5.3.2 Expression of wild-type and mutant leptins 
Induction of mutant leptins was confirmed by SDS-PAGE (Fig. 5.1). As 
has been previously reported leptin E100 expresses well in E. coli and 
there was a clear band at the 4 hour timepoint with each construct. This 
provided sufficient evidence that further purification could continue. 
In all cases the majority of recombinant leptin was in the form of 
inclusion bodies. The yield was approximately 30 mg/l of crude protein 
after a 4 hour induction. Washing of the inclusion bodies (Fig. 5.2) and 
analysis by reducing SDS-PAGE showed that contaminants were 
successfully removed and the majority of protein obtained gave a band 
of between 10 and 15 kDa. Leptin is approximately 16 kDa though 
typically runs at an apparently smaller size in SDS-PAGE (Dr Byron 
Carpenter, personal communication). 
Refolding of recombinant leptins 
The washed inclusion body pellet dissolved readily in solubilisation 
buffer producing a slightly turbid solution. This was cleared by 
centrifugation for 20 min at 4,000 xg and the solution placed in dialysis 
membrane (molecular weight cutoff 5 kDa). Following dialysis for 60 
hours there was evidence of a significant precipitate, representing 
amounts of misfolded insoluble material. Analysis of the supernatant by 
Nanodrop showed significant amounts of leptin were in still in solution 
(approximately 20 mg in a total volume of 50 ml of dialysate). Samples 
of this material were analysed by SDS-PAGE and showed a single 
band between 10 and 15 kDa. Accordingly the material was taken 
forward to the next stage of purification.  
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Figure 5.1. SDS-PAGE analysis of recombinant leptin induction. 
Induction of wild-type leptin expression by addition of 1 mM IPTG was 
analysed by SDS-PAGE. Sample of E. coli lysates were analysed by 
electrophoresis at T0 immediately prior to induction and at 4 hours (T4). An 
evidently induced band of protein was observed between 10 and 15 kDa. Lane 
M: molecular weight marker, lane T0: Uninduced sample and T4 at 4 hours 
post induction. The T37A and T121S constructs gave similar results. 
 
 
 
Figure 5.2. Washing and analysis of inclusion bodies. (A) Inclusion 
body preparations were washed in a series of steps as described. The image 
shows SDS-PAGE analysis of inclusion body samples after 5 sequential 
washes. (B) SDS-PAGE (15%) of purified mutant leptins analysed on a 15% 
gel and stained with Coomassie brilliant blue R-250. (M) Molecular weight 
markers. 
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5.3.3 Purification of recombinant leptins 
Size fractionation of refolded leptins showed the elution of three major 
peaks (representative data shown in Fig. 5.3). In all leptin preparations 
an early eluting peak at approximately 30 min was evident. This 
represented misfolded proteins. The peak at 75 min was believed to 
represent leptin dimers that form during refolding (oral communication 
Dr. B Carpenter) and this was confirmed by non-denaturing PAGE. The 
final peak at 90 min was confirmed as leptin monomer. The purified 
leptins were concentrated to 1 mg/ml using Vivaspin centrifugal filtration 
units (molecular weight cutoff 3 kDa) and stored at -80°C. 
5.3 Leptin bioassay 
Purified leptins were analysed by leptin bioassay. A range of doses 
were examined from 0 to 5 nM. The results are shown in Fig. 5.4. 
Commercial leptin showed an increasing signal up to a 2.5-fold 
induction in luciferase activity at 1.25 nM concentration. The signal 
appeared to plateau at this point. Leptin T37A/T121S produced a 
maximum induction of 2-fold at 1.25 nM and this did not increase at 5 
nM concentration. Leptin T37A produced an induction of only 1.5-fold at 
1.25 nM and a maximum of 2.3-fold at 5 nM. Leptin T121S exhibited a 
slightly increased activity, achieving a maximum induction of 3-fold at 
1.25 nM, at which point the assay plateaued. Leptin T121S produced a 
2.3-fold signal at 0.31 nM and a maximum induction of 2.5-fold at 1.25 
nM. There was an apparent drop in signal at 5 nM, falling to 
approximately 2.15-fold. This sigmoidal response has been previously 
observed in leptin bioassays (Peelman et al., 2004). 
 112 
 
 
Figure 5.3. Gel filtration of refolded leptin. Refolded leptins were size 
fractionated on a Sephacryl S-200 gel filtration column (120 ml). Refolded 
leptin was separated at a flow rate of 1 ml/min, and fractions collected at 750 
µl intervals. The blue line shows the absorbance at 280 nm. Purified leptin 
eluted as a dimer and monomer. 
 
 
 
 
Figure 5.4 Leptin bioassay. Wild-type and mutant leptins were assayed for 
leptin receptor activation using a STAT-3 driven luciferase bioassay. Maximal 
activation by wt-leptin gave a 3.7-fold induction of luciferase activity. 
T37A/T121S double mutant and the T37A, T121S single mutants were all able 
to activate the receptor, giving a maximum induction of 2, 2.3, and 2.5 fold 
respectively. 
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5.4 Affinity studies by BLItz 
Samples of wild-type and mutant leptins were analysed for leptin 
receptor binding kinetics using the BLItz biolayer interferometry system 
(FortéBIO). Real time binding data is summarised in Fig. 5.5. The initial 
portion of the traces shows the loading of the protein A probe with leptin 
receptor Fc fusion protein (100 µg/ml). Probe saturation typically 
occurred within 350 seconds. The step was equilibration of the probe in 
sample buffer (PBS). The portion of the trace from approximately 550 to 
850 seconds shows the binding of leptin to the receptor. After this point 
the probe was immersed in sample buffer to record the dissociation of 
the hormone from receptor. 
Binding data was used to calculate the binding characteristics of the 
different leptin preparations using proprietary software (FortéBIO). The 
results are shown in Table 5.2. The association rate constant kon and 
disassociation rate constant koff were determined and used to calculate 
the dissociation constant KD for each molecule. Wild-type leptin had a 
KD of approximately 1.5 x 10
-8, which was in agreement with published 
data based on surface plasmon resonance. The wt-leptin ka (kon) and kd 
(koff) values were 1.27 x 10
4 (1/Ms) and 1.9 x 10-4 (1/s) respectively. The 
KD value for T37A/T121S double mutant was 2.23 x 10-9 M, indicating a 
6.7 fold higher affinity for the receptor than wt-leptin. The ka of 
T37A/T121S was 4.25 x 105, was 35 fold higher than wt-leptin, 
suggesting an increased receptor binding rate for the double mutant. 
The kd of the double mutant was approximately 5 times that of wt-leptin 
indicating that the leptin/receptor complex was less stable than that of 
the wild-type. The single T37A mutant had a KD of 2.8 x 10
-6, some 186 
times lower than wt-leptin. The T37A on rate (ka) was some 18 times 
lower than wt-leptin at 7 x 102, and the off rate (kd) was 10 times higher 
than wt-leptin. This is supported by the luciferase activation data where 
T37A only showed significant receptor activation at the highest 
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concentration (5 nM). The T121S single mutant had an affinity of 2.19 x 
10-9, 6.8 times higher than wt-leptin. The ka and kd values were a little 
lower than those of the double mutant at 2.85 x 105 and 6.24 x 10-4 
respectively.  
 
 
 
 
 KD (M) ka (1/Ms) kd (1/s) 
wt-leptin 1.5 x 10-8 1.27 x 104 1.9 x 10-4 
T37A/T121S 2.23 x 10-9 4.25 x 105 9.46 x 10-4 
T37A 2.8 x 10-6 7.0 x 102 1.96 x 10-3 
T121S 2.19 x 10-9 2.85 x 105 6.24 x 10-4 
 
Table 5.2. Summary of wild-type leptin and mutant receptor binding 
kinetics. 
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Figure 5.5. BLItz leptin receptor binding data. The kinetics of leptin 
receptor binding of wild-type and mutant leptins was investigated using a 
range of concentrations. Each run captured receptor binding and elution 
properties for a given concentration of leptin. 
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5.4 Discussion 
The aim of this part of the study was to investigate the properties of two 
of the most commonly observed mutants selected from the leptin phage 
library. The T121S mutation was the most frequently observed mutation 
in the combined round 2 and round 4 enriched libraries. This mutation 
was also observed in combination with the T37A mutation in a number 
of clones. Phage binding ELISAs suggested that these clones had 
higher affinity for the leptin receptor than wild-type leptin and the 
individual mutants were expressed as protein to investigate their 
binding and receptor activating properties. 
Physically the single and double mutants behaved similarly to wild-type 
leptin and purification of the recombinant proteins did not show any 
altered properties such as increased aggregation or changes in 
solubility. In the leptin bioassay both the single and double mutants 
were able to activate the receptor showing that they did not act as 
antagonists. In general the activity of all the recombinant proteins was 
slightly reduced relative to commercial leptin and we cannot be sure this 
was due to the mutations or limitations of the expression and 
purification method. It became clear during this study that the stability of 
recombinant leptins was an important consideration and the functional 
half-life of purified leptins was of the order of weeks, even when stored 
at -80°C. Samples had to be prepared and used promptly.  
All three mutants were active in the bioassay, indicating they were not 
acting as antagonists. With respect to the T121S mutation this was an 
interesting finding as a mutation at position T121 had been previously 
reported to be an antagonist, that could bind but not activate the 
receptor (Peelman et al., 2004). In this study by Peelman however, the 
T121A mutation was only investigated in combination with a second 
mutation S120A. The double mutant T37A/T121S produced a maximum 
signal in the assay at 0.125 nM and this contrasted with the T37A single 
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mutation which showed a rather steeper dose response curve, with 
maximum stimulation only being achieved at 5 nM. This indicated that 
the T37A mutant was less active in the bioassay and this was 
supported by the BLItz affinity data that indicated that T37A had much 
reduced affinity for the leptin receptor (approximately 186 times lower 
than wt-leptin). Interestingly the T121S double mutant had similar 
activating characteristics to the T37A/T121S double mutant and actually 
appeared to reach maximum stimulation at a lower concentration of 
0.31 nM, though this may have been within the variation of the assay. In 
terms of affinity the T121S single mutant was comparable to the 
T37A/T121S double mutant with approximately 6.8 fold higher affinity 
than wt-leptin. 
The relatively high frequency of the T37A/T121S double mutations was 
an interesting observation. It is possible that the T37A mutation simply 
represented a random mutation that occurred in a clone bearing the 
T121S mutation and the frequency of the double mutation represents 
the enrichment of this T121S clone in the phage library. It was evident 
from the results in chapter 4 that the enriched phage libraries had 
higher mutation frequency than the starting library. The synthesised 
leptin mutant library was designed to have a high proportion of single 
mutants and this was confirmed by sequencing of a library sample. Both 
the round 2 and round 4 enriched libraries had a high proportion of 
clones with multiple mutations. In round 2 70% of sequenced clones 
showed 3 or more mutations. It was not clear. A possible explanation is 
that for each round of enrichment a relatively small number of phage 
are captured, typically 50,000 from an initial aliquot of 109. These 
clones are then grown up to produce the library for the next round of 
selection. It is possible that random neutral mutations can accumulate 
in these clones and contribute to subsequent phage populations. 
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However, the results indicated that position T37 does play a role in 
receptor binding, as mutation to alanine at this site reduced the affinity 
by 186 fold (Shpilman et al., 2011). This result was rather unexpected 
as it was presumed that the T37A mutation would either be neutral in 
effect and recovered as a result of co-selection with the T121A 
mutation, or alternatively contribute to an increase in receptor affinity of 
the leptin mutant. The profoundly negative effect of T37A on receptor 
affinity appeared to be offset by the presence of the T121S mutation. It 
is possible that the T121S mutation has a stronger influence on 
receptor binding and was able to overcome this reduction in the double 
mutant to produce a high affinity variant. To a degree this hypothesis 
appears unsatisfactory given that the T37A reduced receptor affinity by 
some 186 fold. An alternative possibility is that structural changes in the 
leptin molecule caused by both mutations can accommodate or offset 
the negative effect of the T37A mutation and still lead to high affinity 
binding. Further insights into understanding this phenomenon will 
require the acquisition of more complete crystallographic data for the 
leptin structure. 
In summary, following 4 rounds of enrichment we were able to identify a 
leptin mutation that increased receptor affinity. Originally selected on 
the basis of sequence analysis the mutant leptin was expressed and 
purified and its binding and activating properties characterised. Using 
biolayer interferometry it was determined that the T121S leptin mutant 
had an approximately 6.8 fold higher affinity for the leptin receptor than 
wild-type leptin. This result demonstrated that phage display of 
recombinant leptin offers a novel technique for the recovery of new 
variants with novel properties. 
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Chapter 6  
 
 
 
 
Discussion 
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6.1 Discussion 
Leptin is a pleiotropic polypeptide hormone with roles in a number of 
physiological processes. The discovery of leptin was based on the 
analysis of a mutant mouse strain featuring a morbidly obese 
phenotype, raising hopes that this hormone would provide novel 
approaches to the understanding of human obesity and metabolic 
regulation. Accordingly, leptin has been the subject of extensive studies 
into the genetic basis of human metabolic diseases and as a possible 
therapeutic agent in human diseases featuring metabolic dysfunction, 
must commonly morbid obesity. It has since become clear that the 
origins of human obesity are more complex than originally conceived 
and only a subset of conditions are directly associated with direct 
genetic defects in the leptin pathway (reviewed in Crujeiras et al., 
2015). However, leptin resistance, characterised by normal levels of 
circulating leptin together with disruption of hormone signalling, is 
important feature of not only obesity, but is a risk factor for other 
conditions including cardiovascular disease, osteoporosis, and diabetes 
(Santoro et al., 2015). Leptin has also proven to be a significant 
modulator of inflammation, and has been implicated in the aetiology of 
rheumatoid arthritis and a number of other autoimmune conditions. For 
these reasons the development of novel forms of leptin with enhanced 
agonist and antagonistic properties is an important research goal.  
The goals of this study were to investigate the possibility of expressing 
the polypeptide hormone leptin on the surface of filamentous phage and 
to exploit this technique to select novel leptin variants with increased 
affinity for the leptin receptor. A number of proteins have been 
successfully expressed on the phage surface, most commonly, antibody 
fragments (Lerner et al., 1992). It is known that immunoglobulin 
domains, such as Fab fragments, would assemble in the Gram-negative 
periplasmic region of bacteria and form necessary disulphide bonds. 
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Previously, bacterial expression of leptin has been in the form of 
inclusion bodies which necessitated a refolding step to produce 
functional hormone (Zhang et al., 1997). Expression of leptin in 
bacterial hosts has been described previously though this always 
required refolding to produce biologically active hormone. In the current 
study we were able to establish that functional leptin can be produced 
and secreted from E coli culture. Importantly we were able to 
demonstrate that the leptin-bearing phage could be captured on 
immobilised receptor, a key requirement for the intended enrichment 
strategy. 
Having achieved the first goal of the study we went on to generate a 
library of random leptin mutants in a phage display vector using an 
error-prone PCR method. The goal was to generate a library of mainly 
single amino acid mutations by controlling the PCR conditions. 
Sequence analysis of the mutant library confirmed that the majority of 
observed mutations were single amino acid substitutions. 
The next stage of the project involved establishing the appropriate 
conditions for the enrichment of leptin phage mutants. Initially 
investigating the use of chemical denaturants we were able, following a 
series of experiments, to show that inclusion of competing 
concentrations of recombinant leptin enabled the selective binding of 
control reagent comprising a high affinity leptin variant.  
Using these conditions we carried out a series of selective enrichments 
of the leptin mutant library. Analysis of these rounds by sequencing 
showed that the population of eluted leptin clones was becoming more 
restricted in the later stages of the biopanning process. Two clones 
were chosen for further analysis based on the frequency of observation 
in the final library. Expression of these clones as phage particles was 
used to demonstrate that both appeared to have a higher affinity for the 
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leptin receptor than wild-type leptin. To confirm these observations 
these mutants were used to express and purify leptin protein. Analysis 
of these recombinant proteins showed that all possessed stimulating 
activity for the leptin receptor. Direct measurements of affinity were 
carried out using biolayer interferometry and we were able to show that 
one mutant T121S had approximately 6.8 times the receptor affinity of 
wild-type leptin. The second mutant T37A had approximately 186 times 
less receptor affinity than wild-type leptin and appeared to have been 
recovered as a result of random co-selection. It was interesting that this 
mutation did not seem to reduce the affinity of the double mutant with 
both the T37A and T121S mutations. The isolation of the T121S leptin 
variant demonstrated that phage display offers a powerful new 
approach to the recovery of novel forms of leptin with improved 
properties. 
Future work will include the conversion of the T121S leptin mutant to an 
antagonist. This is a straightforward process and one documented 
approach involves the introduction of alanine substitutions at 3 positions 
L39, D40, and F41 (Peelman et al., 2004). The selection strategy 
employed in this study may not have been optimised. The presence of 
significant numbers of leptin mutants in the round 4 library, with little 
evidence of highly dominant clones, suggested that a significant level of 
background non-specific binding was still occurring. Here we used a 
competitive leptin dose of 40 nM in the enrichment process. Further 
experiments could be carried out in which the competing level of leptin 
could be increased, and the effect on the distribution of recovered 
mutants analysed. It may be possible to isolate leptin variants with even 
higher levels of affinity. In addition, a new leptin library could be 
synthesised using the T121S mutant as the starting template. In this 
way the effects of multiple contributory mutations could be investigated.  
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One advantage of phage display selection was only touched upon in 
this study. This is the remarkable stability of phage to extreme chemical 
and physical conditions. We examined selection in the presence of urea 
and diethylamine and found receptor binding still occurred under these 
conditions. Phage are also highly resistant to heat. The selection of 
heat-stable leptin variants could be attempted. Engineering of heat 
stable proteins is a frequent strategy in the area of biological 
therapeutics as resistance to thermal breakdown appears in parallel 
with extended shelf life and stability. 
The success of the phage display approach to the engineering of leptin 
suggests that other polypeptide hormones could be investigated using 
this technology. To date only one other hormone, growth hormone, has 
been investigated using phage display. A number of other polypeptide 
hormones have important therapeutic applications, including G-CSF, 
thyrotropin, and grehlin. Future work could include feasibility studies of 
the possibility of applying phage display to these and other peptide 
hormones.  
 
 
  
 124 
 
 
References 
 
AHIMA, R. S. & OSEI, S. Y. 2004. Leptin signaling. Physiol Behav, 81, 
223-41. 
AHIMA, R. S., PRABAKARAN, D., MANTZOROS, C., QU, D., 
LOWELL, B., MARATOS-FLIER, E. & FLIER, J. S. 1996. Role of 
leptin in the neuroendocrine response to fasting. Nature, 382, 
250-2. 
ALBERTS, B., A. JOHNSON, ET AL 2002. Molecular biology of the cell. 
ALTMANN, S. W., TIMANS, J. C., ROCK, F. L., BAZAN, J. F. & 
KASTELEIN, R. A. 1995. Expression and purification of a 
synthetic human obese gene product. Protein Expr Purif, 6, 722-
6. 
AN, T. Q., ZHOU, Y. J., QIU, H. J., TONG, G. Z., WANG, Y. F., LIU, J. 
X. & YANG, J. Y. 2005. Identification of a novel B cell epitope on 
the nucleocapsid protein of porcine reproductive and respiratory 
syndrome virus by phage display. Virus Genes, 31, 81-7. 
ARITOMI, M., KUNISHIMA, N., OKAMOTO, T., KUROKI, R., OTA, Y. & 
MORIKAWA, K. 1999. Atomic structure of the GCSF-receptor 
complex showing a new cytokine-receptor recognition scheme. 
Nature, 401, 713-7. 
ARMSTRONG, J., PERHAM, R. N. & WALKER, J. E. 1981. Domain 
structure of bacteriophage fd adsorption protein. FEBS Lett, 135, 
167-72. 
BAEK, H., SUK, K. H., KIM, Y. H. & CHA, S. 2002. An improved helper 
phage system for efficient isolation of specific antibody 
molecules in phage display. Nucleic Acids Res, 30, e18. 
BALLAND, E. & COWLEY, M. A. 2015. New insights in leptin resistance 
mechanisms in mice. Front Neuroendocrinol, 39, 59-65. 
BANKS, A. S., DAVIS, S. M., BATES, S. H. & MYERS, M. G., JR. 2000. 
Activation of downstream signals by the long form of the leptin 
receptor. J Biol Chem, 275, 14563-72. 
BASS, S., GREENE, R. & WELLS, J. A. 1990. Hormone phage: an 
enrichment method for variant proteins with altered binding 
properties. Proteins, 8, 309-14. 
BELTOWSKI, J. 2012. Leptin and the regulation of endothelial function 
in physiological and pathological conditions. Clin Exp Pharmacol 
Physiol, 39, 168-78. 
BETTER, M., CHANG, C. P., ROBINSON, R. R. & HORWITZ, A. H. 
1988. Escherichia coli secretion of an active chimeric antibody 
fragment. Science, 240, 1041-3. 
 125 
 
BILES, B. D. & CONNOLLY, B. A. 2004. Low-fidelity Pyrococcus 
furiosus DNA polymerase mutants useful in error-prone PCR. 
Nucleic Acids Res, 32, e176. 
BJORBAEK, C., UOTANI, S., DA SILVA, B. & FLIER, J. S. 1997. 
Divergent signaling capacities of the long and short isoforms of 
the leptin receptor. J Biol Chem, 272, 32686-95. 
BLUHER, S. & MANTZOROS, C. S. 2009. Leptin in humans: lessons 
from translational research. Am J Clin Nutr, 89, 991s-997s. 
BOULANGER, M. J., CHOW, D. C., BREVNOVA, E. E. & GARCIA, K. 
C. 2003. Hexameric structure and assembly of the interleukin-
6/IL-6 alpha-receptor/gp130 complex. Science, 300, 2101-4. 
BOUTE, N., ZILBERFARB, V., CAMOIN, L., BONNAFOUS, S., LE 
MARCHAND-BRUSTEL, Y. & ISSAD, T. 2004. The formation of 
an intrachain disulfide bond in the leptin protein is necessary for 
efficient leptin secretion. Biochimie, 86, 351-6. 
BRAVO, J., STAUNTON, D., HEATH, J. K. & JONES, E. Y. 1998. 
Crystal structure of a cytokine-binding region of gp130. Embo j, 
17, 1665-74. 
BRIGATI, J., WILLIAMS, D. D., SOROKULOVA, I. B., NANDURI, V., 
CHEN, I. H., TURNBOUGH, C. L. & PETRENKO, V. A. 2004. 
Diagnostic probes for Bacillus anthracis spores selected from a 
landscape phage library. Clin Chem, 50, 1899-906. 
BURTON, D. R. & BARBAS, C. F., 3RD 1992. Antibodies from libraries. 
Nature, 359, 782-3. 
CALAPAI, G., CORICA, F., ALLEGRA, A., CORSONELLO, A., 
SAUTEBIN, L., DE GREGORIO, T., DI ROSA, M., 
COSTANTINO, G., BUEMI, M. & CAPUTI, A. P. 1998. Effects of 
intracerebroventricular leptin administration on food intake, body 
weight gain and diencephalic nitric oxide synthase activity in the 
mouse. Br J Pharmacol, 125, 798-802. 
CAMPFIELD, L. A. 2000. Central mechanisms responsible for the 
actions of OB protein (leptin) on food intake, metabolism and 
body energy storage. Front Horm Res, 26, 12-20. 
CAMPFIELD, L. A., SMITH, F. J., GUISEZ, Y., DEVOS, R. & BURN, P. 
1995. Recombinant mouse OB protein: evidence for a peripheral 
signal linking adiposity and central neural networks. Science, 
269, 546-9. 
CARPENTER, B., HEMSWORTH, G. R., WU, Z., MAAMRA, M., 
STRASBURGER, C. J., ROSS, R. J. & ARTYMIUK, P. J. 2012. 
Structure of the human obesity receptor leptin-binding domain 
reveals the mechanism of leptin antagonism by a monoclonal 
antibody. Structure, 20, 487-97. 
CHARLTON, H. M. 1984. Mouse mutants as models in endocrine 
research. Q J Exp Physiol, 69, 655-76. 
 126 
 
CHEHAB, F. F., LIM, M. E. & LU, R. 1996. Correction of the sterility 
defect in homozygous obese female mice by treatment with the 
human recombinant leptin. Nat Genet, 12, 318-20. 
CHOW, D., HO, J., NGUYEN PHAM, T. L., ROSE-JOHN, S. & 
GARCIA, K. C. 2001. In vitro reconstitution of recognition and 
activation complexes between interleukin-6 and gp130. 
Biochemistry, 40, 7593-603. 
COLEMAN, D. L. 1973. Effects of parabiosis of obese with diabetes and 
normal mice. Diabetologia, 9, 294-8. 
COLEMAN, D. L. & HUMMEL, K. P. 1969. Effects of parabiosis of 
normal with genetically diabetic mice. Am J Physiol, 217, 1298-
304. 
CONSIDINE, R. V., CONSIDINE, E. L., WILLIAMS, C. J., HYDE, T. M. 
& CARO, J. F. 1996a. The hypothalamic leptin receptor in 
humans: identification of incidental sequence polymorphisms and 
absence of the db/db mouse and fa/fa rat mutations. Diabetes, 
45, 992-4. 
CONSIDINE, R. V., SINHA, M. K., HEIMAN, M. L., KRIAUCIUNAS, A., 
STEPHENS, T. W., NYCE, M. R., OHANNESIAN, J. P., 
MARCO, C. C., MCKEE, L. J., BAUER, T. L. & ET AL. 1996b. 
Serum immunoreactive-leptin concentrations in normal-weight 
and obese humans. N Engl J Med, 334, 292-5. 
COWLEY, M. A., SMART, J. L., RUBINSTEIN, M., CERDAN, M. G., 
DIANO, S., HORVATH, T. L., CONE, R. D. & LOW, M. J. 2001. 
Leptin activates anorexigenic POMC neurons through a neural 
network in the arcuate nucleus. Nature, 411, 480-4. 
CRAMERI, R. & SUTER, M. 1993. Display of biologically active proteins 
on the surface of filamentous phages: a cDNA cloning system for 
selection of functional gene products linked to the genetic 
information responsible for their production. Gene, 137, 69-75. 
CRESPI, E. J. & DENVER, R. J. 2006. Leptin (ob gene) of the South 
African clawed frog Xenopus laevis. Proc Natl Acad Sci U S A, 
103, 10092-7. 
CRUJEIRAS, A. B., CARREIRA, M. C., CABIA, B., ANDRADE, S., 
AMIL, M. & CASANUEVA, F. F. 2015. Leptin resistance in 
obesity: An epigenetic landscape. Life Sci, 140, 57-63. 
DAM, J. & JOCKERS, R. 2013. Hunting for the functions of short leptin 
receptor isoforms. Mol Metab, 2, 327-8. 
DAVIDSON, L. M., MILLAR, K., JONES, C., FATUM, M. & COWARD, 
K. 2015. Deleterious effects of obesity upon the hormonal and 
molecular mechanisms controlling spermatogenesis and male 
fertility. Hum Fertil (Camb), 18, 184-93. 
DE VOS, P., SALADIN, R., AUWERX, J. & STAELS, B. 1995. Induction 
of ob gene expression by corticosteroids is accompanied by 
body weight loss and reduced food intake. J Biol Chem, 270, 
15958-61. 
 127 
 
DEVOS, R., GUISEZ, Y., VAN DER HEYDEN, J., WHITE, D. W., 
KALAI, M., FOUNTOULAKIS, M. & PLAETINCK, G. 1997. 
Ligand-independent dimerization of the extracellular domain of 
the leptin receptor and determination of the stoichiometry of 
leptin binding. J Biol Chem, 272, 18304-10. 
DUENAS, M., MALMBORG, A. C., CASALVILLA, R., OHLIN, M. & 
BORREBAECK, C. A. 1996. Selection of phage displayed 
antibodies based on kinetic constants. Mol Immunol, 33, 279-85. 
ELIAS, C. F., ASCHKENASI, C., LEE, C., KELLY, J., AHIMA, R. S., 
BJORBAEK, C., FLIER, J. S., SAPER, C. B. & ELMQUIST, J. K. 
1999. Leptin differentially regulates NPY and POMC neurons 
projecting to the lateral hypothalamic area. Neuron, 23, 775-86. 
EMILSSON, V., LIU, Y. L., CAWTHORNE, M. A., MORTON, N. M. & 
DAVENPORT, M. 1997. Expression of the functional leptin 
receptor mRNA in pancreatic islets and direct inhibitory action of 
leptin on insulin secretion. Diabetes, 46, 313-6. 
FABRET, C., PONCET, S., DANIELSEN, S., BORCHERT, T. V., 
EHRLICH, S. D. & JANNIERE, L. 2000. Efficient gene targeted 
random mutagenesis in genetically stable Escherichia coli 
strains. Nucleic Acids Res, 28, E95. 
FAGGIONI, R., FEINGOLD, K. R. & GRUNFELD, C. 2001. Leptin 
regulation of the immune response and the immunodeficiency of 
malnutrition. Faseb J, 15, 2565-71. 
FAROOQI, I. S., MATARESE, G., LORD, G. M., KEOGH, J. M., 
LAWRENCE, E., AGWU, C., SANNA, V., JEBB, S. A., PERNA, 
F., FONTANA, S., LECHLER, R. I., DEPAOLI, A. M. & 
O'RAHILLY, S. 2002. Beneficial effects of leptin on obesity, T cell 
hyporesponsiveness, and neuroendocrine/metabolic dysfunction 
of human congenital leptin deficiency. J Clin Invest, 110, 1093-
103. 
FAROOQI, S., RAU, H., WHITEHEAD, J. & O'RAHILLY, S. 1998. ob 
gene mutations and human obesity. Proc Nutr Soc, 57, 471-5. 
FAZELI, M., ZARKESH-ESFAHANI, H., WU, Z., MAAMRA, M., 
BIDLINGMAIER, M., POCKLEY, A. G., WATSON, P., 
MATARESE, G., STRASBURGER, C. J. & ROSS, R. J. 2006. 
Identification of a monoclonal antibody against the leptin receptor 
that acts as an antagonist and blocks human monocyte and T 
cell activation. J Immunol Methods, 312, 190-200. 
FORRER, P., JUNG, S. & PLUCKTHUN, A. 1999. Beyond binding: 
using phage display to select for structure, folding and enzymatic 
activity in proteins. Curr Opin Struct Biol, 9, 514-20. 
FRANCIS, D. M. & PAGE, R. 2010. Strategies to optimize protein 
expression in E. coli. Curr Protoc Protein Sci, Chapter 5, Unit 
5.24.1-29. 
FREDERICH, R. C., LOLLMANN, B., HAMANN, A., NAPOLITANO-
ROSEN, A., KAHN, B. B., LOWELL, B. B. & FLIER, J. S. 1995. 
 128 
 
Expression of ob mRNA and its encoded protein in rodents. 
Impact of nutrition and obesity. J Clin Invest, 96, 1658-63. 
FREITAS LIMA, L. C., BRAGA, V. A., DO SOCORRO DE FRANCA 
SILVA, M., CRUZ, J. C., SOUSA SANTOS, S. H., DE OLIVEIRA 
MONTEIRO, M. M. & BALARINI, C. M. 2015. Adipokines, 
diabetes and atherosclerosis: an inflammatory association. Front 
Physiol, 6, 304. 
FRIEDMAN, J. M. & HALAAS, J. L. 1998. Leptin and the regulation of 
body weight in mammals. Nature, 395, 763-70. 
FRUHBECK, G. 2001. A heliocentric view of leptin. Proc Nutr Soc, 60, 
301-18. 
FRUHBECK, G. 2006. Intracellular signalling pathways activated by 
leptin. Biochem J, 393, 7-20. 
GARCIA-CARDONA, M. C., HUANG, F., GARCIA-VIVAS, J. M., 
LOPEZ-CAMARILLO, C., DEL RIO NAVARRO, B. E., 
NAVARRO OLIVOS, E., HONG-CHONG, E., BOLANOS-
JIMENEZ, F. & MARCHAT, L. A. 2014. DNA methylation of leptin 
and adiponectin promoters in children is reduced by the 
combined presence of obesity and insulin resistance. Int J Obes 
(Lond), 38, 1457-65. 
GERTLER, A. 2006. Development of leptin antagonists and their 
potential use in experimental biology and medicine. Trends 
Endocrinol Metab, 17, 372-8. 
GERTLER, A. & ELINAV, E. 2014. Novel superactive leptin antagonists 
and their potential therapeutic applications. Curr Pharm Des, 20, 
659-65. 
GERTLER, A., SIMMONS, J. & KEISLER, D. H. 1998. Large-scale 
preparation of biologically active recombinant ovine obese 
protein (leptin). FEBS Lett, 422, 137-40. 
GERTLER, A. & SOLOMON, G. 2013. Leptin-activity blockers: 
development and potential use in experimental biology and 
medicine. Can J Physiol Pharmacol, 91, 873-82. 
GILLESPIE, J. W., GROSS, A. L., PUZYREV, A. T., BEDI, D. & 
PETRENKO, V. A. 2015. Combinatorial synthesis and screening 
of cancer cell-specific nanomedicines targeted via phage fusion 
proteins. Front Microbiol, 6, 628. 
GIORDANO, R. J., CARDO-VILA, M., LAHDENRANTA, J., 
PASQUALINI, R. & ARAP, W. 2001. Biopanning and rapid 
analysis of selective interactive ligands. Nat Med, 7, 1249-53. 
GORISSEN, M., BERNIER, N. J., NABUURS, S. B., FLIK, G. & 
HUISING, M. O. 2009. Two divergent leptin paralogues in 
zebrafish (Danio rerio) that originate early in teleostean 
evolution. J Endocrinol, 201, 329-39. 
GORISSEN, M., DE VRIEZE, E., FLIK, G. & HUISING, M. O. 2011. 
STAT genes display differential evolutionary rates that correlate 
 129 
 
with their roles in the endocrine and immune system. J 
Endocrinol, 209, 175-84. 
GRETCH, D. R., SUTER, M. & STINSKI, M. F. 1987. The use of 
biotinylated monoclonal antibodies and streptavidin affinity 
chromatography to isolate herpesvirus hydrophobic proteins or 
glycoproteins. Anal Biochem, 163, 270-7. 
GRUNFELD, C., ZHAO, C., FULLER, J., POLLACK, A., MOSER, A., 
FRIEDMAN, J. & FEINGOLD, K. R. 1996. Endotoxin and 
cytokines induce expression of leptin, the ob gene product, in 
hamsters. J Clin Invest, 97, 2152-7. 
HALAAS, J. L., GAJIWALA, K. S., MAFFEI, M., COHEN, S. L., CHAIT, 
B. T., RABINOWITZ, D., LALLONE, R. L., BURLEY, S. K. & 
FRIEDMAN, J. M. 1995. Weight-reducing effects of the plasma 
protein encoded by the obese gene. Science, 269, 543-6. 
HANIU, M., ARAKAWA, T., BURES, E. J., YOUNG, Y., HUI, J. O., 
ROHDE, M. F., WELCHER, A. A. & HORAN, T. 1998. Human 
leptin receptor. Determination of disulfide structure and N-
glycosylation sites of the extracellular domain. J Biol Chem, 273, 
28691-9. 
HATAYAMA, K. & IDE, T. 2015. Engineering of erythropoietin receptor 
for use as an affinity ligand. Protein Expr Purif, 111, 1-8. 
HAWKINS, R. E., RUSSELL, S. J. & WINTER, G. 1992. Selection of 
phage antibodies by binding affinity. Mimicking affinity 
maturation. J Mol Biol, 226, 889-96. 
HEGYI, K., FULOP, K., KOVACS, K., TOTH, S. & FALUS, A. 2004. 
Leptin-induced signal transduction pathways. Cell Biol Int, 28, 
159-69. 
HEKERMAN, P., ZEIDLER, J., BAMBERG-LEMPER, S., 
KNOBELSPIES, H., LAVENS, D., TAVERNIER, J., JOOST, H. 
G. & BECKER, W. 2005. Pleiotropy of leptin receptor signalling is 
defined by distinct roles of the intracellular tyrosines. Febs J, 
272, 109-19. 
HELLSTROM, L., WAHRENBERG, H., HRUSKA, K., REYNISDOTTIR, 
S. & ARNER, P. 2000. Mechanisms behind gender differences in 
circulating leptin levels. J Intern Med, 247, 457-62. 
HILL, C. P., OSSLUND, T. D. & EISENBERG, D. 1993. The structure of 
granulocyte-colony-stimulating factor and its relationship to other 
growth factors. Proc Natl Acad Sci U S A, 90, 5167-71. 
HIROIKE, T., HIGO, J., JINGAMI, H. & TOH, H. 2000. Homology 
modeling of human leptin/leptin receptor complex. Biochem 
Biophys Res Commun, 275, 154-8. 
HUISING, M. O., KRUISWIJK, C. P. & FLIK, G. 2006. Phylogeny and 
evolution of class-I helical cytokines. J Endocrinol, 189, 1-25. 
HUMMEL, K. P., DICKIE, M. M. & COLEMAN, D. L. 1966. Diabetes, a 
new mutation in the mouse. Science, 153, 1127-8. 
 130 
 
HYVONEN, M. & LAAKKONEN, P. 2015. Identification and 
Characterization of Homing Peptides Using In Vivo Peptide 
Phage Display. Methods Mol Biol, 1324, 205-22. 
IMAGAWA, K., NUMATA, Y., KATSUURA, G., SAKAGUCHI, I., 
MORITA, A., KIKUOKA, S., MATUMOTO, Y., TSUJI, T., 
TAMAKI, M., SASAKURA, K., TERAOKA, H., HOSODA, K., 
OGAWA, Y. & NAKAO, K. 1998. Structure-function studies of 
human leptin. J Biol Chem, 273, 35245-9. 
INGALLS, A. M., DICKIE, M. M. & SNELL, G. D. 1950. Obese, a new 
mutation in the house mouse. J Hered, 41, 317-8. 
ISERENTANT, H., PEELMAN, F., DEFEAU, D., VANDEKERCKHOVE, 
J., ZABEAU, L. & TAVERNIER, J. 2005. Mapping of the interface 
between leptin and the leptin receptor CRH2 domain. J Cell Sci, 
118, 2519-27. 
ISIDORI, A. M., CAPRIO, M., STROLLO, F., MORETTI, C., FRAJESE, 
G., ISIDORI, A. & FABBRI, A. 1999. Leptin and androgens in 
male obesity: evidence for leptin contribution to reduced 
androgen levels. J Clin Endocrinol Metab, 84, 3673-80. 
ISSE, N., OGAWA, Y., TAMURA, N., MASUZAKI, H., MORI, K., 
OKAZAKI, T., SATOH, N., SHIGEMOTO, M., YOSHIMASA, Y., 
NISHI, S. & ET AL. 1995. Structural organization and 
chromosomal assignment of the human obese gene. J Biol 
Chem, 270, 27728-33. 
KANEKO, I., SABIR, M. S., DUSSIK, C. M., WHITFIELD, G. K., 
KARRYS, A., HSIEH, J. C., HAUSSLER, M. R., MEYER, M. B., 
PIKE, J. W. & JURUTKA, P. W. 2015. 1,25-Dihydroxyvitamin D 
regulates expression of the tryptophan hydroxylase 2 and leptin 
genes: implication for behavioral influences of vitamin D. Faseb j. 
KAWWASS, J. F., SUMMER, R. & KALLEN, C. B. 2015. Direct effects 
of leptin and adiponectin on peripheral reproductive tissues: a 
critical review. Mol Hum Reprod, 21, 617-32. 
KIEFFER, T. J., HELLER, R. S., LEECH, C. A., HOLZ, G. G. & 
HABENER, J. F. 1997. Leptin suppression of insulin secretion by 
the activation of ATP-sensitive K+ channels in pancreatic beta-
cells. Diabetes, 46, 1087-93. 
KONSTANTINIDES, S., SCHAFER, K., NEELS, J. G., DELLAS, C. & 
LOSKUTOFF, D. J. 2004. Inhibition of endogenous leptin 
protects mice from arterial and venous thrombosis. Arterioscler 
Thromb Vasc Biol, 24, 2196-201. 
LAEMMLI, U. K. 1970. Cleavage of structural proteins during the 
assembly of the head of bacteriophage T4. Nature, 227, 680-5. 
LEKKERKERKER, A. & LOGTENBERG, T. 1999. Phage antibodies 
against human dendritic cell subpopulations obtained by flow 
cytometry-based selection on freshly isolated cells. J Immunol 
Methods, 231, 53-63. 
 131 
 
LERNER, R. A., KANG, A. S., BAIN, J. D., BURTON, D. R. & BARBAS, 
C. F., 3RD 1992. Antibodies without immunization. Science, 258, 
1313-4. 
LI, J., LI, C., XIAO, W., YUAN, D., WAN, G. & MA, L. 2008. Site-
directed mutagenesis by combination of homologous 
recombination and DpnI digestion of the plasmid template in 
Escherichia coli. Anal Biochem, 373, 389-91. 
LI, Z., CECCARINI, G., EISENSTEIN, M., TAN, K. & FRIEDMAN, J. M. 
2013. Phenotypic effects of an induced mutation of the ObRa 
isoform of the leptin receptor. Mol Metab, 2, 364-75. 
LICINIO, J., NEGRAO, A. B., MANTZOROS, C., KAKLAMANI, V., 
WONG, M. L., BONGIORNO, P. B., NEGRO, P. P., MULLA, A., 
VELDHUIS, J. D., CEARNAL, L., FLIER, J. S. & GOLD, P. W. 
1998. Sex differences in circulating human leptin pulse 
amplitude: clinical implications. J Clin Endocrinol Metab, 83, 
4140-7. 
LIONGUE, C. & WARD, A. C. 2007. Evolution of Class I cytokine 
receptors. BMC Evol Biol, 7, 120. 
LOFFREDA, S., YANG, S. Q., LIN, H. Z., KARP, C. L., BRENGMAN, M. 
L., WANG, D. J., KLEIN, A. S., BULKLEY, G. B., BAO, C., 
NOBLE, P. W., LANE, M. D. & DIEHL, A. M. 1998. Leptin 
regulates proinflammatory immune responses. FASEB J, 12, 57-
65. 
LORD, G. M., MATARESE, G., HOWARD, J. K., BAKER, R. J., 
BLOOM, S. R. & LECHLER, R. I. 1998. Leptin modulates the T-
cell immune response and reverses starvation-induced 
immunosuppression. Nature, 394, 897-901. 
LOWMAN, H. B. & WELLS, J. A. 1993. Affinity maturation of human 
growth hormone by monovalent phage display. J Mol Biol, 234, 
564-78. 
LU, Y. H., DALLNER, O. S., BIRSOY, K., FAYZIKHODJAEVA, G. & 
FRIEDMAN, J. M. 2015. Nuclear Factor-Y is an adipogenic factor 
that regulates leptin gene expression. Mol Metab, 4, 392-405. 
MAFFEI, M., FEI, H., LEE, G. H., DANI, C., LEROY, P., ZHANG, Y., 
PROENCA, R., NEGREL, R., AILHAUD, G. & FRIEDMAN, J. M. 
1995. Increased expression in adipocytes of ob RNA in mice with 
lesions of the hypothalamus and with mutations at the db locus. 
Proc Natl Acad Sci U S A, 92, 6957-60. 
MANCUSO, P., CANETTI, C., GOTTSCHALK, A., TITHOF, P. K. & 
PETERS-GOLDEN, M. 2004. Leptin augments alveolar 
macrophage leukotriene synthesis by increasing phospholipase 
activity and enhancing group IVC iPLA2 (cPLA2gamma) protein 
expression. Am J Physiol Lung Cell Mol Physiol, 287, L497-502. 
MANTZOROS, C. S. & MOSCHOS, S. J. 1998. Leptin: in search of 
role(s) in human physiology and pathophysiology. Clin 
Endocrinol (Oxf), 49, 551-67. 
 132 
 
MARCHI, M., LISI, S., CURCIO, M., BARBUTI, S., PIAGGI, P., 
CECCARINI, G., NANNIPIERI, M., ANSELMINO, M., DI SALVO, 
C., VITTI, P., PINCHERA, A., SANTINI, F. & MAFFEI, M. 2011. 
Human leptin tissue distribution, but not weight loss-dependent 
change in expression, is associated with methylation of its 
promoter. Epigenetics, 6, 1198-206. 
MARTIN-ROMERO, C., SANTOS-ALVAREZ, J., GOBERNA, R. & 
SANCHEZ-MARGALET, V. 2000. Human leptin enhances 
activation and proliferation of human circulating T lymphocytes. 
Cell Immunol, 199, 15-24. 
MARVIN, D. A., HALE, R. D., NAVE, C. & HELMER-CITTERICH, M. 
1994. Molecular models and structural comparisons of native 
and mutant class I filamentous bacteriophages Ff (fd, f1, M13), 
If1 and IKe. J Mol Biol, 235, 260-86. 
MATARESE, G., MOSCHOS, S. & MANTZOROS, C. S. 2005. Leptin in 
immunology. J Immunol, 174, 3137-42. 
MATARESE, G., SANNA, V., DI GIACOMO, A., LORD, G. M., 
HOWARD, J. K., BLOOM, S. R., LECHLER, R. I., FONTANA, S. 
& ZAPPACOSTA, S. 2001. Leptin potentiates experimental 
autoimmune encephalomyelitis in SJL female mice and confers 
susceptibility to males. Eur J Immunol, 31, 1324-32. 
MCCULLUM, E. O., WILLIAMS, B. A., ZHANG, J. & CHAPUT, J. C. 
2010. Random mutagenesis by error-prone PCR. Methods Mol 
Biol, 634, 103-9. 
METLAKUNTA, A. S., SAHU, M. & SAHU, A. 2008. Hypothalamic 
phosphatidylinositol 3-kinase pathway of leptin signaling is 
impaired during the development of diet-induced obesity in 
FVB/N mice. Endocrinology, 149, 1121-8. 
MOHARANA, K., ZABEAU, L., PEELMAN, F., RINGLER, P., 
STAHLBERG, H., TAVERNIER, J. & SAVVIDES, S. N. 2014. 
Structural and mechanistic paradigm of leptin receptor activation 
revealed by complexes with wild-type and antagonist leptins. 
Structure, 22, 866-77. 
MUNZBERG, H., FLIER, J. S. & BJORBAEK, C. 2004. Region-specific 
leptin resistance within the hypothalamus of diet-induced obese 
mice. Endocrinology, 145, 4880-9. 
MUNZBERG, H. & MORRISON, C. D. 2015. Structure, production and 
signaling of leptin. Metabolism, 64, 13-23. 
MUNZBERG, H. & MYERS, M. G., JR. 2005. Molecular and anatomical 
determinants of central leptin resistance. Nat Neurosci, 8, 566-
70. 
MYERS, M. G., JR. 2004. Leptin receptor signaling and the regulation 
of mammalian physiology. Recent Prog Horm Res, 59, 287-304. 
NAKAMAYE, K. L. & ECKSTEIN, F. 1986. Inhibition of restriction 
endonuclease Nci I cleavage by phosphorothioate groups and its 
 133 
 
application to oligonucleotide-directed mutagenesis. Nucleic 
Acids Res, 14, 9679-98. 
NIV-SPECTOR, L., GONEN-BERGER, D., GOURDOU, I., BIENER, E., 
GUSSAKOVSKY, E. E., BENOMAR, Y., RAMANUJAN, K. V., 
TAOUIS, M., HERMAN, B., CALLEBAUT, I., DJIANE, J. & 
GERTLER, A. 2005. Identification of the hydrophobic strand in 
the A-B loop of leptin as major binding site III: implications for 
large-scale preparation of potent recombinant human and ovine 
leptin antagonists. Biochem J, 391, 221-30. 
NIV-SPECTOR, L., SHPILMAN, M., BOISCLAIR, Y. & GERTLER, A. 
2012. Large-scale preparation and characterization of non-
pegylated and pegylated superactive ovine leptin antagonist. 
Protein Expr Purif, 81, 186-92. 
NOVAKOVIC, Z. M., LEINUNG, M. C., LEE, D. W. & GRASSO, P. 
2009. Intranasal administration of mouse [D-Leu-4]OB3, a 
synthetic peptide amide with leptin-like activity, enhances total 
uptake and bioavailability in Swiss Webster mice when 
compared to intraperitoneal, subcutaneous, and intramuscular 
delivery systems. Regul Pept, 154, 107-11. 
O'SULLIVAN, L. A., LIONGUE, C., LEWIS, R. S., STEPHENSON, S. E. 
& WARD, A. C. 2007. Cytokine receptor signaling through the 
Jak-Stat-Socs pathway in disease. Mol Immunol, 44, 2497-506. 
OTERO, M., LAGO, R., LAGO, F., CASANUEVA, F. F., DIEGUEZ, C., 
GOMEZ-REINO, J. J. & GUALILLO, O. 2005. Leptin, from fat to 
inflammation: old questions and new insights. FEBS Lett, 579, 
295-301. 
OTVOS, L., JR., KOVALSZKY, I., SCOLARO, L., SZTODOLA, A., 
OLAH, J., CASSONE, M., KNAPPE, D., HOFFMANN, R., 
LOVAS, S., HATFIELD, M. P., BEKO, G., ZHANG, S., WADE, J. 
D. & SURMACZ, E. 2011. Peptide-based leptin receptor 
antagonists for cancer treatment and appetite regulation. 
Biopolymers, 96, 117-25. 
PANDE, J., SZEWCZYK, M. M. & GROVER, A. K. 2010. Phage display: 
concept, innovations, applications and future. Biotechnol Adv, 
28, 849-58. 
PEELMAN, F., ISERENTANT, H., DE SMET, A. S., 
VANDEKERCKHOVE, J., ZABEAU, L. & TAVERNIER, J. 2006. 
Mapping of binding site III in the leptin receptor and modeling of 
a hexameric leptin.leptin receptor complex. J Biol Chem, 281, 
15496-504. 
PEELMAN, F., VAN BENEDEN, K., ZABEAU, L., ISERENTANT, H., 
ULRICHTS, P., DEFEAU, D., VERHEE, A., CATTEEUW, D., 
ELEWAUT, D. & TAVERNIER, J. 2004. Mapping of the leptin 
binding sites and design of a leptin antagonist. J Biol Chem, 279, 
41038-46. 
 134 
 
PEELMAN, F., ZABEAU, L., MOHARANA, K., SAVVIDES, S. N. & 
TAVERNIER, J. 2014. 20 years of leptin: insights into signaling 
assemblies of the leptin receptor. J Endocrinol, 223, T9-23. 
PINEIRO, V., CASABIELL, X., PEINO, R., LAGE, M., CAMINA, J. P., 
MENENDEZ, C., BALTAR, J., DIEGUEZ, C. & CASANUEVA, F. 
1999. Dihydrotestosterone, stanozolol, androstenedione and 
dehydroepiandrosterone sulphate inhibit leptin secretion in 
female but not in male samples of omental adipose tissue in 
vitro: lack of effect of testosterone. J Endocrinol, 160, 425-32. 
RAKONJAC, J., FENG, J. & MODEL, P. 1999. Filamentous phage are 
released from the bacterial membrane by a two-step mechanism 
involving a short C-terminal fragment of pIII. J Mol Biol, 289, 
1253-65. 
REN, H., ZHAO, H., WANG, T., YANG, Y., HAN, Z., LIU, B., WU, Z., 
TAO, J., ZHOU, B., ZHANG, L., YANG, R. & HAN, Z. C. 2006. 
Leptin enhances in vitro secretion of IgG antiplatelet antibodies 
by splenocytes and peripheral blood mononuclear cells from 
patients with chronic idiopathic thrombocytopenic purpura. Clin 
Immunol, 120, 205-11. 
ROZHAVSKAYA-ARENA, M., LEE, D. W., LEINUNG, M. C. & 
GRASSO, P. 2000. Design of a synthetic leptin agonist: effects 
on energy balance, glucose homeostasis, and thermoregulation. 
Endocrinology, 141, 2501-7. 
RUSSEL, M., KIDD, S. & KELLEY, M. R. 1986. An improved 
filamentous helper phage for generating single-stranded plasmid 
DNA. Gene, 45, 333-8. 
RUSSEL, M., LINDEROTH, N. A. & SALI, A. 1997. Filamentous phage 
assembly: variation on a protein export theme. Gene, 192, 23-32. 
SAAD, M. F., DAMANI, S., GINGERICH, R. L., RIAD-GABRIEL, M. G., 
KHAN, A., BOYADJIAN, R., JINAGOUDA, S. D., EL-TAWIL, K., 
RUDE, R. K. & KAMDAR, V. 1997. Sexual dimorphism in plasma 
leptin concentration. J Clin Endocrinol Metab, 82, 579-84. 
SALADIN, R., DE VOS, P., GUERRE-MILLO, M., LETURQUE, A., 
GIRARD, J., STAELS, B. & AUWERX, J. 1995. Transient 
increase in obese gene expression after food intake or insulin 
administration. Nature, 377, 527-9. 
SAMBROOK, J. & GETHING, M. J. 1989. Protein structure. 
Chaperones, paperones. Nature, 342, 224-5. 
SAMBROOK, J. & RUSSELL, D. W. 2001. Molecular Cloning: A 
Laboratory Manual, Cold Spring Harbor Laboratory Press. 
SANDOWSKI, Y., RAVER, N., GUSSAKOVSKY, E. E., SHOCHAT, S., 
DYM, O., LIVNAH, O., RUBINSTEIN, M., KRISHNA, R. & 
GERTLER, A. 2002. Subcloning, expression, purification, and 
characterization of recombinant human leptin-binding domain. J 
Biol Chem, 277, 46304-9. 
 135 
 
SANTORO, A., MATTACE RASO, G. & MELI, R. 2015. Drug targeting 
of leptin resistance. Life Sci. 
SANTOS-ALVAREZ, J., GOBERNA, R. & SÁNCHEZ-MARGALET, V. 
1999. Human leptin stimulates proliferation and activation of 
human circulating monocytes. Cell Immunol, 194, 6-11. 
SCHIER, R. & MARKS, J. D. 1996. Efficient in vitro affinity maturation of 
phage antibodies using BIAcore guided selections. Hum 
Antibodies Hybridomas, 7, 97-105. 
SCHWARTZ, M. W., PESKIND, E., RASKIND, M., BOYKO, E. J. & 
PORTE, D., JR. 1996. Cerebrospinal fluid leptin levels: 
relationship to plasma levels and to adiposity in humans. Nat 
Med, 2, 589-93. 
SCHWARTZ, M. W., WOODS, S. C., PORTE, D., JR., SEELEY, R. J. & 
BASKIN, D. G. 2000. Central nervous system control of food 
intake. Nature, 404, 661-71. 
SCOTT, J. K. & SMITH, G. P. 1990. Searching for peptide ligands with 
an epitope library. Science, 249, 386-90. 
SHAH, N. B. & DUNCAN, T. M. 2014. Bio-layer interferometry for 
measuring kinetics of protein-protein interactions and allosteric 
ligand effects. J Vis Exp, e51383. 
SHIN, J. S., RYU, S. H., LEE, C. & YU, M. H. 2006. Misfolding-assisted 
selection of stable protein variants using phage displays. J 
Biochem Mol Biol, 39, 55-60. 
SHPILMAN, M., NIV-SPECTOR, L., KATZ, M., VAROL, C., SOLOMON, 
G., AYALON-SOFFER, M., BODER, E., HALPERN, Z., ELINAV, 
E. & GERTLER, A. 2011. Development and characterization of 
high affinity leptins and leptin antagonists. J Biol Chem, 286, 
4429-42. 
SIDHU, S. S. 2001. Engineering M13 for phage display. Biomol Eng, 
18, 57-63. 
SIMONS, G. F., BEINTEMA, J., DUISTERWINKEL, F. J., KONINGS, R. 
N. & SCHOENMAKERS, J. G. 1981. Genes VI, VII and IX of 
bacteriophage M13: identification of their products as minor 
capsid proteins. Prog Clin Biol Res, 64, 401-11. 
SKERRA, A. & PLUCKTHUN, A. 1988. Assembly of a functional 
immunoglobulin Fv fragment in Escherichia coli. Science, 240, 
1038-41. 
SLIEKER, L. J., SLOOP, K. W., SURFACE, P. L., KRIAUCIUNAS, A., 
LAQUIER, F., MANETTA, J., BUE-VALLESKEY, J. & 
STEPHENS, T. W. 1996. Regulation of expression of ob mRNA 
and protein by glucocorticoids and cAMP. J Biol Chem, 271, 
5301-4. 
SMITH, G. P. 1985. Filamentous fusion phage: novel expression 
vectors that display cloned antigens on the virion surface. 
Science, 228, 1315-7. 
 136 
 
SMITH, G. P. & SCOTT, J. K. 1993. Libraries of peptides and proteins 
displayed on filamentous phage. Methods Enzymol, 217, 228-57. 
SPEAKMAN, J. R. & O'RAHILLY, S. 2012. Fat: an evolving issue. Dis 
Model Mech, 5, 569-73. 
TAMADA, T., HONJO, E., MAEDA, Y., OKAMOTO, T., ISHIBASHI, M., 
TOKUNAGA, M. & KUROKI, R. 2006. Homodimeric cross-over 
structure of the human granulocyte colony-stimulating factor 
(GCSF) receptor signaling complex. Proc Natl Acad Sci U S A, 
103, 3135-40. 
TANAKA, A. S., SILVA, M. M., TORQUATO, R. J., NOGUTI, M. A., 
SAMPAIO, C. A., FRITZ, H. & AUERSWALD, E. A. 1999. 
Functional phage display of leech-derived tryptase inhibitor 
(LDTI): construction of a library and selection of thrombin 
inhibitors. FEBS Lett, 458, 11-6. 
TARTAGLIA, L. A., DEMBSKI, M., WENG, X., DENG, N., 
CULPEPPER, J., DEVOS, R., RICHARDS, G. J., CAMPFIELD, 
L. A., CLARK, F. T., DEEDS, J., MUIR, C., SANKER, S., 
MORIARTY, A., MOORE, K. J., SMUTKO, J. S., MAYS, G. G., 
WOOL, E. A., MONROE, C. A. & TEPPER, R. I. 1995. 
Identification and expression cloning of a leptin receptor, OB-R. 
Cell, 83, 1263-71. 
TU, H., HSUCHOU, H., KASTIN, A. J., WU, X. & PAN, W. 2010. Unique 
leptin trafficking by a tailless receptor. FASEB J, 24, 2281-91. 
TURNER, K. B., ZABETAKIS, D., GOLDMAN, E. R. & ANDERSON, G. 
P. 2014. Enhanced stabilization of a stable single domain 
antibody for SEB toxin by random mutagenesis and stringent 
selection. Protein Eng Des Sel, 27, 89-95. 
VAN DER VUURST DE VRIES, A. R. & LOGTENBERG, T. 1999. A 
phage antibody identifying an 80-kDa membrane glycoprotein 
exclusively expressed on a subpopulation of activated B cells 
and hairy cell leukemia B cells. Eur J Immunol, 29, 3898-907. 
VAN HEEK, M., COMPTON, D. S., FRANCE, C. F., TEDESCO, R. P., 
FAWZI, A. B., GRAZIANO, M. P., SYBERTZ, E. J., STRADER, 
C. D. & DAVIS, H. R., JR. 1997. Diet-induced obese mice 
develop peripheral, but not central, resistance to leptin. J Clin 
Invest, 99, 385-90. 
VAUGHAN, T. J., WILLIAMS, A. J., PRITCHARD, K., OSBOURN, J. K., 
POPE, A. R., EARNSHAW, J. C., MCCAFFERTY, J., HODITS, 
R. A., WILTON, J. & JOHNSON, K. S. 1996. Human antibodies 
with sub-nanomolar affinities isolated from a large non-
immunized phage display library. Nat Biotechnol, 14, 309-14. 
VERPLOEGEN, S. A., PLAETINCK, G., DEVOS, R., VAN DER 
HEYDEN, J. & GUISEZ, Y. 1997. A human leptin mutant induces 
weight gain in normal mice. FEBS Lett, 405, 237-40. 
 137 
 
WALDUCK, A. K. & BECHER, D. 2012. Leptin, CD4(+) T(reg) and the 
prospects for vaccination against H. pylori infection. Front 
Immunol, 3, 316. 
WELLS, J. A., CUNNINGHAM, B. C., FUH, G., LOWMAN, H. B., BASS, 
S. H., MULKERRIN, M. G., ULTSCH, M. & DEVOS, A. M. 1993. 
The molecular basis for growth hormone-receptor interactions. 
Recent Prog Horm Res, 48, 253-75. 
WHITE, D. W. & TARTAGLIA, L. A. 1999. Evidence for ligand-
independent homo-oligomerization of leptin receptor (OB-R) 
isoforms: a proposed mechanism permitting productive long-form 
signaling in the presence of excess short-form expression. J Cell 
Biochem, 73, 278-88. 
WHITE, D. W., WANG, D. W., CHUA, S. C., JR., MORGENSTERN, J. 
P., LEIBEL, R. L., BAUMANN, H. & TARTAGLIA, L. A. 1997. 
Constitutive and impaired signaling of leptin receptors containing 
the Gln --> Pro extracellular domain fatty mutation. Proc Natl 
Acad Sci U S A, 94, 10657-62. 
WILLATS, W. G. 2002. Phage display: practicalities and prospects. 
Plant Mol Biol, 50, 837-54. 
XU, A. W., KAELIN, C. B., TAKEDA, K., AKIRA, S., SCHWARTZ, M. W. 
& BARSH, G. S. 2005. PI3K integrates the action of insulin and 
leptin on hypothalamic neurons. J Clin Invest, 115, 951-8. 
YANG, R. & BAROUCH, L. A. 2007. Leptin signaling and obesity: 
cardiovascular consequences. Circ Res, 101, 545-59. 
ZABEAU, L., DEFEAU, D., ISERENTANT, H., VANDEKERCKHOVE, 
J., PEELMAN, F. & TAVERNIER, J. 2005. Leptin receptor 
activation depends on critical cysteine residues in its fibronectin 
type III subdomains. J Biol Chem, 280, 22632-40. 
ZABEAU, L., DEFEAU, D., VAN DER HEYDEN, J., ISERENTANT, H., 
VANDEKERCKHOVE, J. & TAVERNIER, J. 2004. Functional 
analysis of leptin receptor activation using a Janus kinase/signal 
transducer and activator of transcription complementation assay. 
Mol Endocrinol, 18, 150-61. 
ZABEAU, L., LAVENS, D., PEELMAN, F., EYCKERMAN, S., 
VANDEKERCKHOVE, J. & TAVERNIER, J. 2003. The ins and 
outs of leptin receptor activation. FEBS Lett, 546, 45-50. 
ZABEAU, L., PEELMAN, F. & TAVERNIER, J. 2015. Leptin: From 
structural insights to the design of antagonists. Life Sci. 
ZABEAU, L., VERHEE, A., CATTEEUW, D., FAES, L., SEEUWS, S., 
DECRUY, T., ELEWAUT, D., PEELMAN, F. & TAVERNIER, J. 
2012. Selection of non-competitive leptin antagonists using a 
random nanobody-based approach. Biochem J, 441, 425-34. 
ZARKESH-ESFAHANI, H., POCKLEY, A. G., WU, Z., HELLEWELL, P. 
G., WEETMAN, A. P. & ROSS, R. J. 2004. Leptin indirectly 
activates human neutrophils via induction of TNF-alpha. J 
Immunol, 172, 1809-14. 
 138 
 
ZEIDAN, A., PURDHAM, D. M., RAJAPUROHITAM, V., JAVADOV, S., 
CHAKRABARTI, S. & KARMAZYN, M. 2005. Leptin induces 
vascular smooth muscle cell hypertrophy through angiotensin II- 
and endothelin-1-dependent mechanisms and mediates stretch-
induced hypertrophy. J Pharmacol Exp Ther, 315, 1075-84. 
ZHANG, F., BASINSKI, M. B., BEALS, J. M., BRIGGS, S. L., 
CHURGAY, L. M., CLAWSON, D. K., DIMARCHI, R. D., 
FURMAN, T. C., HALE, J. E., HSIUNG, H. M., SCHONER, B. E., 
SMITH, D. P., ZHANG, X. Y., WERY, J. P. & SCHEVITZ, R. W. 
1997. Crystal structure of the obese protein leptin-E100. Nature, 
387, 206-9. 
ZHANG, Y., PROENCA, R., MAFFEI, M., BARONE, M., LEOPOLD, L. 
& FRIEDMAN, J. M. 1994. Positional cloning of the mouse obese 
gene and its human homologue. Nature, 372, 425-32. 
ZHAO, Y., SUN, R., YOU, L., GAO, C. & TIAN, Z. 2003. Expression of 
leptin receptors and response to leptin stimulation of human 
natural killer cell lines. Biochem Biophys Res Commun, 300, 
247-52. 
ZOLLER, M. J. & SMITH, M. 1982. Oligonucleotide-directed 
mutagenesis using M13-derived vectors: an efficient and general 
procedure for the production of point mutations in any fragment 
of DNA. Nucleic Acids Res, 10, 6487-500. 
 
